id	sid	tid	token	lemma	pos
fbem-7835	1	1	frontiers	frontier	NOUN
fbem-7835	1	2	in	in	ADP
fbem-7835	1	3	business	business	NOUN
fbem-7835	1	4	,	,	PUNCT
fbem-7835	1	5	economics	economic	NOUN
fbem-7835	1	6	and	and	CCONJ
fbem-7835	1	7	management	management	NOUN
fbem-7835	1	8	issn	issn	PROPN
fbem-7835	1	9	:	:	PUNCT
fbem-7835	1	10	2766	2766	NUM
fbem-7835	1	11	-	-	PUNCT
fbem-7835	1	12	824x	824x	NUM
fbem-7835	1	13	|	|	ADJ
fbem-7835	1	14	vol	vol	NOUN
fbem-7835	1	15	.	.	PROPN
fbem-7835	1	16	8	8	NUM
fbem-7835	1	17	,	,	PUNCT
fbem-7835	1	18	no	no	INTJ
fbem-7835	1	19	.	.	NOUN
fbem-7835	1	20	3	3	NUM
fbem-7835	1	21	,	,	PUNCT
fbem-7835	1	22	2023	2023	NUM
fbem-7835	1	23	178	178	NUM
fbem-7835	1	24	cost‐utilities	cost‐utilitie	NOUN
fbem-7835	1	25	analysis	analysis	NOUN
fbem-7835	1	26	of	of	ADP
fbem-7835	1	27	polatuzumab	polatuzumab	NOUN
fbem-7835	1	28	vedotin	vedotin	ADV
fbem-7835	1	29	combined	combine	VERB
fbem-7835	1	30	with	with	ADP
fbem-7835	1	31	bendamustine	bendamustine	NOUN
fbem-7835	1	32	and	and	CCONJ
fbem-7835	1	33	rituximab	rituximab	NOUN
fbem-7835	1	34	for	for	ADP
fbem-7835	1	35	relapsed	relapse	VERB
fbem-7835	1	36	/	/	SYM
fbem-7835	1	37	refractory	refractory	NOUN
fbem-7835	1	38	diffuse	diffuse	VERB
fbem-7835	1	39	large	large	ADJ
fbem-7835	1	40	b‐cell	b‐cell	PUNCT
fbem-7835	1	41	lymphoma	lymphoma	NOUN
fbem-7835	1	42	which	which	PRON
fbem-7835	1	43	is	be	AUX
fbem-7835	1	44	unsuited	unsuited	ADJ
fbem-7835	1	45	for	for	ADP
fbem-7835	1	46	hematopoietic	hematopoietic	ADJ
fbem-7835	1	47	stem	stem	NOUN
fbem-7835	1	48	cell	cell	NOUN
fbem-7835	1	49	transplantation	transplantation	NOUN
fbem-7835	1	50	lan	lan	PROPN
fbem-7835	1	51	yang1	yang1	PROPN
fbem-7835	1	52	,	,	PUNCT
fbem-7835	1	53	2	2	NUM
fbem-7835	1	54	,	,	PUNCT
fbem-7835	1	55	aixia	aixia	PROPN
fbem-7835	1	56	ma1	ma1	PROPN
fbem-7835	1	57	,	,	PUNCT
fbem-7835	1	58	2	2	NUM
fbem-7835	1	59	,	,	PUNCT
fbem-7835	1	60	*	*	PUNCT
fbem-7835	2	1	1school	1school	NUM
fbem-7835	2	2	of	of	ADP
fbem-7835	2	3	international	international	ADJ
fbem-7835	2	4	pharmaceutical	pharmaceutical	NOUN
fbem-7835	2	5	business	business	NOUN
fbem-7835	2	6	,	,	PUNCT
fbem-7835	2	7	china	china	PROPN
fbem-7835	2	8	pharmaceutical	pharmaceutical	PROPN
fbem-7835	2	9	university	university	PROPN
fbem-7835	2	10	,	,	PUNCT
fbem-7835	2	11	nanjing	nanjing	PROPN
fbem-7835	2	12	211198	211198	NUM
fbem-7835	2	13	,	,	PUNCT
fbem-7835	2	14	p.	p.	PROPN
fbem-7835	2	15	r.	r.	PROPN
fbem-7835	3	1	china	china	PROPN
fbem-7835	3	2	2pharmacoeconomic	2pharmacoeconomic	PROPN
fbem-7835	3	3	evaluation	evaluation	NOUN
fbem-7835	3	4	research	research	NOUN
fbem-7835	3	5	center	center	NOUN
fbem-7835	3	6	,	,	PUNCT
fbem-7835	3	7	china	china	PROPN
fbem-7835	3	8	pharmaceutical	pharmaceutical	PROPN
fbem-7835	3	9	university	university	PROPN
fbem-7835	3	10	,	,	PUNCT
fbem-7835	3	11	nanjing	nanjing	PROPN
fbem-7835	3	12	211198	211198	NUM
fbem-7835	3	13	,	,	PUNCT
fbem-7835	4	1	p.	p.	PROPN
fbem-7835	4	2	r.	r.	PROPN
fbem-7835	5	1	china	china	PROPN
fbem-7835	5	2	*	*	PUNCT
fbem-7835	5	3	corresponding	correspond	VERB
fbem-7835	5	4	author	author	NOUN
fbem-7835	5	5	:	:	PUNCT
fbem-7835	5	6	ma	ma	PROPN
fbem-7835	5	7	aixia	aixia	PROPN
fbem-7835	5	8	,	,	PUNCT
fbem-7835	5	9	email	email	NOUN
fbem-7835	5	10	:	:	PUNCT
fbem-7835	5	11	ma86128@sina.com	ma86128@sina.com	X
fbem-7835	5	12	abstract	abstract	NOUN
fbem-7835	5	13	:	:	PUNCT
fbem-7835	5	14	objectives	objective	NOUN
fbem-7835	5	15	to	to	PART
fbem-7835	5	16	evaluate	evaluate	VERB
fbem-7835	5	17	the	the	DET
fbem-7835	5	18	cost	cost	NOUN
fbem-7835	5	19	-	-	PUNCT
fbem-7835	5	20	utilities	utility	NOUN
fbem-7835	5	21	of	of	ADP
fbem-7835	5	22	polatuzumab	polatuzumab	NOUN
fbem-7835	5	23	vedotin	vedotin	PROPN
fbem-7835	5	24	(	(	PUNCT
fbem-7835	5	25	polivy	polivy	NOUN
fbem-7835	5	26	)	)	PUNCT
fbem-7835	5	27	combined	combine	VERB
fbem-7835	5	28	with	with	ADP
fbem-7835	5	29	bendamustine	bendamustine	NOUN
fbem-7835	5	30	and	and	CCONJ
fbem-7835	5	31	rituximab	rituximab	VERB
fbem-7835	5	32	regimen	regiman	NOUN
fbem-7835	5	33	(	(	PUNCT
fbem-7835	5	34	br	br	NOUN
fbem-7835	5	35	)	)	PUNCT
fbem-7835	5	36	for	for	ADP
fbem-7835	5	37	relapsed	relapse	VERB
fbem-7835	5	38	/	/	SYM
fbem-7835	5	39	refractory	refractory	NOUN
fbem-7835	5	40	diffuse	diffuse	VERB
fbem-7835	5	41	large	large	ADJ
fbem-7835	5	42	b	b	NUM
fbem-7835	5	43	-	-	PUNCT
fbem-7835	5	44	cell	cell	NOUN
fbem-7835	5	45	lymphoma	lymphoma	NOUN
fbem-7835	5	46	(	(	PUNCT
fbem-7835	5	47	dlbcl	dlbcl	NOUN
fbem-7835	5	48	)	)	PUNCT
fbem-7835	5	49	which	which	PRON
fbem-7835	5	50	is	be	AUX
fbem-7835	5	51	unsuited	unsuited	ADJ
fbem-7835	5	52	for	for	ADP
fbem-7835	5	53	hematopoietic	hematopoietic	ADJ
fbem-7835	5	54	stem	stem	NOUN
fbem-7835	5	55	cell	cell	NOUN
fbem-7835	5	56	transplantation	transplantation	NOUN
fbem-7835	5	57	.	.	PUNCT
fbem-7835	6	1	methods	method	NOUN
fbem-7835	6	2	from	from	ADP
fbem-7835	6	3	the	the	DET
fbem-7835	6	4	perspective	perspective	NOUN
fbem-7835	6	5	of	of	ADP
fbem-7835	6	6	the	the	DET
fbem-7835	6	7	china	china	PROPN
fbem-7835	6	8	's	's	PART
fbem-7835	6	9	health	health	NOUN
fbem-7835	6	10	system	system	NOUN
fbem-7835	6	11	,	,	PUNCT
fbem-7835	6	12	the	the	DET
fbem-7835	6	13	cost	cost	NOUN
fbem-7835	6	14	-	-	PUNCT
fbem-7835	6	15	utilities	utility	NOUN
fbem-7835	6	16	analysis	analysis	NOUN
fbem-7835	6	17	of	of	ADP
fbem-7835	6	18	br	br	NOUN
fbem-7835	6	19	regimen	regiman	NOUN
fbem-7835	6	20	combined	combine	VERB
fbem-7835	6	21	with	with	ADP
fbem-7835	6	22	polatuzumab	polatuzumab	NOUN
fbem-7835	6	23	vedotin	vedotin	PROPN
fbem-7835	6	24	(	(	PUNCT
fbem-7835	6	25	polivy	polivy	NOUN
fbem-7835	6	26	)	)	PUNCT
fbem-7835	6	27	and	and	CCONJ
fbem-7835	6	28	br	br	ADP
fbem-7835	6	29	regimen	regiman	NOUN
fbem-7835	6	30	alone	alone	ADV
fbem-7835	6	31	for	for	ADP
fbem-7835	6	32	relapsed	relapse	VERB
fbem-7835	6	33	/	/	SYM
fbem-7835	6	34	refractory	refractory	NOUN
fbem-7835	6	35	dlbcl	dlbcl	NOUN
fbem-7835	6	36	which	which	PRON
fbem-7835	6	37	is	be	AUX
fbem-7835	6	38	unsuited	unsuited	ADJ
fbem-7835	6	39	for	for	ADP
fbem-7835	6	40	hematopoietic	hematopoietic	ADJ
fbem-7835	6	41	stem	stem	NOUN
fbem-7835	6	42	cell	cell	NOUN
fbem-7835	6	43	transplantation	transplantation	NOUN
fbem-7835	6	44	was	be	AUX
fbem-7835	6	45	analyzed	analyze	VERB
fbem-7835	6	46	by	by	ADP
fbem-7835	6	47	using	use	VERB
fbem-7835	6	48	partitioned	partition	VERB
fbem-7835	6	49	survival	survival	NOUN
fbem-7835	6	50	model	model	NOUN
fbem-7835	6	51	(	(	PUNCT
fbem-7835	6	52	psm	psm	PROPN
fbem-7835	6	53	)	)	PUNCT
fbem-7835	6	54	.	.	PUNCT
fbem-7835	7	1	results	result	NOUN
fbem-7835	7	2	compared	compare	VERB
fbem-7835	7	3	with	with	ADP
fbem-7835	7	4	br	br	NOUN
fbem-7835	7	5	regimen	regiman	NOUN
fbem-7835	7	6	alone	alone	ADV
fbem-7835	7	7	,	,	PUNCT
fbem-7835	7	8	br	br	ADP
fbem-7835	7	9	regimen	regiman	NOUN
fbem-7835	7	10	combined	combine	VERB
fbem-7835	7	11	with	with	ADP
fbem-7835	7	12	polatuzumab	polatuzumab	NOUN
fbem-7835	7	13	vedotin	vedotin	PROPN
fbem-7835	7	14	(	(	PUNCT
fbem-7835	7	15	polivy	polivy	NOUN
fbem-7835	7	16	)	)	PUNCT
fbem-7835	7	17	for	for	ADP
fbem-7835	7	18	relapsed	relapse	VERB
fbem-7835	7	19	/	/	SYM
fbem-7835	7	20	refractory	refractory	NOUN
fbem-7835	7	21	dlbcl	dlbcl	NOUN
fbem-7835	7	22	which	which	PRON
fbem-7835	7	23	is	be	AUX
fbem-7835	7	24	unsuited	unsuited	ADJ
fbem-7835	7	25	for	for	ADP
fbem-7835	7	26	hematopoietic	hematopoietic	ADJ
fbem-7835	7	27	stem	stem	NOUN
fbem-7835	7	28	cell	cell	NOUN
fbem-7835	7	29	transplantation	transplantation	NOUN
fbem-7835	7	30	patients	patient	NOUN
fbem-7835	7	31	can	can	AUX
fbem-7835	7	32	increase	increase	VERB
fbem-7835	7	33	1.1706	1.1706	NUM
fbem-7835	7	34	qalys	qaly	NOUN
fbem-7835	7	35	in	in	ADP
fbem-7835	7	36	15	15	NUM
fbem-7835	7	37	years	year	NOUN
fbem-7835	7	38	,	,	PUNCT
fbem-7835	7	39	the	the	DET
fbem-7835	7	40	total	total	ADJ
fbem-7835	7	41	cost	cost	NOUN
fbem-7835	7	42	is	be	AUX
fbem-7835	7	43	increased	increase	VERB
fbem-7835	7	44	by	by	ADP
fbem-7835	7	45	231	231	NUM
fbem-7835	7	46	117.9	117.9	NUM
fbem-7835	7	47	yuan	yuan	NOUN
fbem-7835	7	48	,	,	PUNCT
fbem-7835	7	49	and	and	CCONJ
fbem-7835	7	50	the	the	DET
fbem-7835	7	51	icur	icur	NOUN
fbem-7835	7	52	value	value	NOUN
fbem-7835	7	53	is	be	AUX
fbem-7835	7	54	197	197	NUM
fbem-7835	7	55	434.7	434.7	NUM
fbem-7835	7	56	yuan	yuan	NOUN
fbem-7835	7	57	/	/	SYM
fbem-7835	7	58	qaly	qaly	PROPN
fbem-7835	7	59	.	.	PUNCT
fbem-7835	8	1	the	the	DET
fbem-7835	8	2	sensitivity	sensitivity	NOUN
fbem-7835	8	3	analysis	analysis	NOUN
fbem-7835	8	4	confirmed	confirm	VERB
fbem-7835	8	5	the	the	DET
fbem-7835	8	6	robustness	robustness	NOUN
fbem-7835	8	7	of	of	ADP
fbem-7835	8	8	the	the	DET
fbem-7835	8	9	results	result	NOUN
fbem-7835	8	10	.	.	PUNCT
fbem-7835	9	1	conclusion	conclusion	NOUN
fbem-7835	9	2	in	in	ADP
fbem-7835	9	3	the	the	DET
fbem-7835	9	4	long	long	ADJ
fbem-7835	9	5	run	run	NOUN
fbem-7835	9	6	,	,	PUNCT
fbem-7835	9	7	compared	compare	VERB
fbem-7835	9	8	with	with	ADP
fbem-7835	9	9	br	br	NOUN
fbem-7835	9	10	alone	alone	ADV
fbem-7835	9	11	,	,	PUNCT
fbem-7835	9	12	br	br	PROPN
fbem-7835	9	13	combined	combine	VERB
fbem-7835	9	14	with	with	ADP
fbem-7835	9	15	polatuzumab	polatuzumab	NOUN
fbem-7835	9	16	vedotin	vedotin	PROPN
fbem-7835	9	17	(	(	PUNCT
fbem-7835	9	18	polivy	polivy	NOUN
fbem-7835	9	19	)	)	PUNCT
fbem-7835	9	20	does	do	AUX
fbem-7835	9	21	n’t	not	PART
fbem-7835	9	22	have	have	VERB
fbem-7835	9	23	cost	cost	NOUN
fbem-7835	9	24	-	-	PUNCT
fbem-7835	9	25	effectiveness	effectiveness	NOUN
fbem-7835	9	26	advantages	advantage	NOUN
fbem-7835	9	27	for	for	ADP
fbem-7835	9	28	relapsed	relapse	VERB
fbem-7835	9	29	/	/	SYM
fbem-7835	9	30	refractory	refractory	NOUN
fbem-7835	9	31	dlbcl	dlbcl	NOUN
fbem-7835	9	32	which	which	PRON
fbem-7835	9	33	is	be	AUX
fbem-7835	9	34	unsuited	unsuited	ADJ
fbem-7835	9	35	for	for	ADP
fbem-7835	9	36	hematopoietic	hematopoietic	ADJ
fbem-7835	9	37	stem	stem	NOUN
fbem-7835	9	38	cell	cell	NOUN
fbem-7835	9	39	transplantation	transplantation	NOUN
fbem-7835	9	40	patients	patient	NOUN
fbem-7835	9	41	.	.	PUNCT
fbem-7835	10	1	keywords	keyword	NOUN
fbem-7835	10	2	:	:	PUNCT
fbem-7835	10	3	polatuzumab	polatuzumab	NOUN
fbem-7835	10	4	vedotin	vedotin	PROPN
fbem-7835	10	5	(	(	PUNCT
fbem-7835	10	6	polivy	polivy	NOUN
fbem-7835	10	7	)	)	PUNCT
fbem-7835	10	8	,	,	PUNCT
fbem-7835	10	9	relapsed	relapse	VERB
fbem-7835	10	10	/	/	SYM
fbem-7835	10	11	refractory	refractory	NOUN
fbem-7835	10	12	diffuse	diffuse	VERB
fbem-7835	10	13	large	large	ADJ
fbem-7835	10	14	b	b	NUM
fbem-7835	10	15	-	-	PUNCT
fbem-7835	10	16	cell	cell	NOUN
fbem-7835	10	17	lymphoma	lymphoma	NOUN
fbem-7835	10	18	,	,	PUNCT
fbem-7835	10	19	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	10	20	analysis	analysis	NOUN
fbem-7835	10	21	.	.	PUNCT
fbem-7835	11	1	1	1	X
fbem-7835	11	2	.	.	X
fbem-7835	11	3	introduction	introduction	NOUN
fbem-7835	11	4	diffuse	diffuse	VERB
fbem-7835	11	5	large	large	ADJ
fbem-7835	11	6	b	b	NOUN
fbem-7835	11	7	-	-	PUNCT
fbem-7835	11	8	cell	cell	NOUN
fbem-7835	11	9	lymphoma	lymphoma	NOUN
fbem-7835	11	10	(	(	PUNCT
fbem-7835	11	11	dlbcl	dlbcl	NOUN
fbem-7835	11	12	)	)	PUNCT
fbem-7835	11	13	is	be	AUX
fbem-7835	11	14	the	the	DET
fbem-7835	11	15	most	most	ADV
fbem-7835	11	16	common	common	ADJ
fbem-7835	11	17	subtype	subtype	NOUN
fbem-7835	11	18	of	of	ADP
fbem-7835	11	19	non	non	ADJ
fbem-7835	11	20	-	-	ADJ
fbem-7835	11	21	hodgkin	hodgkin	ADJ
fbem-7835	11	22	lymphoma	lymphoma	NOUN
fbem-7835	11	23	(	(	PUNCT
fbem-7835	11	24	nhl	nhl	PROPN
fbem-7835	11	25	)	)	PUNCT
fbem-7835	11	26	,	,	PUNCT
fbem-7835	11	27	accounting	account	VERB
fbem-7835	11	28	for	for	ADP
fbem-7835	11	29	35	35	NUM
fbem-7835	11	30	%	%	NOUN
fbem-7835	11	31	-50	-50	PUNCT
fbem-7835	11	32	%	%	NOUN
fbem-7835	11	33	of	of	ADP
fbem-7835	11	34	adult	adult	NOUN
fbem-7835	11	35	nhl	nhl	PROPN
fbem-7835	11	36	in	in	ADP
fbem-7835	11	37	china[1	china[1	NOUN
fbem-7835	11	38	]	]	PUNCT
fbem-7835	11	39	.	.	PUNCT
fbem-7835	12	1	after	after	ADP
fbem-7835	12	2	first	first	ADJ
fbem-7835	12	3	-	-	PUNCT
fbem-7835	12	4	line	line	NOUN
fbem-7835	12	5	treatment	treatment	NOUN
fbem-7835	12	6	,	,	PUNCT
fbem-7835	12	7	about	about	ADV
fbem-7835	12	8	30	30	NUM
fbem-7835	12	9	%	%	NOUN
fbem-7835	12	10	-40	-40	PROPN
fbem-7835	12	11	%	%	NOUN
fbem-7835	12	12	of	of	ADP
fbem-7835	12	13	dlbcl	dlbcl	NOUN
fbem-7835	12	14	patients	patient	NOUN
fbem-7835	12	15	have	have	AUX
fbem-7835	12	16	relapsed	relapse	VERB
fbem-7835	12	17	or	or	CCONJ
fbem-7835	12	18	refractory	refractory	NOUN
fbem-7835	12	19	(	(	PUNCT
fbem-7835	12	20	r	r	NOUN
fbem-7835	12	21	/	/	SYM
fbem-7835	12	22	r	r	NOUN
fbem-7835	12	23	)	)	PUNCT
fbem-7835	12	24	,	,	PUNCT
fbem-7835	12	25	and	and	CCONJ
fbem-7835	12	26	50	50	NUM
fbem-7835	12	27	%	%	NOUN
fbem-7835	12	28	of	of	ADP
fbem-7835	12	29	these	these	DET
fbem-7835	12	30	r	r	NOUN
fbem-7835	12	31	/	/	SYM
fbem-7835	12	32	r	r	NOUN
fbem-7835	12	33	patients	patient	NOUN
fbem-7835	12	34	are	be	AUX
fbem-7835	12	35	not	not	PART
fbem-7835	12	36	suitable	suitable	ADJ
fbem-7835	12	37	for	for	ADP
fbem-7835	12	38	autologous	autologous	ADJ
fbem-7835	12	39	hematopoietic	hematopoietic	ADJ
fbem-7835	12	40	stem	stem	NOUN
fbem-7835	12	41	cell	cell	NOUN
fbem-7835	12	42	transplantation	transplantation	NOUN
fbem-7835	12	43	(	(	PUNCT
fbem-7835	12	44	auto	auto	NOUN
fbem-7835	12	45	-	-	PUNCT
fbem-7835	12	46	hsct	hsct	NOUN
fbem-7835	12	47	)	)	PUNCT
fbem-7835	13	1	[	[	X
fbem-7835	13	2	2][3].therefore	2][3].therefore	NUM
fbem-7835	13	3	,	,	PUNCT
fbem-7835	13	4	the	the	DET
fbem-7835	13	5	prognosis	prognosis	NOUN
fbem-7835	13	6	of	of	ADP
fbem-7835	13	7	these	these	DET
fbem-7835	13	8	patients	patient	NOUN
fbem-7835	13	9	is	be	AUX
fbem-7835	13	10	poor	poor	ADJ
fbem-7835	13	11	,	,	PUNCT
fbem-7835	13	12	and	and	CCONJ
fbem-7835	13	13	their	their	PRON
fbem-7835	13	14	quality	quality	NOUN
fbem-7835	13	15	of	of	ADP
fbem-7835	13	16	life	life	NOUN
fbem-7835	13	17	and	and	CCONJ
fbem-7835	13	18	health	health	NOUN
fbem-7835	13	19	are	be	AUX
fbem-7835	13	20	also	also	ADV
fbem-7835	13	21	greatly	greatly	ADV
fbem-7835	13	22	threatened	threaten	VERB
fbem-7835	13	23	.	.	PUNCT
fbem-7835	14	1	at	at	ADP
fbem-7835	14	2	present	present	ADJ
fbem-7835	14	3	,	,	PUNCT
fbem-7835	14	4	there	there	PRON
fbem-7835	14	5	is	be	VERB
fbem-7835	14	6	no	no	DET
fbem-7835	14	7	unified	unified	ADJ
fbem-7835	14	8	standard	standard	NOUN
fbem-7835	14	9	of	of	ADP
fbem-7835	14	10	care	care	NOUN
fbem-7835	14	11	treatment	treatment	NOUN
fbem-7835	14	12	for	for	ADP
fbem-7835	14	13	r	r	NOUN
fbem-7835	14	14	/	/	SYM
fbem-7835	14	15	r	r	NOUN
fbem-7835	14	16	dlbcl	dlbcl	NOUN
fbem-7835	14	17	.	.	PUNCT
fbem-7835	15	1	the	the	DET
fbem-7835	15	2	main	main	ADJ
fbem-7835	15	3	commonly	commonly	ADV
fbem-7835	15	4	used	use	VERB
fbem-7835	15	5	treatments	treatment	NOUN
fbem-7835	15	6	are	be	AUX
fbem-7835	15	7	rituximab	rituximab	NOUN
fbem-7835	15	8	combined	combine	VERB
fbem-7835	15	9	with	with	ADP
fbem-7835	15	10	gemcitabine	gemcitabine	NOUN
fbem-7835	15	11	and	and	CCONJ
fbem-7835	15	12	oxaliplatin	oxaliplatin	NOUN
fbem-7835	15	13	(	(	PUNCT
fbem-7835	15	14	r	r	NOUN
fbem-7835	15	15	-	-	PUNCT
fbem-7835	15	16	gemox	gemox	NOUN
fbem-7835	15	17	)	)	PUNCT
fbem-7835	15	18	,	,	PUNCT
fbem-7835	15	19	bendamustine	bendamustine	NOUN
fbem-7835	15	20	combined	combine	VERB
fbem-7835	15	21	with	with	ADP
fbem-7835	15	22	rituximab	rituximab	NOUN
fbem-7835	15	23	(	(	PUNCT
fbem-7835	15	24	br	br	PROPN
fbem-7835	15	25	)	)	PUNCT
fbem-7835	15	26	and	and	CCONJ
fbem-7835	15	27	anti	anti	ADJ
fbem-7835	15	28	-	-	ADJ
fbem-7835	15	29	cd19	cd19	ADJ
fbem-7835	15	30	chimeric	chimeric	ADJ
fbem-7835	15	31	antigen	antigen	ADJ
fbem-7835	15	32	receptor	receptor	NOUN
fbem-7835	15	33	t	t	NOUN
fbem-7835	15	34	-	-	PUNCT
fbem-7835	15	35	cell	cell	NOUN
fbem-7835	15	36	(	(	PUNCT
fbem-7835	15	37	car	car	NOUN
fbem-7835	15	38	-	-	PUNCT
fbem-7835	15	39	t	t	NOUN
fbem-7835	15	40	)	)	PUNCT
fbem-7835	15	41	.	.	PUNCT
fbem-7835	16	1	the	the	DET
fbem-7835	16	2	application	application	NOUN
fbem-7835	16	3	of	of	ADP
fbem-7835	16	4	polatuzumab	polatuzumab	NOUN
fbem-7835	16	5	vedotin	vedotin	PROPN
fbem-7835	16	6	(	(	PUNCT
fbem-7835	16	7	trade	trade	NOUN
fbem-7835	16	8	name	name	NOUN
fbem-7835	16	9	“	"	PUNCT
fbem-7835	16	10	youluohua	youluohua	NOUN
fbem-7835	16	11	”	"	PUNCT
fbem-7835	16	12	,	,	PUNCT
fbem-7835	16	13	pola	pola	PROPN
fbem-7835	16	14	)	)	PUNCT
fbem-7835	16	15	may	may	AUX
fbem-7835	16	16	provide	provide	VERB
fbem-7835	16	17	a	a	DET
fbem-7835	16	18	new	new	ADJ
fbem-7835	16	19	clinical	clinical	ADJ
fbem-7835	16	20	treatment	treatment	NOUN
fbem-7835	16	21	option	option	NOUN
fbem-7835	16	22	for	for	ADP
fbem-7835	16	23	patients	patient	NOUN
fbem-7835	16	24	.	.	PUNCT
fbem-7835	17	1	in	in	ADP
fbem-7835	17	2	january	january	PROPN
fbem-7835	17	3	2023	2023	NUM
fbem-7835	17	4	,	,	PUNCT
fbem-7835	17	5	based	base	VERB
fbem-7835	17	6	on	on	ADP
fbem-7835	17	7	a	a	DET
fbem-7835	17	8	multicenter	multicenter	NOUN
fbem-7835	17	9	phase	phase	NOUN
fbem-7835	17	10	ii	ii	NOUN
fbem-7835	17	11	randomized	randomize	VERB
fbem-7835	17	12	controlled	control	VERB
fbem-7835	17	13	trial	trial	NOUN
fbem-7835	17	14	(	(	PUNCT
fbem-7835	17	15	go29365)[4	go29365)[4	PROPN
fbem-7835	17	16	]	]	PUNCT
fbem-7835	17	17	,	,	PUNCT
fbem-7835	17	18	the	the	DET
fbem-7835	17	19	national	national	ADJ
fbem-7835	17	20	medical	medical	PROPN
fbem-7835	17	21	products	product	NOUN
fbem-7835	17	22	administration	administration	PROPN
fbem-7835	17	23	(	(	PUNCT
fbem-7835	17	24	nmpa	nmpa	PROPN
fbem-7835	17	25	)	)	PUNCT
fbem-7835	17	26	approved	approve	VERB
fbem-7835	17	27	the	the	DET
fbem-7835	17	28	listing	listing	NOUN
fbem-7835	17	29	of	of	ADP
fbem-7835	17	30	polatuzumab	polatuzumab	NOUN
fbem-7835	17	31	vedotin	vedotin	ADV
fbem-7835	17	32	(	(	PUNCT
fbem-7835	17	33	“	"	PUNCT
fbem-7835	17	34	youluohua	youluohua	NOUN
fbem-7835	17	35	”	"	PUNCT
fbem-7835	17	36	)	)	PUNCT
fbem-7835	17	37	in	in	ADP
fbem-7835	17	38	china	china	PROPN
fbem-7835	17	39	,	,	PUNCT
fbem-7835	17	40	mainly	mainly	ADV
fbem-7835	17	41	for	for	ADP
fbem-7835	17	42	the	the	DET
fbem-7835	17	43	treatment	treatment	NOUN
fbem-7835	17	44	of	of	ADP
fbem-7835	17	45	diffuse	diffuse	NOUN
fbem-7835	17	46	large	large	ADJ
fbem-7835	17	47	b	b	NOUN
fbem-7835	17	48	-	-	PUNCT
fbem-7835	17	49	cell	cell	NOUN
fbem-7835	17	50	lymphoma	lymphoma	NOUN
fbem-7835	17	51	.	.	PUNCT
fbem-7835	18	1	one	one	NUM
fbem-7835	18	2	of	of	ADP
fbem-7835	18	3	its	its	PRON
fbem-7835	18	4	approved	approve	VERB
fbem-7835	18	5	indications	indication	NOUN
fbem-7835	18	6	is	be	AUX
fbem-7835	18	7	the	the	DET
fbem-7835	18	8	combination	combination	NOUN
fbem-7835	18	9	of	of	ADP
fbem-7835	18	10	br	br	NOUN
fbem-7835	18	11	to	to	PART
fbem-7835	18	12	treat	treat	VERB
fbem-7835	18	13	r	r	NOUN
fbem-7835	18	14	/	/	SYM
fbem-7835	18	15	r	r	NOUN
fbem-7835	18	16	dlbcl	dlbcl	NOUN
fbem-7835	18	17	patients	patient	NOUN
fbem-7835	18	18	who	who	PRON
fbem-7835	18	19	are	be	AUX
fbem-7835	18	20	not	not	PART
fbem-7835	18	21	suitable	suitable	ADJ
fbem-7835	18	22	for	for	ADP
fbem-7835	18	23	hematopoietic	hematopoietic	ADJ
fbem-7835	18	24	stem	stem	NOUN
fbem-7835	18	25	cell	cell	NOUN
fbem-7835	18	26	transplantation	transplantation	NOUN
fbem-7835	18	27	.	.	PUNCT
fbem-7835	19	1	this	this	DET
fbem-7835	19	2	clinical	clinical	ADJ
fbem-7835	19	3	trial	trial	NOUN
fbem-7835	19	4	showed	show	VERB
fbem-7835	19	5	that	that	SCONJ
fbem-7835	19	6	polatuzumab	polatuzumab	NOUN
fbem-7835	19	7	vedotin	vedotin	ADV
fbem-7835	19	8	combined	combine	VERB
fbem-7835	19	9	with	with	ADP
fbem-7835	19	10	br	br	NOUN
fbem-7835	19	11	can	can	AUX
fbem-7835	19	12	significantly	significantly	ADV
fbem-7835	19	13	improve	improve	VERB
fbem-7835	19	14	the	the	DET
fbem-7835	19	15	survival	survival	NOUN
fbem-7835	19	16	benefit	benefit	NOUN
fbem-7835	19	17	of	of	ADP
fbem-7835	19	18	r	r	NOUN
fbem-7835	19	19	/	/	SYM
fbem-7835	19	20	r	r	NOUN
fbem-7835	19	21	dlbcl	dlbcl	NOUN
fbem-7835	19	22	patients	patient	NOUN
fbem-7835	19	23	compared	compare	VERB
fbem-7835	19	24	with	with	ADP
fbem-7835	19	25	br	br	NOUN
fbem-7835	19	26	alone	alone	ADV
fbem-7835	19	27	.	.	PUNCT
fbem-7835	20	1	the	the	DET
fbem-7835	20	2	median	median	ADJ
fbem-7835	20	3	overall	overall	ADJ
fbem-7835	20	4	survival	survival	NOUN
fbem-7835	20	5	(	(	PUNCT
fbem-7835	20	6	os	os	NOUN
fbem-7835	20	7	)	)	PUNCT
fbem-7835	20	8	was	be	AUX
fbem-7835	20	9	extended	extend	VERB
fbem-7835	20	10	from	from	ADP
fbem-7835	20	11	4.7	4.7	NUM
fbem-7835	20	12	months	month	NOUN
fbem-7835	20	13	to	to	ADP
fbem-7835	20	14	12.4	12.4	NUM
fbem-7835	20	15	months	month	NOUN
fbem-7835	20	16	,	,	PUNCT
fbem-7835	20	17	the	the	DET
fbem-7835	20	18	median	median	ADJ
fbem-7835	20	19	progression	progression	NOUN
fbem-7835	20	20	-	-	PUNCT
fbem-7835	20	21	free	free	ADJ
fbem-7835	20	22	survival	survival	NOUN
fbem-7835	20	23	(	(	PUNCT
fbem-7835	20	24	pfs	pfs	PROPN
fbem-7835	20	25	)	)	PUNCT
fbem-7835	20	26	was	be	AUX
fbem-7835	20	27	extended	extend	VERB
fbem-7835	20	28	from	from	ADP
fbem-7835	20	29	2	2	NUM
fbem-7835	20	30	months	month	NOUN
fbem-7835	20	31	to	to	ADP
fbem-7835	20	32	7.5	7.5	NUM
fbem-7835	20	33	months	month	NOUN
fbem-7835	20	34	,	,	PUNCT
fbem-7835	20	35	and	and	CCONJ
fbem-7835	20	36	the	the	DET
fbem-7835	20	37	objective	objective	ADJ
fbem-7835	20	38	response	response	NOUN
fbem-7835	20	39	rate	rate	NOUN
fbem-7835	20	40	(	(	PUNCT
fbem-7835	20	41	orr	orr	PROPN
fbem-7835	20	42	)	)	PUNCT
fbem-7835	20	43	was	be	AUX
fbem-7835	20	44	increased	increase	VERB
fbem-7835	20	45	from	from	ADP
fbem-7835	20	46	25	25	NUM
fbem-7835	20	47	%	%	NOUN
fbem-7835	20	48	to	to	ADP
fbem-7835	20	49	62.5	62.5	NUM
fbem-7835	20	50	%	%	NOUN
fbem-7835	20	51	.	.	PUNCT
fbem-7835	21	1	in	in	ADP
fbem-7835	21	2	terms	term	NOUN
fbem-7835	21	3	of	of	ADP
fbem-7835	21	4	safety	safety	NOUN
fbem-7835	21	5	,	,	PUNCT
fbem-7835	21	6	both	both	DET
fbem-7835	21	7	groups	group	NOUN
fbem-7835	21	8	exposed	expose	VERB
fbem-7835	21	9	similar	similar	ADJ
fbem-7835	21	10	adverse	adverse	ADJ
fbem-7835	21	11	reactions	reaction	NOUN
fbem-7835	21	12	and	and	CCONJ
fbem-7835	21	13	the	the	DET
fbem-7835	21	14	incidence	incidence	NOUN
fbem-7835	21	15	of	of	ADP
fbem-7835	21	16	adverse	adverse	ADJ
fbem-7835	21	17	event	event	NOUN
fbem-7835	21	18	above	above	ADP
fbem-7835	21	19	grade	grade	NOUN
fbem-7835	21	20	3	3	NUM
fbem-7835	21	21	was	be	AUX
fbem-7835	21	22	similar[4	similar[4	NOUN
fbem-7835	21	23	]	]	PUNCT
fbem-7835	21	24	.	.	PUNCT
fbem-7835	22	1	although	although	SCONJ
fbem-7835	22	2	the	the	DET
fbem-7835	22	3	clinical	clinical	ADJ
fbem-7835	22	4	effect	effect	NOUN
fbem-7835	22	5	of	of	ADP
fbem-7835	22	6	polatuzumab	polatuzumab	NOUN
fbem-7835	22	7	vedotin	vedotin	PROPN
fbem-7835	22	8	has	have	AUX
fbem-7835	22	9	been	be	AUX
fbem-7835	22	10	proved	prove	VERB
fbem-7835	22	11	,	,	PUNCT
fbem-7835	22	12	there	there	PRON
fbem-7835	22	13	is	be	VERB
fbem-7835	22	14	no	no	DET
fbem-7835	22	15	study	study	NOUN
fbem-7835	22	16	in	in	ADP
fbem-7835	22	17	china	china	PROPN
fbem-7835	22	18	to	to	PART
fbem-7835	22	19	evaluate	evaluate	VERB
fbem-7835	22	20	the	the	DET
fbem-7835	22	21	economy	economy	NOUN
fbem-7835	22	22	of	of	ADP
fbem-7835	22	23	polatuzumab	polatuzumab	NOUN
fbem-7835	22	24	vedotin	vedotin	ADV
fbem-7835	22	25	combined	combine	VERB
fbem-7835	22	26	with	with	ADP
fbem-7835	22	27	br	br	NOUN
fbem-7835	22	28	regimen	regiman	NOUN
fbem-7835	22	29	and	and	CCONJ
fbem-7835	22	30	br	br	NOUN
fbem-7835	22	31	regimen	regiman	NOUN
fbem-7835	22	32	alone	alone	ADV
fbem-7835	22	33	in	in	ADP
fbem-7835	22	34	the	the	DET
fbem-7835	22	35	treatment	treatment	NOUN
fbem-7835	22	36	of	of	ADP
fbem-7835	22	37	r	r	NOUN
fbem-7835	22	38	/	/	SYM
fbem-7835	22	39	r	r	NOUN
fbem-7835	22	40	dlbcl	dlbcl	NOUN
fbem-7835	22	41	.	.	PUNCT
fbem-7835	23	1	therefore	therefore	ADV
fbem-7835	23	2	,	,	PUNCT
fbem-7835	23	3	based	base	VERB
fbem-7835	23	4	on	on	ADP
fbem-7835	23	5	the	the	DET
fbem-7835	23	6	cost	cost	NOUN
fbem-7835	23	7	environment	environment	NOUN
fbem-7835	23	8	in	in	ADP
fbem-7835	23	9	china	china	PROPN
fbem-7835	23	10	,	,	PUNCT
fbem-7835	23	11	this	this	DET
fbem-7835	23	12	study	study	NOUN
fbem-7835	23	13	intends	intend	VERB
fbem-7835	23	14	to	to	PART
fbem-7835	23	15	analyze	analyze	VERB
fbem-7835	23	16	the	the	DET
fbem-7835	23	17	costutility	costutility	NOUN
fbem-7835	23	18	of	of	ADP
fbem-7835	23	19	polatuzumab	polatuzumab	NOUN
fbem-7835	23	20	vedotin	vedotin	ADV
fbem-7835	23	21	combined	combine	VERB
fbem-7835	23	22	with	with	ADP
fbem-7835	23	23	br	br	PROPN
fbem-7835	23	24	regimen	regimen	PROPN
fbem-7835	23	25	(	(	PUNCT
fbem-7835	23	26	pola_br	pola_br	NOUN
fbem-7835	23	27	)	)	PUNCT
fbem-7835	23	28	in	in	ADP
fbem-7835	23	29	the	the	DET
fbem-7835	23	30	treatment	treatment	NOUN
fbem-7835	23	31	of	of	ADP
fbem-7835	23	32	r	r	NOUN
fbem-7835	23	33	/	/	SYM
fbem-7835	23	34	r	r	NOUN
fbem-7835	23	35	dlbcl	dlbcl	NOUN
fbem-7835	23	36	which	which	PRON
fbem-7835	23	37	is	be	AUX
fbem-7835	23	38	not	not	PART
fbem-7835	23	39	suitable	suitable	ADJ
fbem-7835	23	40	for	for	ADP
fbem-7835	23	41	hematopoietic	hematopoietic	ADJ
fbem-7835	23	42	stem	stem	NOUN
fbem-7835	23	43	cell	cell	NOUN
fbem-7835	23	44	transplantation	transplantation	NOUN
fbem-7835	23	45	from	from	ADP
fbem-7835	23	46	the	the	DET
fbem-7835	23	47	perspective	perspective	NOUN
fbem-7835	23	48	of	of	ADP
fbem-7835	23	49	medical	medical	ADJ
fbem-7835	23	50	and	and	CCONJ
fbem-7835	23	51	health	health	NOUN
fbem-7835	23	52	system	system	NOUN
fbem-7835	23	53	in	in	ADP
fbem-7835	23	54	china	china	PROPN
fbem-7835	23	55	,	,	PUNCT
fbem-7835	23	56	so	so	SCONJ
fbem-7835	23	57	as	as	SCONJ
fbem-7835	23	58	to	to	PART
fbem-7835	23	59	provide	provide	VERB
fbem-7835	23	60	a	a	DET
fbem-7835	23	61	basis	basis	NOUN
fbem-7835	23	62	for	for	ADP
fbem-7835	23	63	clinicians	clinician	NOUN
fbem-7835	23	64	to	to	PART
fbem-7835	23	65	use	use	VERB
fbem-7835	23	66	drugs	drug	NOUN
fbem-7835	23	67	rationally	rationally	ADV
fbem-7835	23	68	and	and	CCONJ
fbem-7835	23	69	provide	provide	VERB
fbem-7835	23	70	reference	reference	NOUN
fbem-7835	23	71	for	for	ADP
fbem-7835	23	72	medical	medical	ADJ
fbem-7835	23	73	insurance	insurance	NOUN
fbem-7835	23	74	and	and	CCONJ
fbem-7835	23	75	health	health	NOUN
fbem-7835	23	76	-	-	PUNCT
fbem-7835	23	77	related	relate	VERB
fbem-7835	23	78	policy	policy	NOUN
fbem-7835	23	79	formulation	formulation	NOUN
fbem-7835	23	80	.	.	PUNCT
fbem-7835	24	1	2	2	X
fbem-7835	24	2	.	.	X
fbem-7835	24	3	material	material	NOUN
fbem-7835	24	4	and	and	CCONJ
fbem-7835	24	5	method	method	VERB
fbem-7835	24	6	2.1	2.1	NUM
fbem-7835	24	7	.	.	PUNCT
fbem-7835	25	1	material	material	NOUN
fbem-7835	25	2	this	this	DET
fbem-7835	25	3	study	study	NOUN
fbem-7835	25	4	uses	use	VERB
fbem-7835	25	5	the	the	DET
fbem-7835	25	6	perspective	perspective	NOUN
fbem-7835	25	7	of	of	ADP
fbem-7835	25	8	the	the	DET
fbem-7835	25	9	china	china	PROPN
fbem-7835	25	10	’s	’s	PART
fbem-7835	25	11	health	health	NOUN
fbem-7835	25	12	system	system	NOUN
fbem-7835	25	13	,	,	PUNCT
fbem-7835	25	14	which	which	PRON
fbem-7835	25	15	is	be	AUX
fbem-7835	25	16	from	from	ADP
fbem-7835	25	17	the	the	DET
fbem-7835	25	18	standpoint	standpoint	NOUN
fbem-7835	25	19	of	of	ADP
fbem-7835	25	20	health	health	NOUN
fbem-7835	25	21	system	system	NOUN
fbem-7835	25	22	decision	decision	NOUN
fbem-7835	25	23	makers	maker	NOUN
fbem-7835	25	24	,	,	PUNCT
fbem-7835	25	25	considering	consider	VERB
fbem-7835	25	26	the	the	DET
fbem-7835	25	27	consumption	consumption	NOUN
fbem-7835	25	28	of	of	ADP
fbem-7835	25	29	health	health	NOUN
fbem-7835	25	30	resources	resource	NOUN
fbem-7835	25	31	caused	cause	VERB
fbem-7835	25	32	by	by	ADP
fbem-7835	25	33	intervention	intervention	NOUN
fbem-7835	25	34	measure	measure	NOUN
fbem-7835	25	35	and	and	CCONJ
fbem-7835	25	36	control	control	NOUN
fbem-7835	25	37	measure	measure	NOUN
fbem-7835	25	38	and	and	CCONJ
fbem-7835	25	39	the	the	DET
fbem-7835	25	40	benefits	benefit	NOUN
fbem-7835	25	41	to	to	ADP
fbem-7835	25	42	patients	patient	NOUN
fbem-7835	25	43	in	in	ADP
fbem-7835	25	44	the	the	DET
fbem-7835	25	45	medical	medical	ADJ
fbem-7835	25	46	system	system	NOUN
fbem-7835	25	47	.	.	PUNCT
fbem-7835	26	1	therefore	therefore	ADV
fbem-7835	26	2	,	,	PUNCT
fbem-7835	26	3	costs	cost	NOUN
fbem-7835	26	4	only	only	ADV
fbem-7835	26	5	consider	consider	VERB
fbem-7835	26	6	direct	direct	ADJ
fbem-7835	26	7	medical	medical	ADJ
fbem-7835	26	8	costs	cost	NOUN
fbem-7835	26	9	,	,	PUNCT
fbem-7835	26	10	excluding	exclude	VERB
fbem-7835	26	11	direct	direct	ADJ
fbem-7835	26	12	non	non	ADJ
fbem-7835	26	13	-	-	ADJ
fbem-7835	26	14	medical	medical	ADJ
fbem-7835	26	15	costs	cost	NOUN
fbem-7835	26	16	,	,	PUNCT
fbem-7835	26	17	indirect	indirect	ADJ
fbem-7835	26	18	costs	cost	NOUN
fbem-7835	26	19	and	and	CCONJ
fbem-7835	26	20	hidden	hide	VERB
fbem-7835	26	21	costs[5	costs[5	NOUN
fbem-7835	26	22	]	]	PUNCT
fbem-7835	26	23	.	.	PUNCT
fbem-7835	27	1	the	the	DET
fbem-7835	27	2	target	target	NOUN
fbem-7835	27	3	population	population	NOUN
fbem-7835	27	4	was	be	AUX
fbem-7835	27	5	adult	adult	NOUN
fbem-7835	27	6	r	r	NOUN
fbem-7835	27	7	/	/	SYM
fbem-7835	27	8	r	r	NOUN
fbem-7835	27	9	dlbcl	dlbcl	NOUN
fbem-7835	27	10	patients	patient	NOUN
fbem-7835	27	11	who	who	PRON
fbem-7835	27	12	were	be	AUX
fbem-7835	27	13	not	not	PART
fbem-7835	27	14	suitable	suitable	ADJ
fbem-7835	27	15	for	for	ADP
fbem-7835	27	16	hematopoietic	hematopoietic	ADJ
fbem-7835	27	17	stem	stem	NOUN
fbem-7835	27	18	cell	cell	NOUN
fbem-7835	27	19	transplantation	transplantation	NOUN
fbem-7835	27	20	in	in	ADP
fbem-7835	27	21	china	china	PROPN
fbem-7835	27	22	.	.	PUNCT
fbem-7835	28	1	the	the	DET
fbem-7835	28	2	economics	economic	NOUN
fbem-7835	28	3	of	of	ADP
fbem-7835	28	4	polatuzumab	polatuzumab	NOUN
fbem-7835	28	5	vedotin	vedotin	ADV
fbem-7835	28	6	combined	combine	VERB
fbem-7835	28	7	with	with	ADP
fbem-7835	28	8	br	br	PROPN
fbem-7835	28	9	regimen	regimen	PROPN
fbem-7835	28	10	(	(	PUNCT
fbem-7835	28	11	pola_br	pola_br	NOUN
fbem-7835	28	12	)	)	PUNCT
fbem-7835	28	13	and	and	CCONJ
fbem-7835	28	14	br	br	NOUN
fbem-7835	28	15	regimen	regiman	NOUN
fbem-7835	28	16	alone	alone	ADV
fbem-7835	28	17	were	be	AUX
fbem-7835	28	18	compared	compare	VERB
fbem-7835	28	19	.	.	PUNCT
fbem-7835	29	1	179	179	NUM
fbem-7835	29	2	2.2	2.2	NUM
fbem-7835	29	3	.	.	PUNCT
fbem-7835	30	1	method	method	PROPN
fbem-7835	30	2	2.2.1	2.2.1	NUM
fbem-7835	30	3	.	.	PUNCT
fbem-7835	30	4	research	research	NOUN
fbem-7835	30	5	design	design	NOUN
fbem-7835	30	6	in	in	ADP
fbem-7835	30	7	this	this	DET
fbem-7835	30	8	study	study	NOUN
fbem-7835	30	9	,	,	PUNCT
fbem-7835	30	10	the	the	DET
fbem-7835	30	11	partitioned	partition	VERB
fbem-7835	30	12	survival	survival	NOUN
fbem-7835	30	13	model	model	NOUN
fbem-7835	30	14	was	be	AUX
fbem-7835	30	15	used	use	VERB
fbem-7835	30	16	to	to	PART
fbem-7835	30	17	simulate	simulate	VERB
fbem-7835	30	18	the	the	DET
fbem-7835	30	19	proportion	proportion	NOUN
fbem-7835	30	20	of	of	ADP
fbem-7835	30	21	patients	patient	NOUN
fbem-7835	30	22	in	in	ADP
fbem-7835	30	23	each	each	DET
fbem-7835	30	24	cycle	cycle	NOUN
fbem-7835	30	25	under	under	ADP
fbem-7835	30	26	different	different	ADJ
fbem-7835	30	27	health	health	NOUN
fbem-7835	30	28	states	state	NOUN
fbem-7835	30	29	through	through	ADP
fbem-7835	30	30	the	the	DET
fbem-7835	30	31	overall	overall	ADJ
fbem-7835	30	32	survival	survival	NOUN
fbem-7835	30	33	(	(	PUNCT
fbem-7835	30	34	os	os	NOUN
fbem-7835	30	35	)	)	PUNCT
fbem-7835	30	36	curve	curve	NOUN
fbem-7835	30	37	and	and	CCONJ
fbem-7835	30	38	progression	progression	NOUN
fbem-7835	30	39	free	free	ADJ
fbem-7835	30	40	survival	survival	NOUN
fbem-7835	30	41	(	(	PUNCT
fbem-7835	30	42	pfs	pfs	PROPN
fbem-7835	30	43	)	)	PUNCT
fbem-7835	30	44	survival	survival	NOUN
fbem-7835	30	45	curve	curve	NOUN
fbem-7835	30	46	of	of	ADP
fbem-7835	30	47	the	the	DET
fbem-7835	30	48	study	study	NOUN
fbem-7835	30	49	group	group	NOUN
fbem-7835	30	50	and	and	CCONJ
fbem-7835	30	51	the	the	DET
fbem-7835	30	52	control	control	NOUN
fbem-7835	30	53	group	group	NOUN
fbem-7835	30	54	,	,	PUNCT
fbem-7835	30	55	and	and	CCONJ
fbem-7835	30	56	the	the	DET
fbem-7835	30	57	partitioned	partition	VERB
fbem-7835	30	58	survival	survival	NOUN
fbem-7835	30	59	model	model	NOUN
fbem-7835	30	60	was	be	AUX
fbem-7835	30	61	built	build	VERB
fbem-7835	30	62	by	by	ADP
fbem-7835	30	63	using	use	VERB
fbem-7835	30	64	excel	excel	NOUN
fbem-7835	30	65	software	software	NOUN
fbem-7835	30	66	.	.	PUNCT
fbem-7835	31	1	the	the	DET
fbem-7835	31	2	quality	quality	NOUN
fbem-7835	31	3	-	-	PUNCT
fbem-7835	31	4	adjusted	adjust	VERB
fbem-7835	31	5	life	life	NOUN
fbem-7835	31	6	years	year	NOUN
fbem-7835	31	7	(	(	PUNCT
fbem-7835	31	8	qalys	qaly	NOUN
fbem-7835	31	9	)	)	PUNCT
fbem-7835	31	10	and	and	CCONJ
fbem-7835	31	11	treatment	treatment	NOUN
fbem-7835	31	12	costs	cost	NOUN
fbem-7835	31	13	of	of	ADP
fbem-7835	31	14	polatuzumab	polatuzumab	NOUN
fbem-7835	31	15	vedotin	vedotin	ADV
fbem-7835	31	16	combined	combine	VERB
fbem-7835	31	17	with	with	ADP
fbem-7835	31	18	br	br	NOUN
fbem-7835	31	19	regimen	regiman	NOUN
fbem-7835	31	20	and	and	CCONJ
fbem-7835	31	21	br	br	NOUN
fbem-7835	31	22	regimen	regiman	NOUN
fbem-7835	31	23	alone	alone	ADV
fbem-7835	31	24	were	be	AUX
fbem-7835	31	25	compared	compare	VERB
fbem-7835	31	26	,	,	PUNCT
fbem-7835	31	27	and	and	CCONJ
fbem-7835	31	28	the	the	DET
fbem-7835	31	29	incremental	incremental	ADJ
fbem-7835	31	30	costutility	costutility	NOUN
fbem-7835	31	31	ratio	ratio	NOUN
fbem-7835	31	32	(	(	PUNCT
fbem-7835	31	33	icur	icur	NOUN
fbem-7835	31	34	)	)	PUNCT
fbem-7835	31	35	index	index	NOUN
fbem-7835	31	36	was	be	AUX
fbem-7835	31	37	calculated	calculate	VERB
fbem-7835	31	38	.	.	PUNCT
fbem-7835	32	1	the	the	DET
fbem-7835	32	2	sensitivity	sensitivity	NOUN
fbem-7835	32	3	analysis	analysis	NOUN
fbem-7835	32	4	of	of	ADP
fbem-7835	32	5	this	this	DET
fbem-7835	32	6	study	study	NOUN
fbem-7835	32	7	includes	include	VERB
fbem-7835	32	8	one	one	NUM
fbem-7835	32	9	-	-	PUNCT
fbem-7835	32	10	way	way	NOUN
fbem-7835	32	11	sensitivity	sensitivity	NOUN
fbem-7835	32	12	analysis	analysis	NOUN
fbem-7835	32	13	and	and	CCONJ
fbem-7835	32	14	probability	probability	NOUN
fbem-7835	32	15	sensitivity	sensitivity	NOUN
fbem-7835	32	16	analysis	analysis	NOUN
fbem-7835	32	17	.	.	PUNCT
fbem-7835	33	1	the	the	DET
fbem-7835	33	2	one	one	NUM
fbem-7835	33	3	-	-	PUNCT
fbem-7835	33	4	way	way	NOUN
fbem-7835	33	5	sensitivity	sensitivity	NOUN
fbem-7835	33	6	analysis	analysis	NOUN
fbem-7835	33	7	reflects	reflect	VERB
fbem-7835	33	8	the	the	DET
fbem-7835	33	9	influence	influence	NOUN
fbem-7835	33	10	of	of	ADP
fbem-7835	33	11	single	single	ADJ
fbem-7835	33	12	uncertainty	uncertainty	NOUN
fbem-7835	33	13	factor	factor	NOUN
fbem-7835	33	14	on	on	ADP
fbem-7835	33	15	the	the	DET
fbem-7835	33	16	results	result	NOUN
fbem-7835	33	17	through	through	ADP
fbem-7835	33	18	the	the	DET
fbem-7835	33	19	tornado	tornado	NOUN
fbem-7835	33	20	diagram	diagram	NOUN
fbem-7835	33	21	.	.	PUNCT
fbem-7835	34	1	the	the	DET
fbem-7835	34	2	specific	specific	ADJ
fbem-7835	34	3	parameters	parameter	NOUN
fbem-7835	34	4	and	and	CCONJ
fbem-7835	34	5	variation	variation	NOUN
fbem-7835	34	6	range	range	NOUN
fbem-7835	34	7	are	be	AUX
fbem-7835	34	8	shown	show	VERB
fbem-7835	34	9	in	in	ADP
fbem-7835	34	10	table	table	NOUN
fbem-7835	34	11	2	2	NUM
fbem-7835	34	12	.	.	PUNCT
fbem-7835	34	13	among	among	ADP
fbem-7835	34	14	them	they	PRON
fbem-7835	34	15	,	,	PUNCT
fbem-7835	34	16	for	for	ADP
fbem-7835	34	17	some	some	DET
fbem-7835	34	18	parameters	parameter	NOUN
fbem-7835	34	19	that	that	PRON
fbem-7835	34	20	can	can	AUX
fbem-7835	34	21	not	not	PART
fbem-7835	34	22	obtain	obtain	VERB
fbem-7835	34	23	the	the	DET
fbem-7835	34	24	upper	upper	ADJ
fbem-7835	34	25	and	and	CCONJ
fbem-7835	34	26	lower	low	ADJ
fbem-7835	34	27	limits	limit	NOUN
fbem-7835	34	28	,	,	PUNCT
fbem-7835	34	29	such	such	ADJ
fbem-7835	34	30	as	as	ADP
fbem-7835	34	31	utility	utility	NOUN
fbem-7835	34	32	value	value	NOUN
fbem-7835	34	33	,	,	PUNCT
fbem-7835	34	34	incidence	incidence	NOUN
fbem-7835	34	35	of	of	ADP
fbem-7835	34	36	adverse	adverse	ADJ
fbem-7835	34	37	events	event	NOUN
fbem-7835	34	38	,	,	PUNCT
fbem-7835	34	39	etc	etc	X
fbem-7835	34	40	.	.	X
fbem-7835	34	41	,	,	PUNCT
fbem-7835	34	42	±	±	NUM
fbem-7835	34	43	20	20	NUM
fbem-7835	34	44	%	%	NOUN
fbem-7835	34	45	of	of	ADP
fbem-7835	34	46	the	the	DET
fbem-7835	34	47	baseline	baseline	NOUN
fbem-7835	34	48	value	value	NOUN
fbem-7835	34	49	is	be	AUX
fbem-7835	34	50	taken	take	VERB
fbem-7835	34	51	as	as	ADP
fbem-7835	34	52	the	the	DET
fbem-7835	34	53	upper	upper	ADJ
fbem-7835	34	54	and	and	CCONJ
fbem-7835	34	55	lower	low	ADJ
fbem-7835	34	56	limits	limit	NOUN
fbem-7835	34	57	;	;	PUNCT
fbem-7835	34	58	probabilistic	probabilistic	ADJ
fbem-7835	34	59	sensitivity	sensitivity	NOUN
fbem-7835	34	60	analysis	analysis	NOUN
fbem-7835	34	61	can	can	AUX
fbem-7835	34	62	simulate	simulate	VERB
fbem-7835	34	63	the	the	DET
fbem-7835	34	64	comprehensive	comprehensive	ADJ
fbem-7835	34	65	influence	influence	NOUN
fbem-7835	34	66	of	of	ADP
fbem-7835	34	67	the	the	DET
fbem-7835	34	68	uncertainty	uncertainty	NOUN
fbem-7835	34	69	of	of	ADP
fbem-7835	34	70	all	all	DET
fbem-7835	34	71	parameters	parameter	NOUN
fbem-7835	34	72	in	in	ADP
fbem-7835	34	73	the	the	DET
fbem-7835	34	74	model	model	NOUN
fbem-7835	34	75	on	on	ADP
fbem-7835	34	76	the	the	DET
fbem-7835	34	77	results	result	NOUN
fbem-7835	34	78	.	.	PUNCT
fbem-7835	35	1	it	it	PRON
fbem-7835	35	2	is	be	AUX
fbem-7835	35	3	assumed	assume	VERB
fbem-7835	35	4	that	that	SCONJ
fbem-7835	35	5	the	the	DET
fbem-7835	35	6	cost	cost	NOUN
fbem-7835	35	7	parameter	parameter	NOUN
fbem-7835	35	8	in	in	ADP
fbem-7835	35	9	the	the	DET
fbem-7835	35	10	model	model	NOUN
fbem-7835	35	11	obeys	obey	VERB
fbem-7835	35	12	the	the	DET
fbem-7835	35	13	gamma	gamma	NOUN
fbem-7835	35	14	distribution	distribution	NOUN
fbem-7835	35	15	,	,	PUNCT
fbem-7835	35	16	the	the	DET
fbem-7835	35	17	utility	utility	NOUN
fbem-7835	35	18	value	value	NOUN
fbem-7835	35	19	obeys	obey	VERB
fbem-7835	35	20	the	the	DET
fbem-7835	35	21	beta	beta	ADJ
fbem-7835	35	22	distribution	distribution	NOUN
fbem-7835	35	23	,	,	PUNCT
fbem-7835	35	24	and	and	CCONJ
fbem-7835	35	25	the	the	DET
fbem-7835	35	26	fitting	fitting	ADJ
fbem-7835	35	27	distribution	distribution	NOUN
fbem-7835	35	28	parameters	parameter	NOUN
fbem-7835	35	29	of	of	ADP
fbem-7835	35	30	the	the	DET
fbem-7835	35	31	survival	survival	NOUN
fbem-7835	35	32	function	function	NOUN
fbem-7835	35	33	are	be	AUX
fbem-7835	35	34	corrected	correct	VERB
fbem-7835	35	35	by	by	ADP
fbem-7835	35	36	the	the	DET
fbem-7835	35	37	cholesky	cholesky	ADJ
fbem-7835	35	38	decomposition	decomposition	NOUN
fbem-7835	35	39	method[6	method[6	NOUN
fbem-7835	35	40	]	]	PUNCT
fbem-7835	35	41	.	.	PUNCT
fbem-7835	36	1	and	and	CCONJ
fbem-7835	36	2	through	through	ADP
fbem-7835	36	3	monte	monte	PROPN
fbem-7835	36	4	carlo	carlo	PROPN
fbem-7835	36	5	simulation	simulation	PROPN
fbem-7835	36	6	,	,	PUNCT
fbem-7835	36	7	repeated	repeat	VERB
fbem-7835	36	8	sampling	sample	VERB
fbem-7835	36	9	1	1	NUM
fbem-7835	36	10	000	000	NUM
fbem-7835	36	11	times	time	NOUN
fbem-7835	36	12	,	,	PUNCT
fbem-7835	36	13	the	the	DET
fbem-7835	36	14	simulation	simulation	NOUN
fbem-7835	36	15	results	result	NOUN
fbem-7835	36	16	are	be	AUX
fbem-7835	36	17	presented	present	VERB
fbem-7835	36	18	as	as	ADP
fbem-7835	36	19	cost	cost	NOUN
fbem-7835	36	20	-	-	PUNCT
fbem-7835	36	21	utility	utility	NOUN
fbem-7835	36	22	scatter	scatter	NOUN
fbem-7835	36	23	plot	plot	NOUN
fbem-7835	36	24	and	and	CCONJ
fbem-7835	36	25	cost	cost	NOUN
fbem-7835	36	26	-	-	PUNCT
fbem-7835	36	27	utility	utility	NOUN
fbem-7835	36	28	acceptable	acceptable	ADJ
fbem-7835	36	29	curve	curve	NOUN
fbem-7835	36	30	.	.	PUNCT
fbem-7835	37	1	2.2.2	2.2.2	X
fbem-7835	37	2	.	.	PUNCT
fbem-7835	37	3	model	model	NOUN
fbem-7835	37	4	structure	structure	NOUN
fbem-7835	37	5	the	the	DET
fbem-7835	37	6	model	model	NOUN
fbem-7835	37	7	includes	include	VERB
fbem-7835	37	8	three	three	NUM
fbem-7835	37	9	states	state	NOUN
fbem-7835	37	10	:	:	PUNCT
fbem-7835	37	11	progression	progression	NOUN
fbem-7835	37	12	free	free	ADJ
fbem-7835	37	13	survival	survival	NOUN
fbem-7835	37	14	(	(	PUNCT
fbem-7835	37	15	pfs	pfs	PROPN
fbem-7835	37	16	)	)	PUNCT
fbem-7835	37	17	,	,	PUNCT
fbem-7835	37	18	progression	progression	NOUN
fbem-7835	37	19	disease	disease	NOUN
fbem-7835	37	20	(	(	PUNCT
fbem-7835	37	21	pd	pd	NOUN
fbem-7835	37	22	)	)	PUNCT
fbem-7835	37	23	and	and	CCONJ
fbem-7835	37	24	death	death	NOUN
fbem-7835	37	25	(	(	PUNCT
fbem-7835	37	26	d	d	NOUN
fbem-7835	37	27	)	)	PUNCT
fbem-7835	37	28	.	.	PUNCT
fbem-7835	38	1	in	in	ADP
fbem-7835	38	2	each	each	DET
fbem-7835	38	3	cycle	cycle	NOUN
fbem-7835	38	4	,	,	PUNCT
fbem-7835	38	5	the	the	DET
fbem-7835	38	6	proportion	proportion	NOUN
fbem-7835	38	7	of	of	ADP
fbem-7835	38	8	patients	patient	NOUN
fbem-7835	38	9	with	with	ADP
fbem-7835	38	10	pfs	pfs	PROPN
fbem-7835	38	11	states	state	NOUN
fbem-7835	38	12	was	be	AUX
fbem-7835	38	13	determined	determine	VERB
fbem-7835	38	14	by	by	ADP
fbem-7835	38	15	the	the	DET
fbem-7835	38	16	area	area	NOUN
fbem-7835	38	17	under	under	ADP
fbem-7835	38	18	the	the	DET
fbem-7835	38	19	pfs	pfs	PROPN
fbem-7835	38	20	curve	curve	NOUN
fbem-7835	38	21	of	of	ADP
fbem-7835	38	22	the	the	DET
fbem-7835	38	23	corresponding	corresponding	ADJ
fbem-7835	38	24	time	time	NOUN
fbem-7835	38	25	,	,	PUNCT
fbem-7835	38	26	the	the	DET
fbem-7835	38	27	proportion	proportion	NOUN
fbem-7835	38	28	of	of	ADP
fbem-7835	38	29	patients	patient	NOUN
fbem-7835	38	30	with	with	ADP
fbem-7835	38	31	pd	pd	PROPN
fbem-7835	38	32	states	state	NOUN
fbem-7835	38	33	was	be	AUX
fbem-7835	38	34	obtained	obtain	VERB
fbem-7835	38	35	by	by	ADP
fbem-7835	38	36	subtracting	subtract	VERB
fbem-7835	38	37	the	the	DET
fbem-7835	38	38	area	area	NOUN
fbem-7835	38	39	under	under	ADP
fbem-7835	38	40	the	the	DET
fbem-7835	38	41	pfs	pfs	PROPN
fbem-7835	38	42	curve	curve	NOUN
fbem-7835	38	43	from	from	ADP
fbem-7835	38	44	the	the	DET
fbem-7835	38	45	area	area	NOUN
fbem-7835	38	46	under	under	ADP
fbem-7835	38	47	the	the	DET
fbem-7835	38	48	os	os	NOUN
fbem-7835	38	49	curve	curve	NOUN
fbem-7835	38	50	,	,	PUNCT
fbem-7835	38	51	and	and	CCONJ
fbem-7835	38	52	the	the	DET
fbem-7835	38	53	proportion	proportion	NOUN
fbem-7835	38	54	of	of	ADP
fbem-7835	38	55	patients	patient	NOUN
fbem-7835	38	56	with	with	ADP
fbem-7835	38	57	d	d	PROPN
fbem-7835	38	58	states	state	NOUN
fbem-7835	38	59	was	be	AUX
fbem-7835	38	60	obtained	obtain	VERB
fbem-7835	38	61	by	by	ADP
fbem-7835	38	62	subtracting	subtract	VERB
fbem-7835	38	63	the	the	DET
fbem-7835	38	64	area	area	NOUN
fbem-7835	38	65	under	under	ADP
fbem-7835	38	66	the	the	DET
fbem-7835	38	67	os	os	NOUN
fbem-7835	38	68	curve	curve	NOUN
fbem-7835	38	69	from	from	ADP
fbem-7835	38	70	1[7	1[7	NUM
fbem-7835	38	71	]	]	PUNCT
fbem-7835	38	72	.	.	PUNCT
fbem-7835	39	1	the	the	DET
fbem-7835	39	2	model	model	NOUN
fbem-7835	39	3	structure	structure	NOUN
fbem-7835	39	4	is	be	AUX
fbem-7835	39	5	shown	show	VERB
fbem-7835	39	6	in	in	ADP
fbem-7835	39	7	fig.1	fig.1	PROPN
fbem-7835	39	8	.	.	PUNCT
fbem-7835	40	1	according	accord	VERB
fbem-7835	40	2	to	to	ADP
fbem-7835	40	3	the	the	DET
fbem-7835	40	4	follow	follow	VERB
fbem-7835	40	5	-	-	PUNCT
fbem-7835	40	6	up	up	NOUN
fbem-7835	40	7	period	period	NOUN
fbem-7835	40	8	of	of	ADP
fbem-7835	40	9	the	the	DET
fbem-7835	40	10	treatment	treatment	NOUN
fbem-7835	40	11	plan	plan	NOUN
fbem-7835	40	12	,	,	PUNCT
fbem-7835	40	13	the	the	DET
fbem-7835	40	14	course	course	NOUN
fbem-7835	40	15	of	of	ADP
fbem-7835	40	16	treatment	treatment	NOUN
fbem-7835	40	17	and	and	CCONJ
fbem-7835	40	18	other	other	ADJ
fbem-7835	40	19	literature	literature	NOUN
fbem-7835	40	20	reports	report	NOUN
fbem-7835	40	21	,	,	PUNCT
fbem-7835	40	22	the	the	DET
fbem-7835	40	23	model	model	NOUN
fbem-7835	40	24	cycle	cycle	NOUN
fbem-7835	40	25	of	of	ADP
fbem-7835	40	26	this	this	DET
fbem-7835	40	27	study	study	NOUN
fbem-7835	40	28	was	be	AUX
fbem-7835	40	29	set	set	VERB
fbem-7835	40	30	to	to	ADP
fbem-7835	40	31	3	3	NUM
fbem-7835	40	32	weeks	week	NOUN
fbem-7835	40	33	(	(	PUNCT
fbem-7835	40	34	21	21	NUM
fbem-7835	40	35	days	day	NOUN
fbem-7835	40	36	)	)	PUNCT
fbem-7835	40	37	.	.	PUNCT
fbem-7835	41	1	the	the	DET
fbem-7835	41	2	time	time	NOUN
fbem-7835	41	3	horizon	horizon	PROPN
fbem-7835	41	4	was	be	AUX
fbem-7835	41	5	15	15	NUM
fbem-7835	41	6	years	year	NOUN
fbem-7835	41	7	to	to	PART
fbem-7835	41	8	obtain	obtain	VERB
fbem-7835	41	9	the	the	DET
fbem-7835	41	10	full	full	ADJ
fbem-7835	41	11	impact	impact	NOUN
fbem-7835	41	12	of	of	ADP
fbem-7835	41	13	the	the	DET
fbem-7835	41	14	intervention	intervention	NOUN
fbem-7835	41	15	program	program	NOUN
fbem-7835	41	16	on	on	ADP
fbem-7835	41	17	patient	patient	ADJ
fbem-7835	41	18	costs	cost	NOUN
fbem-7835	41	19	and	and	CCONJ
fbem-7835	41	20	health	health	NOUN
fbem-7835	41	21	outcomes	outcome	NOUN
fbem-7835	41	22	.	.	PUNCT
fbem-7835	42	1	the	the	DET
fbem-7835	42	2	patients	patient	NOUN
fbem-7835	42	3	were	be	AUX
fbem-7835	42	4	in	in	ADP
fbem-7835	42	5	a	a	DET
fbem-7835	42	6	progression	progression	NOUN
fbem-7835	42	7	-	-	PUNCT
fbem-7835	42	8	free	free	ADJ
fbem-7835	42	9	state	state	NOUN
fbem-7835	42	10	at	at	ADP
fbem-7835	42	11	the	the	DET
fbem-7835	42	12	time	time	NOUN
fbem-7835	42	13	of	of	ADP
fbem-7835	42	14	enrollment	enrollment	NOUN
fbem-7835	42	15	.	.	PUNCT
fbem-7835	43	1	in	in	ADP
fbem-7835	43	2	each	each	DET
fbem-7835	43	3	cycle	cycle	NOUN
fbem-7835	43	4	of	of	ADP
fbem-7835	43	5	simulation	simulation	NOUN
fbem-7835	43	6	,	,	PUNCT
fbem-7835	43	7	the	the	DET
fbem-7835	43	8	patients	patient	NOUN
fbem-7835	43	9	would	would	AUX
fbem-7835	43	10	exist	exist	VERB
fbem-7835	43	11	in	in	ADP
fbem-7835	43	12	a	a	DET
fbem-7835	43	13	certain	certain	ADJ
fbem-7835	43	14	state	state	NOUN
fbem-7835	43	15	and	and	CCONJ
fbem-7835	43	16	receive	receive	VERB
fbem-7835	43	17	related	related	ADJ
fbem-7835	43	18	drug	drug	NOUN
fbem-7835	43	19	treatment	treatment	NOUN
fbem-7835	43	20	.	.	PUNCT
fbem-7835	44	1	the	the	DET
fbem-7835	44	2	treatment	treatment	NOUN
fbem-7835	44	3	pathway	pathway	NOUN
fbem-7835	44	4	and	and	CCONJ
fbem-7835	44	5	medication	medication	NOUN
fbem-7835	44	6	regimen	regiman	NOUN
fbem-7835	44	7	of	of	ADP
fbem-7835	44	8	the	the	DET
fbem-7835	44	9	two	two	NUM
fbem-7835	44	10	regimens	regimen	NOUN
fbem-7835	44	11	were	be	AUX
fbem-7835	44	12	in	in	ADP
fbem-7835	44	13	accordance	accordance	NOUN
fbem-7835	44	14	with	with	ADP
fbem-7835	44	15	the	the	DET
fbem-7835	44	16	provisions	provision	NOUN
fbem-7835	44	17	of	of	ADP
fbem-7835	44	18	clinical	clinical	ADJ
fbem-7835	44	19	trials[4	trials[4	NOUN
fbem-7835	44	20	]	]	PUNCT
fbem-7835	44	21	:	:	PUNCT
fbem-7835	44	22	patients	patient	NOUN
fbem-7835	44	23	in	in	ADP
fbem-7835	44	24	the	the	DET
fbem-7835	44	25	pola_br	pola_br	ADJ
fbem-7835	44	26	group	group	NOUN
fbem-7835	44	27	received	receive	VERB
fbem-7835	44	28	an	an	DET
fbem-7835	44	29	intravenous	intravenous	ADJ
fbem-7835	44	30	injection	injection	NOUN
fbem-7835	44	31	of	of	ADP
fbem-7835	44	32	pola	pola	PROPN
fbem-7835	44	33	once	once	ADV
fbem-7835	44	34	per	per	ADP
fbem-7835	44	35	cycle	cycle	NOUN
fbem-7835	44	36	,	,	PUNCT
fbem-7835	44	37	each	each	DET
fbem-7835	44	38	dose	dose	NOUN
fbem-7835	44	39	was	be	AUX
fbem-7835	44	40	administered	administer	VERB
fbem-7835	44	41	at	at	ADP
fbem-7835	44	42	a	a	DET
fbem-7835	44	43	dose	dose	NOUN
fbem-7835	44	44	of	of	ADP
fbem-7835	44	45	1.8	1.8	NUM
fbem-7835	44	46	mg	mg	PROPN
fbem-7835	44	47	/	/	SYM
fbem-7835	44	48	kg	kg	PROPN
fbem-7835	44	49	,	,	PUNCT
fbem-7835	44	50	and	and	CCONJ
fbem-7835	44	51	an	an	DET
fbem-7835	44	52	intravenous	intravenous	ADJ
fbem-7835	44	53	injection	injection	NOUN
fbem-7835	44	54	of	of	ADP
fbem-7835	44	55	rituximab	rituximab	NOUN
fbem-7835	44	56	(	(	PUNCT
fbem-7835	44	57	r	r	NOUN
fbem-7835	44	58	)	)	PUNCT
fbem-7835	44	59	,	,	PUNCT
fbem-7835	44	60	each	each	DET
fbem-7835	44	61	dose	dose	NOUN
fbem-7835	44	62	was	be	AUX
fbem-7835	44	63	administered	administer	VERB
fbem-7835	44	64	at	at	ADP
fbem-7835	44	65	a	a	DET
fbem-7835	44	66	dose	dose	NOUN
fbem-7835	44	67	of	of	ADP
fbem-7835	44	68	375	375	NUM
fbem-7835	44	69	mg	mg	PROPN
fbem-7835	44	70	/	/	SYM
fbem-7835	44	71	m2	m2	PROPN
fbem-7835	44	72	and	and	CCONJ
fbem-7835	44	73	two	two	NUM
fbem-7835	44	74	intravenous	intravenous	ADJ
fbem-7835	44	75	injections	injection	NOUN
fbem-7835	44	76	of	of	ADP
fbem-7835	44	77	bendamustine	bendamustine	NOUN
fbem-7835	44	78	(	(	PUNCT
fbem-7835	44	79	b	b	NOUN
fbem-7835	44	80	)	)	PUNCT
fbem-7835	44	81	,	,	PUNCT
fbem-7835	44	82	each	each	DET
fbem-7835	44	83	dose	dose	NOUN
fbem-7835	44	84	was	be	AUX
fbem-7835	44	85	administered	administer	VERB
fbem-7835	44	86	at	at	ADP
fbem-7835	44	87	a	a	DET
fbem-7835	44	88	dose	dose	NOUN
fbem-7835	44	89	of	of	ADP
fbem-7835	44	90	90	90	NUM
fbem-7835	44	91	mg	mg	PROPN
fbem-7835	44	92	/	/	SYM
fbem-7835	44	93	m2	m2	PROPN
fbem-7835	44	94	,	,	PUNCT
fbem-7835	44	95	up	up	ADP
fbem-7835	44	96	to	to	PART
fbem-7835	44	97	6	6	NUM
fbem-7835	44	98	cycles	cycle	NOUN
fbem-7835	44	99	of	of	ADP
fbem-7835	44	100	treatment	treatment	NOUN
fbem-7835	44	101	;	;	PUNCT
fbem-7835	44	102	the	the	DET
fbem-7835	44	103	regimen	regiman	NOUN
fbem-7835	44	104	and	and	CCONJ
fbem-7835	44	105	dose	dose	NOUN
fbem-7835	44	106	of	of	ADP
fbem-7835	44	107	b	b	PROPN
fbem-7835	44	108	and	and	CCONJ
fbem-7835	44	109	r	r	NOUN
fbem-7835	44	110	in	in	ADP
fbem-7835	44	111	the	the	DET
fbem-7835	44	112	br	br	PROPN
fbem-7835	44	113	group	group	NOUN
fbem-7835	44	114	were	be	AUX
fbem-7835	44	115	consistent	consistent	ADJ
fbem-7835	44	116	with	with	ADP
fbem-7835	44	117	those	those	PRON
fbem-7835	44	118	in	in	ADP
fbem-7835	44	119	the	the	DET
fbem-7835	44	120	pola_br	pola_br	ADJ
fbem-7835	44	121	group	group	NOUN
fbem-7835	44	122	,	,	PUNCT
fbem-7835	44	123	and	and	CCONJ
fbem-7835	44	124	the	the	DET
fbem-7835	44	125	patients	patient	NOUN
fbem-7835	44	126	received	receive	VERB
fbem-7835	44	127	up	up	ADP
fbem-7835	44	128	to	to	PART
fbem-7835	44	129	6	6	NUM
fbem-7835	44	130	cycles	cycle	NOUN
fbem-7835	44	131	of	of	ADP
fbem-7835	44	132	treatment	treatment	NOUN
fbem-7835	44	133	.	.	PUNCT
fbem-7835	45	1	both	both	DET
fbem-7835	45	2	groups	group	NOUN
fbem-7835	45	3	of	of	ADP
fbem-7835	45	4	patients	patient	NOUN
fbem-7835	45	5	stopped	stop	VERB
fbem-7835	45	6	medication	medication	NOUN
fbem-7835	45	7	after	after	ADP
fbem-7835	45	8	progress	progress	NOUN
fbem-7835	45	9	during	during	ADP
fbem-7835	45	10	treatment	treatment	NOUN
fbem-7835	45	11	and	and	CCONJ
fbem-7835	45	12	did	do	AUX
fbem-7835	45	13	not	not	PART
fbem-7835	45	14	consider	consider	VERB
fbem-7835	45	15	subsequent	subsequent	ADJ
fbem-7835	45	16	medication	medication	NOUN
fbem-7835	45	17	.	.	PUNCT
fbem-7835	46	1	figure	figure	NOUN
fbem-7835	46	2	1	1	NUM
fbem-7835	46	3	.	.	PUNCT
fbem-7835	46	4	model	model	NOUN
fbem-7835	46	5	structure	structure	NOUN
fbem-7835	46	6	2.2.3	2.2.3	NUM
fbem-7835	46	7	.	.	PUNCT
fbem-7835	47	1	baseline	baseline	VERB
fbem-7835	47	2	demographic	demographic	ADJ
fbem-7835	47	3	data	datum	NOUN
fbem-7835	47	4	the	the	DET
fbem-7835	47	5	population	population	NOUN
fbem-7835	47	6	baseline	baseline	NOUN
fbem-7835	47	7	data	datum	NOUN
fbem-7835	47	8	of	of	ADP
fbem-7835	47	9	the	the	DET
fbem-7835	47	10	psm	psm	NOUN
fbem-7835	47	11	model	model	NOUN
fbem-7835	47	12	as	as	SCONJ
fbem-7835	47	13	shown	show	VERB
fbem-7835	47	14	in	in	ADP
fbem-7835	47	15	table	table	NOUN
fbem-7835	47	16	1	1	NUM
fbem-7835	47	17	includes	include	VERB
fbem-7835	47	18	median	median	ADJ
fbem-7835	47	19	patient	patient	NOUN
fbem-7835	47	20	age	age	NOUN
fbem-7835	47	21	,	,	PUNCT
fbem-7835	47	22	average	average	ADJ
fbem-7835	47	23	height	height	NOUN
fbem-7835	47	24	,	,	PUNCT
fbem-7835	47	25	average	average	ADJ
fbem-7835	47	26	weight	weight	NOUN
fbem-7835	47	27	,	,	PUNCT
fbem-7835	47	28	and	and	CCONJ
fbem-7835	47	29	average	average	ADJ
fbem-7835	47	30	body	body	NOUN
fbem-7835	47	31	surface	surface	NOUN
fbem-7835	47	32	area	area	NOUN
fbem-7835	47	33	.	.	PUNCT
fbem-7835	48	1	among	among	ADP
fbem-7835	48	2	them	they	PRON
fbem-7835	48	3	,	,	PUNCT
fbem-7835	48	4	the	the	DET
fbem-7835	48	5	median	median	ADJ
fbem-7835	48	6	patient	patient	NOUN
fbem-7835	48	7	age	age	NOUN
fbem-7835	48	8	was	be	AUX
fbem-7835	48	9	derived	derive	VERB
fbem-7835	48	10	from	from	ADP
fbem-7835	48	11	the	the	DET
fbem-7835	48	12	go29365	go29365	PROPN
fbem-7835	48	13	clinical	clinical	ADJ
fbem-7835	48	14	study	study	NOUN
fbem-7835	48	15	,	,	PUNCT
fbem-7835	48	16	and	and	CCONJ
fbem-7835	48	17	the	the	DET
fbem-7835	48	18	average	average	ADJ
fbem-7835	48	19	height	height	NOUN
fbem-7835	48	20	and	and	CCONJ
fbem-7835	48	21	weight	weight	NOUN
fbem-7835	48	22	data	datum	NOUN
fbem-7835	48	23	were	be	AUX
fbem-7835	48	24	derived	derive	VERB
fbem-7835	48	25	from	from	ADP
fbem-7835	48	26	the	the	DET
fbem-7835	48	27	“	"	PUNCT
fbem-7835	48	28	chinese	chinese	ADJ
fbem-7835	48	29	residents	resident	NOUN
fbem-7835	48	30	nutrition	nutrition	VERB
fbem-7835	48	31	and	and	CCONJ
fbem-7835	48	32	chronic	chronic	ADJ
fbem-7835	48	33	disease	disease	NOUN
fbem-7835	48	34	status	status	NOUN
fbem-7835	48	35	report	report	NOUN
fbem-7835	48	36	(	(	PUNCT
fbem-7835	48	37	2020	2020	NUM
fbem-7835	48	38	)	)	PUNCT
fbem-7835	48	39	”	"	PUNCT
fbem-7835	48	40	,	,	PUNCT
fbem-7835	48	41	64.3	64.3	NUM
fbem-7835	48	42	kg	kg	NOUN
fbem-7835	48	43	and	and	CCONJ
fbem-7835	48	44	163.85	163.85	NUM
fbem-7835	48	45	cm	cm	NOUN
fbem-7835	48	46	,	,	PUNCT
fbem-7835	48	47	respectively	respectively	ADV
fbem-7835	48	48	.	.	PUNCT
fbem-7835	49	1	the	the	DET
fbem-7835	49	2	average	average	ADJ
fbem-7835	49	3	body	body	NOUN
fbem-7835	49	4	surface	surface	NOUN
fbem-7835	49	5	area	area	NOUN
fbem-7835	49	6	was	be	AUX
fbem-7835	49	7	1.67	1.67	NUM
fbem-7835	49	8	,	,	PUNCT
fbem-7835	49	9	which	which	PRON
fbem-7835	49	10	was	be	AUX
fbem-7835	49	11	calculated	calculate	VERB
fbem-7835	49	12	by	by	ADP
fbem-7835	49	13	the	the	DET
fbem-7835	49	14	formula	formula	NOUN
fbem-7835	49	15	:	:	PUNCT
fbem-7835	49	16	average	average	ADJ
fbem-7835	49	17	body	body	NOUN
fbem-7835	49	18	surface	surface	NOUN
fbem-7835	49	19	area	area	NOUN
fbem-7835	49	20	(	(	PUNCT
fbem-7835	49	21	m2	m2	PROPN
fbem-7835	49	22	)	)	PUNCT
fbem-7835	49	23	=	=	PUNCT
fbem-7835	50	1	0.0061	0.0061	NUM
fbem-7835	50	2	×	×	NOUN
fbem-7835	50	3	height	height	NOUN
fbem-7835	50	4	(	(	PUNCT
fbem-7835	50	5	cm	cm	NOUN
fbem-7835	50	6	)	)	PUNCT
fbem-7835	50	7	+	+	NUM
fbem-7835	50	8	0.0128	0.0128	NUM
fbem-7835	50	9	×	×	NOUN
fbem-7835	50	10	weight	weight	NOUN
fbem-7835	50	11	(	(	PUNCT
fbem-7835	50	12	kg	kg	NOUN
fbem-7835	50	13	)	)	PUNCT
fbem-7835	50	14	−	−	ADP
fbem-7835	50	15	0.1529	0.1529	NUM
fbem-7835	50	16	.	.	PUNCT
fbem-7835	50	17	table	table	NOUN
fbem-7835	50	18	1	1	NUM
fbem-7835	50	19	.	.	PUNCT
fbem-7835	50	20	demographic	demographic	ADJ
fbem-7835	50	21	data	datum	NOUN
fbem-7835	50	22	parameters	parameter	NOUN
fbem-7835	50	23	value	value	VERB
fbem-7835	50	24	median	median	ADJ
fbem-7835	50	25	patient	patient	NOUN
fbem-7835	50	26	age	age	NOUN
fbem-7835	50	27	67	67	NUM
fbem-7835	50	28	years	year	NOUN
fbem-7835	50	29	old	old	ADJ
fbem-7835	50	30	average	average	ADJ
fbem-7835	50	31	height	height	NOUN
fbem-7835	50	32	163.85	163.85	NUM
fbem-7835	50	33	cm	cm	NOUN
fbem-7835	50	34	average	average	ADJ
fbem-7835	50	35	weight	weight	NOUN
fbem-7835	50	36	64.3	64.3	NUM
fbem-7835	50	37	kg	kg	NOUN
fbem-7835	50	38	average	average	ADJ
fbem-7835	50	39	body	body	NOUN
fbem-7835	50	40	surface	surface	NOUN
fbem-7835	50	41	area	area	NOUN
fbem-7835	50	42	1.67m2	1.67m2	NUM
fbem-7835	50	43	2.2.4	2.2.4	NUM
fbem-7835	50	44	.	.	PUNCT
fbem-7835	51	1	survival	survival	NOUN
fbem-7835	51	2	analysis	analysis	NOUN
fbem-7835	51	3	due	due	ADP
fbem-7835	51	4	to	to	ADP
fbem-7835	51	5	the	the	DET
fbem-7835	51	6	limited	limited	ADJ
fbem-7835	51	7	follow	follow	NOUN
fbem-7835	51	8	-	-	PUNCT
fbem-7835	51	9	up	up	NOUN
fbem-7835	51	10	time	time	NOUN
fbem-7835	51	11	of	of	ADP
fbem-7835	51	12	go29365	go29365	PROPN
fbem-7835	51	13	clinical	clinical	ADJ
fbem-7835	51	14	research	research	NOUN
fbem-7835	51	15	,	,	PUNCT
fbem-7835	51	16	the	the	DET
fbem-7835	51	17	long	long	ADJ
fbem-7835	51	18	-	-	PUNCT
fbem-7835	51	19	term	term	NOUN
fbem-7835	51	20	efficacy	efficacy	NOUN
fbem-7835	51	21	of	of	ADP
fbem-7835	51	22	the	the	DET
fbem-7835	51	23	target	target	NOUN
fbem-7835	51	24	population	population	NOUN
fbem-7835	51	25	is	be	AUX
fbem-7835	51	26	difficult	difficult	ADJ
fbem-7835	51	27	to	to	PART
fbem-7835	51	28	be	be	AUX
fbem-7835	51	29	reflected	reflect	VERB
fbem-7835	51	30	in	in	ADP
fbem-7835	51	31	the	the	DET
fbem-7835	51	32	data	datum	NOUN
fbem-7835	51	33	of	of	ADP
fbem-7835	51	34	clinical	clinical	ADJ
fbem-7835	51	35	trials	trial	NOUN
fbem-7835	51	36	,	,	PUNCT
fbem-7835	51	37	so	so	SCONJ
fbem-7835	51	38	this	this	DET
fbem-7835	51	39	study	study	NOUN
fbem-7835	51	40	will	will	AUX
fbem-7835	51	41	reasonably	reasonably	ADV
fbem-7835	51	42	extrapolate	extrapolate	VERB
fbem-7835	51	43	the	the	DET
fbem-7835	51	44	research	research	NOUN
fbem-7835	51	45	results	result	NOUN
fbem-7835	51	46	of	of	ADP
fbem-7835	51	47	go29365	go29365	NOUN
fbem-7835	51	48	.	.	PUNCT
fbem-7835	52	1	first	first	ADV
fbem-7835	52	2	,	,	PUNCT
fbem-7835	52	3	getdata	getdata	ADJ
fbem-7835	52	4	graph	graph	NOUN
fbem-7835	52	5	digitizer	digitizer	NOUN
fbem-7835	52	6	2.24	2.24	NUM
fbem-7835	52	7	software	software	NOUN
fbem-7835	52	8	was	be	AUX
fbem-7835	52	9	used	use	VERB
fbem-7835	52	10	to	to	PART
fbem-7835	52	11	obtain	obtain	VERB
fbem-7835	52	12	the	the	DET
fbem-7835	52	13	original	original	ADJ
fbem-7835	52	14	survival	survival	NOUN
fbem-7835	52	15	data	datum	NOUN
fbem-7835	52	16	of	of	ADP
fbem-7835	52	17	the	the	DET
fbem-7835	52	18	patients	patient	NOUN
fbem-7835	52	19	from	from	ADP
fbem-7835	52	20	the	the	DET
fbem-7835	52	21	pfs	pfs	PROPN
fbem-7835	52	22	curve	curve	NOUN
fbem-7835	52	23	and	and	CCONJ
fbem-7835	52	24	os	os	NOUN
fbem-7835	52	25	curve	curve	NOUN
fbem-7835	52	26	(	(	PUNCT
fbem-7835	52	27	kaplan	kaplan	PROPN
fbem-7835	52	28	-	-	PUNCT
fbem-7835	52	29	meier	meier	PROPN
fbem-7835	52	30	analysis	analysis	NOUN
fbem-7835	52	31	,	,	PUNCT
fbem-7835	52	32	km	km	NOUN
fbem-7835	52	33	curve	curve	NOUN
fbem-7835	52	34	)	)	PUNCT
fbem-7835	52	35	of	of	ADP
fbem-7835	52	36	the	the	DET
fbem-7835	52	37	intervention	intervention	NOUN
fbem-7835	52	38	groups	group	NOUN
fbem-7835	52	39	,	,	PUNCT
fbem-7835	52	40	and	and	CCONJ
fbem-7835	52	41	then	then	ADV
fbem-7835	52	42	the	the	DET
fbem-7835	52	43	individual	individual	ADJ
fbem-7835	52	44	data	datum	NOUN
fbem-7835	52	45	was	be	AUX
fbem-7835	52	46	reconstructed	reconstruct	VERB
fbem-7835	52	47	by	by	ADP
fbem-7835	52	48	the	the	DET
fbem-7835	52	49	two	two	NUM
fbem-7835	52	50	software	software	NOUN
fbem-7835	52	51	packages	package	NOUN
fbem-7835	52	52	“	"	PUNCT
fbem-7835	52	53	survhe	survhe	NOUN
fbem-7835	52	54	”	"	PUNCT
fbem-7835	52	55	and	and	CCONJ
fbem-7835	52	56	“	"	PUNCT
fbem-7835	52	57	ggthemes	ggtheme	NOUN
fbem-7835	52	58	”	"	PUNCT
fbem-7835	52	59	in	in	ADP
fbem-7835	52	60	r	r	NOUN
fbem-7835	52	61	4.2.1	4.2.1	NUM
fbem-7835	52	62	,	,	PUNCT
fbem-7835	52	63	and	and	CCONJ
fbem-7835	52	64	then	then	ADV
fbem-7835	52	65	the	the	DET
fbem-7835	52	66	six	six	NUM
fbem-7835	52	67	parameter	parameter	NOUN
fbem-7835	52	68	distributions	distribution	NOUN
fbem-7835	52	69	of	of	ADP
fbem-7835	52	70	exponential	exponential	NOUN
fbem-7835	52	71	,	,	PUNCT
fbem-7835	52	72	gamma	gamma	NOUN
fbem-7835	52	73	,	,	PUNCT
fbem-7835	52	74	gompertz	gompertz	PROPN
fbem-7835	52	75	,	,	PUNCT
fbem-7835	52	76	weibull	weibull	NOUN
fbem-7835	52	77	,	,	PUNCT
fbem-7835	52	78	loglogistic	loglogistic	ADJ
fbem-7835	52	79	and	and	CCONJ
fbem-7835	52	80	lognormal	lognormal	ADJ
fbem-7835	52	81	were	be	AUX
fbem-7835	52	82	used	use	VERB
fbem-7835	52	83	for	for	ADP
fbem-7835	52	84	survival	survival	NOUN
fbem-7835	52	85	analysis	analysis	NOUN
fbem-7835	52	86	and	and	CCONJ
fbem-7835	52	87	fitting	fitting	NOUN
fbem-7835	52	88	of	of	ADP
fbem-7835	52	89	two	two	NUM
fbem-7835	52	90	groups	group	NOUN
fbem-7835	52	91	of	of	ADP
fbem-7835	52	92	reconstructed	reconstructed	ADJ
fbem-7835	52	93	individual	individual	ADJ
fbem-7835	52	94	patient	patient	ADJ
fbem-7835	52	95	level	level	NOUN
fbem-7835	52	96	data[8	data[8	PROPN
fbem-7835	52	97	]	]	PUNCT
fbem-7835	52	98	.	.	PUNCT
fbem-7835	53	1	according	accord	VERB
fbem-7835	53	2	to	to	ADP
fbem-7835	53	3	the	the	DET
fbem-7835	53	4	akaike	akaike	ADJ
fbem-7835	53	5	information	information	NOUN
fbem-7835	53	6	criterion	criterion	NOUN
fbem-7835	53	7	(	(	PUNCT
fbem-7835	53	8	aic	aic	PROPN
fbem-7835	53	9	)	)	PUNCT
fbem-7835	53	10	and	and	CCONJ
fbem-7835	53	11	bayesian	bayesian	NOUN
fbem-7835	53	12	information	information	NOUN
fbem-7835	53	13	criterion	criterion	NOUN
fbem-7835	53	14	(	(	PUNCT
fbem-7835	53	15	bic	bic	PROPN
fbem-7835	53	16	)	)	PUNCT
fbem-7835	53	17	,	,	PUNCT
fbem-7835	53	18	the	the	DET
fbem-7835	53	19	optimal	optimal	ADJ
fbem-7835	53	20	fitting	fitting	ADJ
fbem-7835	53	21	distribution	distribution	NOUN
fbem-7835	53	22	is	be	AUX
fbem-7835	53	23	selected	select	VERB
fbem-7835	53	24	,	,	PUNCT
fbem-7835	53	25	and	and	CCONJ
fbem-7835	53	26	the	the	DET
fbem-7835	53	27	minimum	minimum	NOUN
fbem-7835	53	28	aic	aic	PROPN
fbem-7835	53	29	and	and	CCONJ
fbem-7835	53	30	bic	bic	PROPN
fbem-7835	53	31	is	be	AUX
fbem-7835	53	32	the	the	DET
fbem-7835	53	33	optimal	optimal	ADJ
fbem-7835	53	34	fitting	fitting	ADJ
fbem-7835	53	35	distribution	distribution	NOUN
fbem-7835	53	36	.	.	PUNCT
fbem-7835	54	1	2.2.5	2.2.5	X
fbem-7835	54	2	.	.	PUNCT
fbem-7835	54	3	cost	cost	NOUN
fbem-7835	54	4	and	and	CCONJ
fbem-7835	54	5	utility	utility	NOUN
fbem-7835	54	6	since	since	SCONJ
fbem-7835	54	7	this	this	DET
fbem-7835	54	8	study	study	NOUN
fbem-7835	54	9	is	be	AUX
fbem-7835	54	10	from	from	ADP
fbem-7835	54	11	the	the	DET
fbem-7835	54	12	perspective	perspective	NOUN
fbem-7835	54	13	of	of	ADP
fbem-7835	54	14	china	china	PROPN
fbem-7835	54	15	's	's	PART
fbem-7835	54	16	health	health	NOUN
fbem-7835	54	17	system	system	NOUN
fbem-7835	54	18	,	,	PUNCT
fbem-7835	54	19	only	only	ADV
fbem-7835	54	20	direct	direct	ADJ
fbem-7835	54	21	medical	medical	ADJ
fbem-7835	54	22	costs	cost	NOUN
fbem-7835	54	23	are	be	AUX
fbem-7835	54	24	considered	consider	VERB
fbem-7835	54	25	,	,	PUNCT
fbem-7835	54	26	including	include	VERB
fbem-7835	54	27	drug	drug	NOUN
fbem-7835	54	28	costs	cost	NOUN
fbem-7835	54	29	,	,	PUNCT
fbem-7835	54	30	disease	disease	NOUN
fbem-7835	54	31	management	management	NOUN
fbem-7835	54	32	costs	cost	NOUN
fbem-7835	54	33	,	,	PUNCT
fbem-7835	54	34	follow	follow	VERB
fbem-7835	54	35	-	-	PUNCT
fbem-7835	54	36	up	up	ADP
fbem-7835	54	37	costs	cost	NOUN
fbem-7835	54	38	,	,	PUNCT
fbem-7835	54	39	and	and	CCONJ
fbem-7835	54	40	adverse	adverse	ADJ
fbem-7835	54	41	event	event	NOUN
fbem-7835	54	42	costs	cost	NOUN
fbem-7835	54	43	.	.	PUNCT
fbem-7835	55	1	go29365	go29365	PROPN
fbem-7835	55	2	study	study	PROPN
fbem-7835	55	3	did	do	AUX
fbem-7835	55	4	not	not	PART
fbem-7835	55	5	publish	publish	VERB
fbem-7835	55	6	utility	utility	NOUN
fbem-7835	55	7	data	datum	NOUN
fbem-7835	55	8	,	,	PUNCT
fbem-7835	55	9	so	so	SCONJ
fbem-7835	55	10	the	the	DET
fbem-7835	55	11	health	health	NOUN
fbem-7835	55	12	utility	utility	NOUN
fbem-7835	55	13	value	value	NOUN
fbem-7835	55	14	of	of	ADP
fbem-7835	55	15	this	this	DET
fbem-7835	55	16	study	study	NOUN
fbem-7835	55	17	comes	come	VERB
fbem-7835	55	18	from	from	ADP
fbem-7835	55	19	the	the	DET
fbem-7835	55	20	published	publish	VERB
fbem-7835	55	21	literature	literature	NOUN
fbem-7835	55	22	,	,	PUNCT
fbem-7835	55	23	in	in	ADP
fbem-7835	55	24	which	which	PRON
fbem-7835	55	25	the	the	DET
fbem-7835	55	26	utility	utility	NOUN
fbem-7835	55	27	value	value	NOUN
fbem-7835	55	28	of	of	ADP
fbem-7835	55	29	pfs	pfs	PROPN
fbem-7835	55	30	state	state	NOUN
fbem-7835	55	31	is	be	AUX
fbem-7835	55	32	0.83	0.83	NUM
fbem-7835	55	33	,	,	PUNCT
fbem-7835	55	34	and	and	CCONJ
fbem-7835	55	35	the	the	DET
fbem-7835	55	36	utility	utility	NOUN
fbem-7835	55	37	value	value	NOUN
fbem-7835	55	38	of	of	ADP
fbem-7835	55	39	pd	pd	PROPN
fbem-7835	55	40	state	state	NOUN
fbem-7835	55	41	is	be	AUX
fbem-7835	55	42	0.39[9	0.39[9	PROPN
fbem-7835	55	43	]	]	X
fbem-7835	55	44	.	.	PUNCT
fbem-7835	56	1	the	the	DET
fbem-7835	56	2	drug	drug	NOUN
fbem-7835	56	3	prices	price	NOUN
fbem-7835	56	4	of	of	ADP
fbem-7835	56	5	bendamustine	bendamustine	NOUN
fbem-7835	56	6	and	and	CCONJ
fbem-7835	56	7	rituximab	rituximab	NOUN
fbem-7835	56	8	were	be	AUX
fbem-7835	56	9	derived	derive	VERB
fbem-7835	56	10	from	from	ADP
fbem-7835	56	11	the	the	DET
fbem-7835	56	12	median	median	ADJ
fbem-7835	56	13	,	,	PUNCT
fbem-7835	56	14	maximum	maximum	ADJ
fbem-7835	56	15	and	and	CCONJ
fbem-7835	56	16	minimum	minimum	ADJ
fbem-7835	56	17	bid	bid	NOUN
fbem-7835	56	18	prices	price	NOUN
fbem-7835	56	19	of	of	ADP
fbem-7835	56	20	drugs	drug	NOUN
fbem-7835	56	21	in	in	ADP
fbem-7835	56	22	2022	2022	NUM
fbem-7835	56	23	in	in	ADP
fbem-7835	56	24	the	the	DET
fbem-7835	56	25	yaozhi	yaozhi	PROPN
fbem-7835	56	26	database	database	NOUN
fbem-7835	56	27	(	(	PUNCT
fbem-7835	56	28	https://db.yaozh.com	https://db.yaozh.com	X
fbem-7835	56	29	)	)	PUNCT
fbem-7835	56	30	.	.	PUNCT
fbem-7835	57	1	polatuzumab	polatuzumab	PROPN
fbem-7835	57	2	vedotin	vedotin	PROPN
fbem-7835	57	3	has	have	AUX
fbem-7835	57	4	just	just	ADV
fbem-7835	57	5	been	be	AUX
fbem-7835	57	6	approved	approve	VERB
fbem-7835	57	7	for	for	ADP
fbem-7835	57	8	listing	list	VERB
fbem-7835	57	9	in	in	ADP
fbem-7835	57	10	china	china	PROPN
fbem-7835	57	11	at	at	ADP
fbem-7835	57	12	the	the	DET
fbem-7835	57	13	beginning	beginning	NOUN
fbem-7835	57	14	of	of	ADP
fbem-7835	57	15	this	this	DET
fbem-7835	57	16	year	year	NOUN
fbem-7835	57	17	.	.	PUNCT
fbem-7835	58	1	at	at	ADP
fbem-7835	58	2	present	present	ADJ
fbem-7835	58	3	,	,	PUNCT
fbem-7835	58	4	there	there	PRON
fbem-7835	58	5	is	be	VERB
fbem-7835	58	6	no	no	DET
fbem-7835	58	7	price	price	NOUN
fbem-7835	58	8	in	in	ADP
fbem-7835	58	9	the	the	DET
fbem-7835	58	10	database	database	NOUN
fbem-7835	58	11	.	.	PUNCT
fbem-7835	59	1	therefore	therefore	ADV
fbem-7835	59	2	,	,	PUNCT
fbem-7835	59	3	this	this	DET
fbem-7835	59	4	study	study	NOUN
fbem-7835	59	5	uses	use	VERB
fbem-7835	59	6	the	the	DET
fbem-7835	59	7	approximate	approximate	ADJ
fbem-7835	59	8	price	price	NOUN
fbem-7835	59	9	180	180	NUM
fbem-7835	59	10	provided	provide	VERB
fbem-7835	59	11	by	by	ADP
fbem-7835	59	12	some	some	DET
fbem-7835	59	13	pharmacies	pharmacy	NOUN
fbem-7835	59	14	(	(	PUNCT
fbem-7835	59	15	cny	cny	PROPN
fbem-7835	59	16	10,400	10,400	NUM
fbem-7835	59	17	/	/	SYM
fbem-7835	59	18	30	30	NUM
fbem-7835	59	19	mg	mg	NUM
fbem-7835	59	20	)	)	PUNCT
fbem-7835	59	21	and	and	CCONJ
fbem-7835	59	22	converts	convert	VERB
fbem-7835	59	23	it	it	PRON
fbem-7835	59	24	into	into	ADP
fbem-7835	59	25	a	a	DET
fbem-7835	59	26	unit	unit	NOUN
fbem-7835	59	27	price	price	NOUN
fbem-7835	59	28	,	,	PUNCT
fbem-7835	59	29	that	that	ADV
fbem-7835	59	30	is	is	ADV
fbem-7835	59	31	,	,	PUNCT
fbem-7835	59	32	cny	cny	PROPN
fbem-7835	59	33	346.67	346.67	NUM
fbem-7835	59	34	/	/	SYM
fbem-7835	59	35	mg	mg	PROPN
fbem-7835	59	36	as	as	ADP
fbem-7835	59	37	the	the	DET
fbem-7835	59	38	baseline	baseline	NOUN
fbem-7835	59	39	price	price	NOUN
fbem-7835	59	40	,	,	PUNCT
fbem-7835	59	41	and	and	CCONJ
fbem-7835	59	42	this	this	DET
fbem-7835	59	43	price	price	NOUN
fbem-7835	59	44	is	be	AUX
fbem-7835	59	45	taken	take	VERB
fbem-7835	59	46	as	as	ADP
fbem-7835	59	47	the	the	DET
fbem-7835	59	48	maximum	maximum	ADJ
fbem-7835	59	49	value	value	NOUN
fbem-7835	59	50	of	of	ADP
fbem-7835	59	51	this	this	DET
fbem-7835	59	52	parameter	parameter	NOUN
fbem-7835	59	53	,	,	PUNCT
fbem-7835	59	54	and	and	CCONJ
fbem-7835	59	55	the	the	DET
fbem-7835	59	56	minimum	minimum	ADJ
fbem-7835	59	57	value	value	NOUN
fbem-7835	59	58	is	be	AUX
fbem-7835	59	59	assumed	assume	VERB
fbem-7835	59	60	to	to	PART
fbem-7835	59	61	be	be	AUX
fbem-7835	59	62	80	80	NUM
fbem-7835	59	63	%	%	NOUN
fbem-7835	59	64	of	of	ADP
fbem-7835	59	65	the	the	DET
fbem-7835	59	66	baseline	baseline	NOUN
fbem-7835	59	67	price	price	NOUN
fbem-7835	59	68	.	.	PUNCT
fbem-7835	60	1	the	the	DET
fbem-7835	60	2	drug	drug	NOUN
fbem-7835	60	3	cost	cost	NOUN
fbem-7835	60	4	per	per	ADP
fbem-7835	60	5	cycle	cycle	NOUN
fbem-7835	60	6	of	of	ADP
fbem-7835	60	7	pola_br	pola_br	ADJ
fbem-7835	60	8	group	group	NOUN
fbem-7835	60	9	and	and	CCONJ
fbem-7835	60	10	br	br	PROPN
fbem-7835	60	11	group	group	NOUN
fbem-7835	60	12	was	be	AUX
fbem-7835	60	13	calculated	calculate	VERB
fbem-7835	60	14	according	accord	VERB
fbem-7835	60	15	to	to	ADP
fbem-7835	60	16	their	their	PRON
fbem-7835	60	17	price	price	NOUN
fbem-7835	60	18	,	,	PUNCT
fbem-7835	60	19	medication	medication	NOUN
fbem-7835	60	20	regimen	regiman	NOUN
fbem-7835	60	21	,	,	PUNCT
fbem-7835	60	22	average	average	ADJ
fbem-7835	60	23	weight	weight	NOUN
fbem-7835	60	24	,	,	PUNCT
fbem-7835	60	25	and	and	CCONJ
fbem-7835	60	26	average	average	ADJ
fbem-7835	60	27	body	body	NOUN
fbem-7835	60	28	surface	surface	NOUN
fbem-7835	60	29	area	area	NOUN
fbem-7835	60	30	,	,	PUNCT
fbem-7835	60	31	which	which	PRON
fbem-7835	60	32	were	be	AUX
fbem-7835	60	33	52,521.43	52,521.43	NUM
fbem-7835	60	34	yuan	yuan	NOUN
fbem-7835	60	35	and	and	CCONJ
fbem-7835	60	36	12,397.84	12,397.84	NUM
fbem-7835	60	37	yuan	yuan	NOUN
fbem-7835	60	38	respectively	respectively	ADV
fbem-7835	60	39	.	.	PUNCT
fbem-7835	61	1	the	the	DET
fbem-7835	61	2	follow	follow	VERB
fbem-7835	61	3	-	-	PUNCT
fbem-7835	61	4	up	up	ADP
fbem-7835	61	5	cost	cost	NOUN
fbem-7835	61	6	and	and	CCONJ
fbem-7835	61	7	disease	disease	NOUN
fbem-7835	61	8	management	management	NOUN
fbem-7835	61	9	cost	cost	NOUN
fbem-7835	61	10	came	come	VERB
fbem-7835	61	11	from	from	ADP
fbem-7835	61	12	the	the	DET
fbem-7835	61	13	median	median	ADJ
fbem-7835	61	14	,	,	PUNCT
fbem-7835	61	15	maximum	maximum	ADJ
fbem-7835	61	16	and	and	CCONJ
fbem-7835	61	17	minimum	minimum	ADJ
fbem-7835	61	18	cost	cost	NOUN
fbem-7835	61	19	of	of	ADP
fbem-7835	61	20	each	each	DET
fbem-7835	61	21	medical	medical	ADJ
fbem-7835	61	22	service	service	NOUN
fbem-7835	61	23	item	item	NOUN
fbem-7835	61	24	in	in	ADP
fbem-7835	61	25	the	the	DET
fbem-7835	61	26	medical	medical	ADJ
fbem-7835	61	27	service	service	NOUN
fbem-7835	61	28	price	price	NOUN
fbem-7835	61	29	of	of	ADP
fbem-7835	61	30	14	14	NUM
fbem-7835	61	31	provinces	province	NOUN
fbem-7835	61	32	and	and	CCONJ
fbem-7835	61	33	cities	city	NOUN
fbem-7835	61	34	such	such	ADJ
fbem-7835	61	35	as	as	ADP
fbem-7835	61	36	beijing	beijing	PROPN
fbem-7835	61	37	,	,	PUNCT
fbem-7835	61	38	dongguan	dongguan	PROPN
fbem-7835	61	39	,	,	PUNCT
fbem-7835	61	40	hangzhou	hangzhou	PROPN
fbem-7835	61	41	,	,	PUNCT
fbem-7835	61	42	qingdao	qingdao	PROPN
fbem-7835	61	43	,	,	PUNCT
fbem-7835	61	44	hefei	hefei	PROPN
fbem-7835	61	45	,	,	PUNCT
fbem-7835	61	46	guangxi	guangxi	PROPN
fbem-7835	61	47	,	,	PUNCT
fbem-7835	61	48	hainan	hainan	PROPN
fbem-7835	61	49	and	and	CCONJ
fbem-7835	61	50	ya	ya	PRON
fbem-7835	61	51	'	'	PUNCT
fbem-7835	61	52	an	an	NOUN
fbem-7835	61	53	.	.	PUNCT
fbem-7835	62	1	the	the	DET
fbem-7835	62	2	follow	follow	VERB
fbem-7835	62	3	-	-	PUNCT
fbem-7835	62	4	up	up	ADP
fbem-7835	62	5	examination	examination	NOUN
fbem-7835	62	6	items	item	NOUN
fbem-7835	62	7	,	,	PUNCT
fbem-7835	62	8	disease	disease	NOUN
fbem-7835	62	9	management	management	NOUN
fbem-7835	62	10	items	item	NOUN
fbem-7835	62	11	and	and	CCONJ
fbem-7835	62	12	frequency	frequency	NOUN
fbem-7835	62	13	were	be	AUX
fbem-7835	62	14	set	set	VERB
fbem-7835	62	15	according	accord	VERB
fbem-7835	62	16	to	to	ADP
fbem-7835	62	17	the	the	DET
fbem-7835	62	18	go29365	go29365	PROPN
fbem-7835	62	19	study	study	NOUN
fbem-7835	62	20	.	.	PUNCT
fbem-7835	63	1	considering	consider	VERB
fbem-7835	63	2	that	that	SCONJ
fbem-7835	63	3	most	most	ADJ
fbem-7835	63	4	of	of	ADP
fbem-7835	63	5	the	the	DET
fbem-7835	63	6	adverse	adverse	ADJ
fbem-7835	63	7	events	event	NOUN
fbem-7835	63	8	below	below	ADP
fbem-7835	63	9	grade	grade	NOUN
fbem-7835	63	10	3	3	NUM
fbem-7835	63	11	do	do	AUX
fbem-7835	63	12	not	not	PART
fbem-7835	63	13	require	require	VERB
fbem-7835	63	14	additional	additional	ADJ
fbem-7835	63	15	clinical	clinical	ADJ
fbem-7835	63	16	intervention	intervention	NOUN
fbem-7835	63	17	and	and	CCONJ
fbem-7835	63	18	data	datum	NOUN
fbem-7835	63	19	availability	availability	NOUN
fbem-7835	63	20	,	,	PUNCT
fbem-7835	63	21	this	this	DET
fbem-7835	63	22	study	study	NOUN
fbem-7835	63	23	only	only	ADV
fbem-7835	63	24	considers	consider	VERB
fbem-7835	63	25	adverse	adverse	ADJ
fbem-7835	63	26	events	event	NOUN
fbem-7835	63	27	of	of	ADP
fbem-7835	63	28	grade	grade	NOUN
fbem-7835	63	29	3	3	NUM
fbem-7835	63	30	and	and	CCONJ
fbem-7835	63	31	above	above	ADV
fbem-7835	63	32	with	with	ADP
fbem-7835	63	33	an	an	DET
fbem-7835	63	34	incidence	incidence	NOUN
fbem-7835	63	35	rate	rate	NOUN
fbem-7835	63	36	greater	great	ADJ
fbem-7835	63	37	than	than	ADP
fbem-7835	63	38	5	5	NUM
fbem-7835	63	39	%	%	NOUN
fbem-7835	63	40	.	.	PUNCT
fbem-7835	64	1	according	accord	VERB
fbem-7835	64	2	to	to	ADP
fbem-7835	64	3	the	the	DET
fbem-7835	64	4	results	result	NOUN
fbem-7835	64	5	of	of	ADP
fbem-7835	64	6	go29365	go29365	PROPN
fbem-7835	64	7	study	study	NOUN
fbem-7835	64	8	,	,	PUNCT
fbem-7835	64	9	the	the	DET
fbem-7835	64	10	adverse	adverse	ADJ
fbem-7835	64	11	events	event	NOUN
fbem-7835	64	12	included	include	VERB
fbem-7835	64	13	in	in	ADP
fbem-7835	64	14	pola_br	pola_br	ADJ
fbem-7835	64	15	group	group	NOUN
fbem-7835	64	16	and	and	CCONJ
fbem-7835	64	17	br	br	PROPN
fbem-7835	64	18	group	group	NOUN
fbem-7835	64	19	were	be	AUX
fbem-7835	64	20	mainly	mainly	ADV
fbem-7835	64	21	neutropenia	neutropenia	NOUN
fbem-7835	64	22	,	,	PUNCT
fbem-7835	64	23	thrombocytopenia	thrombocytopenia	PROPN
fbem-7835	64	24	and	and	CCONJ
fbem-7835	64	25	anemia	anemia	NOUN
fbem-7835	64	26	.	.	PUNCT
fbem-7835	65	1	the	the	DET
fbem-7835	65	2	cost	cost	NOUN
fbem-7835	65	3	of	of	ADP
fbem-7835	65	4	adverse	adverse	ADJ
fbem-7835	65	5	event	event	NOUN
fbem-7835	65	6	treatment	treatment	NOUN
fbem-7835	65	7	came	come	VERB
fbem-7835	65	8	from	from	ADP
fbem-7835	65	9	literature[10	literature[10	NOUN
fbem-7835	65	10	]	]	PUNCT
fbem-7835	65	11	.	.	PUNCT
fbem-7835	66	1	according	accord	VERB
fbem-7835	66	2	to	to	ADP
fbem-7835	66	3	the	the	DET
fbem-7835	66	4	recommendations	recommendation	NOUN
fbem-7835	66	5	of	of	ADP
fbem-7835	66	6	the	the	DET
fbem-7835	66	7	“	"	PUNCT
fbem-7835	66	8	chinese	chinese	ADJ
fbem-7835	66	9	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	66	10	evaluation	evaluation	NOUN
fbem-7835	66	11	guide	guide	NOUN
fbem-7835	66	12	2020[5	2020[5	NUM
fbem-7835	66	13	]	]	PUNCT
fbem-7835	66	14	”	"	PUNCT
fbem-7835	66	15	,	,	PUNCT
fbem-7835	66	16	the	the	DET
fbem-7835	66	17	cost	cost	NOUN
fbem-7835	66	18	and	and	CCONJ
fbem-7835	66	19	utility	utility	NOUN
fbem-7835	66	20	of	of	ADP
fbem-7835	66	21	this	this	DET
fbem-7835	66	22	study	study	NOUN
fbem-7835	66	23	were	be	AUX
fbem-7835	66	24	discounted	discount	VERB
fbem-7835	66	25	at	at	ADP
fbem-7835	66	26	an	an	DET
fbem-7835	66	27	annual	annual	ADJ
fbem-7835	66	28	discount	discount	NOUN
fbem-7835	66	29	rate	rate	NOUN
fbem-7835	66	30	of	of	ADP
fbem-7835	66	31	5	5	NUM
fbem-7835	66	32	%	%	NOUN
fbem-7835	66	33	,	,	PUNCT
fbem-7835	66	34	and	and	CCONJ
fbem-7835	66	35	1	1	NUM
fbem-7835	66	36	time	time	NOUN
fbem-7835	66	37	of	of	ADP
fbem-7835	66	38	china	china	PROPN
fbem-7835	66	39	's	's	PART
fbem-7835	66	40	gross	gross	ADJ
fbem-7835	66	41	domestic	domestic	ADJ
fbem-7835	66	42	product	product	NOUN
fbem-7835	66	43	(	(	PUNCT
fbem-7835	66	44	gdp	gdp	NOUN
fbem-7835	66	45	,	,	PUNCT
fbem-7835	66	46	85,698	85,698	NUM
fbem-7835	66	47	yuan[11	yuan[11	NOUN
fbem-7835	66	48	]	]	PUNCT
fbem-7835	66	49	)	)	PUNCT
fbem-7835	66	50	in	in	ADP
fbem-7835	66	51	2022	2022	NUM
fbem-7835	66	52	was	be	AUX
fbem-7835	66	53	selected	select	VERB
fbem-7835	66	54	as	as	ADP
fbem-7835	66	55	the	the	DET
fbem-7835	66	56	willingness	willingness	NOUN
fbem-7835	66	57	-	-	PUNCT
fbem-7835	66	58	to	to	ADP
fbem-7835	66	59	-	-	PUNCT
fbem-7835	66	60	pay	pay	VERB
fbem-7835	66	61	(	(	PUNCT
fbem-7835	66	62	wtp	wtp	NOUN
fbem-7835	66	63	)	)	PUNCT
fbem-7835	66	64	threshold	threshold	NOUN
fbem-7835	66	65	.	.	PUNCT
fbem-7835	67	1	the	the	DET
fbem-7835	67	2	model	model	NOUN
fbem-7835	67	3	parameters	parameter	NOUN
fbem-7835	67	4	and	and	CCONJ
fbem-7835	67	5	distribution	distribution	NOUN
fbem-7835	67	6	are	be	AUX
fbem-7835	67	7	shown	show	VERB
fbem-7835	67	8	in	in	ADP
fbem-7835	67	9	table	table	NOUN
fbem-7835	67	10	2	2	NUM
fbem-7835	67	11	.	.	NOUN
fbem-7835	67	12	3	3	NUM
fbem-7835	67	13	.	.	X
fbem-7835	67	14	result	result	VERB
fbem-7835	67	15	3.1	3.1	NUM
fbem-7835	67	16	.	.	PUNCT
fbem-7835	67	17	result	result	NOUN
fbem-7835	67	18	of	of	ADP
fbem-7835	67	19	survival	survival	NOUN
fbem-7835	67	20	curve	curve	PROPN
fbem-7835	67	21	fitting	fit	VERB
fbem-7835	67	22	the	the	DET
fbem-7835	67	23	fitting	fitting	ADJ
fbem-7835	67	24	results	result	NOUN
fbem-7835	67	25	of	of	ADP
fbem-7835	67	26	the	the	DET
fbem-7835	67	27	six	six	NUM
fbem-7835	67	28	parameter	parameter	NOUN
fbem-7835	67	29	distributions	distribution	NOUN
fbem-7835	67	30	showed	show	VERB
fbem-7835	67	31	that	that	SCONJ
fbem-7835	67	32	the	the	DET
fbem-7835	67	33	optimal	optimal	ADJ
fbem-7835	67	34	fitting	fitting	ADJ
fbem-7835	67	35	distribution	distribution	NOUN
fbem-7835	67	36	of	of	ADP
fbem-7835	67	37	os	os	NOUN
fbem-7835	67	38	curve	curve	NOUN
fbem-7835	67	39	and	and	CCONJ
fbem-7835	67	40	pfs	pfs	PROPN
fbem-7835	67	41	curve	curve	NOUN
fbem-7835	67	42	in	in	ADP
fbem-7835	67	43	the	the	DET
fbem-7835	67	44	pola_br	pola_br	ADJ
fbem-7835	67	45	group	group	NOUN
fbem-7835	67	46	was	be	AUX
fbem-7835	67	47	log	log	NOUN
fbem-7835	67	48	-	-	PUNCT
fbem-7835	67	49	normal	normal	ADJ
fbem-7835	67	50	distribution	distribution	NOUN
fbem-7835	67	51	,	,	PUNCT
fbem-7835	67	52	and	and	CCONJ
fbem-7835	67	53	the	the	DET
fbem-7835	67	54	optimal	optimal	ADJ
fbem-7835	67	55	fitting	fitting	ADJ
fbem-7835	67	56	distribution	distribution	NOUN
fbem-7835	67	57	of	of	ADP
fbem-7835	67	58	os	os	NOUN
fbem-7835	67	59	curve	curve	NOUN
fbem-7835	67	60	and	and	CCONJ
fbem-7835	67	61	pfs	pfs	PROPN
fbem-7835	67	62	curve	curve	NOUN
fbem-7835	67	63	in	in	ADP
fbem-7835	67	64	the	the	DET
fbem-7835	67	65	br	br	PROPN
fbem-7835	67	66	group	group	NOUN
fbem-7835	67	67	was	be	AUX
fbem-7835	67	68	log	log	NOUN
fbem-7835	67	69	-	-	PUNCT
fbem-7835	67	70	logistic	logistic	ADJ
fbem-7835	67	71	distribution	distribution	NOUN
fbem-7835	67	72	,	,	PUNCT
fbem-7835	67	73	as	as	SCONJ
fbem-7835	67	74	shown	show	VERB
fbem-7835	67	75	in	in	ADP
fbem-7835	67	76	table	table	NOUN
fbem-7835	67	77	3	3	NUM
fbem-7835	67	78	,	,	PUNCT
fbem-7835	67	79	table	table	NOUN
fbem-7835	67	80	4	4	NUM
fbem-7835	67	81	,	,	PUNCT
fbem-7835	67	82	figure	figure	NOUN
fbem-7835	67	83	2	2	NUM
fbem-7835	67	84	and	and	CCONJ
fbem-7835	67	85	figure	figure	VERB
fbem-7835	67	86	3	3	NUM
fbem-7835	67	87	.	.	PUNCT
fbem-7835	68	1	in	in	ADP
fbem-7835	68	2	the	the	DET
fbem-7835	68	3	pola_br	pola_br	ADJ
fbem-7835	68	4	group	group	NOUN
fbem-7835	68	5	,	,	PUNCT
fbem-7835	68	6	the	the	DET
fbem-7835	68	7	median	median	PROPN
fbem-7835	68	8	os	os	NOUN
fbem-7835	68	9	and	and	CCONJ
fbem-7835	68	10	pfs	pfs	ADJ
fbem-7835	68	11	values	value	NOUN
fbem-7835	68	12	of	of	ADP
fbem-7835	68	13	the	the	DET
fbem-7835	68	14	survival	survival	NOUN
fbem-7835	68	15	curve	curve	NOUN
fbem-7835	68	16	reconstructed	reconstruct	VERB
fbem-7835	68	17	according	accord	VERB
fbem-7835	68	18	to	to	ADP
fbem-7835	68	19	the	the	DET
fbem-7835	68	20	optimal	optimal	ADJ
fbem-7835	68	21	fitting	fitting	ADJ
fbem-7835	68	22	distribution	distribution	NOUN
fbem-7835	68	23	were	be	AUX
fbem-7835	68	24	12.4	12.4	NUM
fbem-7835	68	25	months	month	NOUN
fbem-7835	68	26	and	and	CCONJ
fbem-7835	68	27	7.38	7.38	NUM
fbem-7835	68	28	months	month	NOUN
fbem-7835	68	29	,	,	PUNCT
fbem-7835	68	30	respectively	respectively	ADV
fbem-7835	68	31	,	,	PUNCT
fbem-7835	68	32	which	which	PRON
fbem-7835	68	33	were	be	AUX
fbem-7835	68	34	basically	basically	ADV
fbem-7835	68	35	consistent	consistent	ADJ
fbem-7835	68	36	with	with	ADP
fbem-7835	68	37	the	the	DET
fbem-7835	68	38	12.4	12.4	NUM
fbem-7835	68	39	months	month	NOUN
fbem-7835	68	40	and	and	CCONJ
fbem-7835	68	41	7.5	7.5	NUM
fbem-7835	68	42	months	month	NOUN
fbem-7835	68	43	in	in	ADP
fbem-7835	68	44	the	the	DET
fbem-7835	68	45	clinical	clinical	NOUN
fbem-7835	68	46	trial[4	trial[4	NOUN
fbem-7835	68	47	]	]	PUNCT
fbem-7835	68	48	.	.	PUNCT
fbem-7835	69	1	the	the	DET
fbem-7835	69	2	median	median	ADJ
fbem-7835	69	3	os	os	NOUN
fbem-7835	69	4	value	value	NOUN
fbem-7835	69	5	and	and	CCONJ
fbem-7835	69	6	median	median	ADJ
fbem-7835	69	7	pfs	pfs	PROPN
fbem-7835	69	8	value	value	NOUN
fbem-7835	69	9	of	of	ADP
fbem-7835	69	10	the	the	DET
fbem-7835	69	11	survival	survival	NOUN
fbem-7835	69	12	curve	curve	NOUN
fbem-7835	69	13	reconstructed	reconstruct	VERB
fbem-7835	69	14	according	accord	VERB
fbem-7835	69	15	to	to	ADP
fbem-7835	69	16	the	the	DET
fbem-7835	69	17	optimal	optimal	ADJ
fbem-7835	69	18	fitting	fitting	ADJ
fbem-7835	69	19	distribution	distribution	NOUN
fbem-7835	69	20	in	in	ADP
fbem-7835	69	21	the	the	DET
fbem-7835	69	22	br	br	PROPN
fbem-7835	69	23	group	group	NOUN
fbem-7835	69	24	were	be	AUX
fbem-7835	69	25	4.76	4.76	NUM
fbem-7835	69	26	months	month	NOUN
fbem-7835	69	27	and	and	CCONJ
fbem-7835	69	28	2	2	NUM
fbem-7835	69	29	months	month	NOUN
fbem-7835	69	30	,	,	PUNCT
fbem-7835	69	31	respectively	respectively	ADV
fbem-7835	69	32	,	,	PUNCT
fbem-7835	69	33	which	which	PRON
fbem-7835	69	34	were	be	AUX
fbem-7835	69	35	basically	basically	ADV
fbem-7835	69	36	consistent	consistent	ADJ
fbem-7835	69	37	with	with	ADP
fbem-7835	69	38	4.7	4.7	NUM
fbem-7835	69	39	months	month	NOUN
fbem-7835	69	40	and	and	CCONJ
fbem-7835	69	41	2	2	NUM
fbem-7835	69	42	months	month	NOUN
fbem-7835	69	43	in	in	ADP
fbem-7835	69	44	the	the	DET
fbem-7835	69	45	clinical	clinical	ADJ
fbem-7835	69	46	trial[4	trial[4	NOUN
fbem-7835	69	47	]	]	PUNCT
fbem-7835	69	48	.	.	PUNCT
fbem-7835	70	1	figure	figure	NOUN
fbem-7835	70	2	2	2	NUM
fbem-7835	70	3	.	.	PUNCT
fbem-7835	71	1	the	the	DET
fbem-7835	71	2	survival	survival	NOUN
fbem-7835	71	3	curve	curve	NOUN
fbem-7835	71	4	of	of	ADP
fbem-7835	71	5	the	the	DET
fbem-7835	71	6	trial	trial	NOUN
fbem-7835	71	7	and	and	CCONJ
fbem-7835	71	8	the	the	DET
fbem-7835	71	9	fitted	fit	VERB
fbem-7835	71	10	survival	survival	NOUN
fbem-7835	71	11	curve	curve	NOUN
fbem-7835	71	12	in	in	ADP
fbem-7835	71	13	pola_br	pola_br	ADJ
fbem-7835	71	14	group	group	NOUN
fbem-7835	71	15	figure	figure	NOUN
fbem-7835	71	16	3	3	NUM
fbem-7835	71	17	.	.	PUNCT
fbem-7835	72	1	the	the	DET
fbem-7835	72	2	survival	survival	NOUN
fbem-7835	72	3	curve	curve	NOUN
fbem-7835	72	4	of	of	ADP
fbem-7835	72	5	the	the	DET
fbem-7835	72	6	trial	trial	NOUN
fbem-7835	72	7	and	and	CCONJ
fbem-7835	72	8	the	the	DET
fbem-7835	72	9	fitted	fit	VERB
fbem-7835	72	10	survival	survival	NOUN
fbem-7835	72	11	curve	curve	NOUN
fbem-7835	72	12	in	in	ADP
fbem-7835	72	13	br	br	PROPN
fbem-7835	72	14	group	group	PROPN
fbem-7835	72	15	3.2	3.2	NUM
fbem-7835	72	16	.	.	PUNCT
fbem-7835	73	1	result	result	NOUN
fbem-7835	73	2	of	of	ADP
fbem-7835	73	3	base	base	NOUN
fbem-7835	73	4	case	case	NOUN
fbem-7835	73	5	the	the	DET
fbem-7835	73	6	basic	basic	ADJ
fbem-7835	73	7	analysis	analysis	NOUN
fbem-7835	73	8	results	result	NOUN
fbem-7835	73	9	of	of	ADP
fbem-7835	73	10	the	the	DET
fbem-7835	73	11	partitioned	partition	VERB
fbem-7835	73	12	survival	survival	NOUN
fbem-7835	73	13	model	model	NOUN
fbem-7835	73	14	in	in	ADP
fbem-7835	73	15	this	this	DET
fbem-7835	73	16	study	study	NOUN
fbem-7835	73	17	showed	show	VERB
fbem-7835	73	18	that	that	SCONJ
fbem-7835	73	19	the	the	DET
fbem-7835	73	20	treatment	treatment	NOUN
fbem-7835	73	21	cost	cost	NOUN
fbem-7835	73	22	of	of	ADP
fbem-7835	73	23	the	the	DET
fbem-7835	73	24	pola_br	pola_br	ADJ
fbem-7835	73	25	group	group	NOUN
fbem-7835	73	26	was	be	AUX
fbem-7835	73	27	274,027.18	274,027.18	NUM
fbem-7835	73	28	yuan	yuan	NOUN
fbem-7835	73	29	,	,	PUNCT
fbem-7835	73	30	and	and	CCONJ
fbem-7835	73	31	the	the	DET
fbem-7835	73	32	quality	quality	NOUN
fbem-7835	73	33	-	-	PUNCT
fbem-7835	73	34	adjusted	adjust	VERB
fbem-7835	73	35	life	life	NOUN
fbem-7835	73	36	years	year	NOUN
fbem-7835	73	37	(	(	PUNCT
fbem-7835	73	38	qalys	qaly	NOUN
fbem-7835	73	39	)	)	PUNCT
fbem-7835	73	40	obtained	obtain	VERB
fbem-7835	73	41	was	be	AUX
fbem-7835	73	42	1.73	1.73	NUM
fbem-7835	73	43	in	in	ADP
fbem-7835	73	44	the	the	DET
fbem-7835	73	45	15	15	NUM
fbem-7835	73	46	-	-	PUNCT
fbem-7835	73	47	year	year	NOUN
fbem-7835	73	48	simulation	simulation	NOUN
fbem-7835	73	49	period	period	NOUN
fbem-7835	73	50	.	.	PUNCT
fbem-7835	74	1	the	the	DET
fbem-7835	74	2	treatment	treatment	NOUN
fbem-7835	74	3	cost	cost	NOUN
fbem-7835	74	4	of	of	ADP
fbem-7835	74	5	the	the	DET
fbem-7835	74	6	br	br	PROPN
fbem-7835	74	7	group	group	NOUN
fbem-7835	74	8	was	be	AUX
fbem-7835	74	9	42,909.27	42,909.27	PROPN
fbem-7835	74	10	yuan	yuan	NOUN
fbem-7835	74	11	,	,	PUNCT
fbem-7835	74	12	the	the	DET
fbem-7835	74	13	quality	quality	NOUN
fbem-7835	74	14	-	-	PUNCT
fbem-7835	74	15	adjusted	adjust	VERB
fbem-7835	74	16	life	life	NOUN
fbem-7835	74	17	years	year	NOUN
fbem-7835	74	18	(	(	PUNCT
fbem-7835	74	19	qalys	qaly	NOUN
fbem-7835	74	20	)	)	PUNCT
fbem-7835	74	21	obtained	obtain	VERB
fbem-7835	74	22	was	be	AUX
fbem-7835	74	23	0.56	0.56	NUM
fbem-7835	74	24	,	,	PUNCT
fbem-7835	74	25	and	and	CCONJ
fbem-7835	74	26	the	the	DET
fbem-7835	74	27	incremental	incremental	ADJ
fbem-7835	74	28	cost	cost	NOUN
fbem-7835	74	29	-	-	PUNCT
fbem-7835	74	30	utility	utility	NOUN
fbem-7835	74	31	ratio	ratio	NOUN
fbem-7835	74	32	(	(	PUNCT
fbem-7835	74	33	icur	icur	NOUN
fbem-7835	74	34	)	)	PUNCT
fbem-7835	74	35	calculated	calculate	VERB
fbem-7835	74	36	from	from	ADP
fbem-7835	74	37	this	this	PRON
fbem-7835	74	38	was	be	AUX
fbem-7835	74	39	197,434.75	197,434.75	NUM
fbem-7835	74	40	yuan	yuan	PROPN
fbem-7835	74	41	/	/	SYM
fbem-7835	74	42	qaly	qaly	PROPN
fbem-7835	74	43	.	.	PUNCT
fbem-7835	75	1	then	then	ADV
fbem-7835	75	2	,	,	PUNCT
fbem-7835	75	3	under	under	ADP
fbem-7835	75	4	the	the	DET
fbem-7835	75	5	premise	premise	NOUN
fbem-7835	75	6	of	of	ADP
fbem-7835	75	7	using	use	VERB
fbem-7835	75	8	1	1	NUM
fbem-7835	75	9	times	time	NOUN
fbem-7835	75	10	china	china	PROPN
fbem-7835	75	11	's	's	PART
fbem-7835	75	12	per	per	ADP
fbem-7835	75	13	capita	capita	X
fbem-7835	75	14	gdp	gdp	NOUN
fbem-7835	75	15	in	in	ADP
fbem-7835	75	16	2022	2022	NUM
fbem-7835	75	17	(	(	PUNCT
fbem-7835	75	18	85,698	85,698	NUM
fbem-7835	75	19	yuan	yuan	NOUN
fbem-7835	75	20	)	)	PUNCT
fbem-7835	75	21	as	as	ADP
fbem-7835	75	22	the	the	DET
fbem-7835	75	23	wtp	wtp	NOUN
fbem-7835	75	24	threshold	threshold	NOUN
fbem-7835	75	25	.	.	PUNCT
fbem-7835	76	1	the	the	DET
fbem-7835	76	2	pola_br	pola_br	PROPN
fbem-7835	76	3	group	group	NOUN
fbem-7835	76	4	did	do	AUX
fbem-7835	76	5	not	not	PART
fbem-7835	76	6	have	have	VERB
fbem-7835	76	7	a	a	DET
fbem-7835	76	8	cost	cost	NOUN
fbem-7835	76	9	-	-	PUNCT
fbem-7835	76	10	utility	utility	NOUN
fbem-7835	76	11	advantage	advantage	NOUN
fbem-7835	76	12	compared	compare	VERB
fbem-7835	76	13	to	to	ADP
fbem-7835	76	14	the	the	DET
fbem-7835	76	15	br	br	PROPN
fbem-7835	76	16	group	group	NOUN
fbem-7835	76	17	.	.	PUNCT
fbem-7835	77	1	181	181	NUM
fbem-7835	77	2	3.3	3.3	NUM
fbem-7835	77	3	.	.	PUNCT
fbem-7835	78	1	result	result	NOUN
fbem-7835	78	2	of	of	ADP
fbem-7835	78	3	sensitivity	sensitivity	NOUN
fbem-7835	78	4	analysis	analysis	NOUN
fbem-7835	78	5	the	the	DET
fbem-7835	78	6	tornado	tornado	NOUN
fbem-7835	78	7	diagram	diagram	NOUN
fbem-7835	78	8	of	of	ADP
fbem-7835	78	9	one	one	NUM
fbem-7835	78	10	-	-	PUNCT
fbem-7835	78	11	way	way	NOUN
fbem-7835	78	12	sensitivity	sensitivity	NOUN
fbem-7835	78	13	analysis	analysis	NOUN
fbem-7835	78	14	(	(	PUNCT
fbem-7835	78	15	fig.4	fig.4	PROPN
fbem-7835	78	16	)	)	PUNCT
fbem-7835	78	17	showed	show	VERB
fbem-7835	78	18	that	that	SCONJ
fbem-7835	78	19	the	the	DET
fbem-7835	78	20	parameters	parameter	NOUN
fbem-7835	78	21	such	such	ADJ
fbem-7835	78	22	as	as	ADP
fbem-7835	78	23	drug	drug	NOUN
fbem-7835	78	24	cost	cost	NOUN
fbem-7835	78	25	per	per	ADP
fbem-7835	78	26	cycle	cycle	NOUN
fbem-7835	78	27	in	in	ADP
fbem-7835	78	28	pola_br	pola_br	PROPN
fbem-7835	78	29	group	group	NOUN
fbem-7835	78	30	,	,	PUNCT
fbem-7835	78	31	pfs	pf	VERB
fbem-7835	78	32	state	state	NOUN
fbem-7835	78	33	utility	utility	NOUN
fbem-7835	78	34	value	value	NOUN
fbem-7835	78	35	,	,	PUNCT
fbem-7835	78	36	discount	discount	NOUN
fbem-7835	78	37	rate	rate	NOUN
fbem-7835	78	38	and	and	CCONJ
fbem-7835	78	39	drug	drug	NOUN
fbem-7835	78	40	cost	cost	NOUN
fbem-7835	78	41	per	per	ADP
fbem-7835	78	42	cycle	cycle	NOUN
fbem-7835	78	43	in	in	ADP
fbem-7835	78	44	br	br	PROPN
fbem-7835	78	45	group	group	NOUN
fbem-7835	78	46	had	have	VERB
fbem-7835	78	47	a	a	DET
fbem-7835	78	48	great	great	ADJ
fbem-7835	78	49	influence	influence	NOUN
fbem-7835	78	50	on	on	ADP
fbem-7835	78	51	the	the	DET
fbem-7835	78	52	results	result	NOUN
fbem-7835	78	53	of	of	ADP
fbem-7835	78	54	cost	cost	NOUN
fbem-7835	78	55	-	-	PUNCT
fbem-7835	78	56	utility	utility	NOUN
fbem-7835	78	57	analysis	analysis	NOUN
fbem-7835	78	58	,	,	PUNCT
fbem-7835	78	59	but	but	CCONJ
fbem-7835	78	60	these	these	DET
fbem-7835	78	61	parameters	parameter	NOUN
fbem-7835	78	62	could	could	AUX
fbem-7835	78	63	not	not	PART
fbem-7835	78	64	lead	lead	VERB
fbem-7835	78	65	to	to	ADP
fbem-7835	78	66	the	the	DET
fbem-7835	78	67	reversal	reversal	NOUN
fbem-7835	78	68	of	of	ADP
fbem-7835	78	69	base	base	NOUN
fbem-7835	78	70	case	case	NOUN
fbem-7835	78	71	results	result	VERB
fbem-7835	78	72	.	.	PUNCT
fbem-7835	79	1	other	other	ADJ
fbem-7835	79	2	parameters	parameter	NOUN
fbem-7835	79	3	,	,	PUNCT
fbem-7835	79	4	such	such	ADJ
fbem-7835	79	5	as	as	ADP
fbem-7835	79	6	follow	follow	NOUN
fbem-7835	79	7	-	-	PUNCT
fbem-7835	79	8	up	up	ADP
fbem-7835	79	9	cost	cost	NOUN
fbem-7835	79	10	,	,	PUNCT
fbem-7835	79	11	disease	disease	NOUN
fbem-7835	79	12	management	management	NOUN
fbem-7835	79	13	cost	cost	NOUN
fbem-7835	79	14	,	,	PUNCT
fbem-7835	79	15	incidence	incidence	NOUN
fbem-7835	79	16	of	of	ADP
fbem-7835	79	17	adverse	adverse	ADJ
fbem-7835	79	18	events	event	NOUN
fbem-7835	79	19	and	and	CCONJ
fbem-7835	79	20	treatment	treatment	NOUN
fbem-7835	79	21	cost	cost	NOUN
fbem-7835	79	22	,	,	PUNCT
fbem-7835	79	23	had	have	VERB
fbem-7835	79	24	little	little	ADJ
fbem-7835	79	25	effect	effect	NOUN
fbem-7835	79	26	on	on	ADP
fbem-7835	79	27	icur	icur	NOUN
fbem-7835	79	28	.	.	PUNCT
fbem-7835	80	1	the	the	DET
fbem-7835	80	2	cost	cost	NOUN
fbem-7835	80	3	-	-	PUNCT
fbem-7835	80	4	utility	utility	NOUN
fbem-7835	80	5	scatter	scatter	NOUN
fbem-7835	80	6	plot	plot	NOUN
fbem-7835	80	7	(	(	PUNCT
fbem-7835	80	8	figure	figure	NOUN
fbem-7835	80	9	5	5	NUM
fbem-7835	80	10	)	)	PUNCT
fbem-7835	80	11	and	and	CCONJ
fbem-7835	80	12	the	the	DET
fbem-7835	80	13	cost	cost	NOUN
fbem-7835	80	14	-	-	PUNCT
fbem-7835	80	15	utility	utility	NOUN
fbem-7835	80	16	acceptable	acceptable	ADJ
fbem-7835	80	17	curve	curve	NOUN
fbem-7835	80	18	(	(	PUNCT
fbem-7835	80	19	figure	figure	NOUN
fbem-7835	80	20	6	6	NUM
fbem-7835	80	21	)	)	PUNCT
fbem-7835	80	22	of	of	ADP
fbem-7835	80	23	the	the	DET
fbem-7835	80	24	probabilistic	probabilistic	ADJ
fbem-7835	80	25	sensitivity	sensitivity	NOUN
fbem-7835	80	26	analysis	analysis	NOUN
fbem-7835	80	27	showed	show	VERB
fbem-7835	80	28	that	that	SCONJ
fbem-7835	80	29	when	when	SCONJ
fbem-7835	80	30	the	the	DET
fbem-7835	80	31	wtp	wtp	NOUN
fbem-7835	80	32	is	be	AUX
fbem-7835	80	33	1	1	NUM
fbem-7835	80	34	times	time	NOUN
fbem-7835	80	35	china	china	PROPN
fbem-7835	80	36	's	's	PART
fbem-7835	80	37	per	per	ADP
fbem-7835	80	38	capita	capita	X
fbem-7835	80	39	gdp	gdp	NOUN
fbem-7835	80	40	in	in	ADP
fbem-7835	80	41	2022	2022	NUM
fbem-7835	80	42	,	,	PUNCT
fbem-7835	80	43	85,698	85,698	NUM
fbem-7835	80	44	yuan	yuan	NOUN
fbem-7835	80	45	/	/	SYM
fbem-7835	80	46	qaly	qaly	PROPN
fbem-7835	80	47	,	,	PUNCT
fbem-7835	80	48	the	the	DET
fbem-7835	80	49	probability	probability	NOUN
fbem-7835	80	50	that	that	SCONJ
fbem-7835	80	51	the	the	DET
fbem-7835	80	52	pola_br	pola_br	PROPN
fbem-7835	80	53	group	group	NOUN
fbem-7835	80	54	has	have	VERB
fbem-7835	80	55	a	a	DET
fbem-7835	80	56	cost	cost	NOUN
fbem-7835	80	57	-	-	PUNCT
fbem-7835	80	58	utility	utility	NOUN
fbem-7835	80	59	advantage	advantage	NOUN
fbem-7835	80	60	is	be	AUX
fbem-7835	80	61	0	0	NUM
fbem-7835	80	62	%	%	NOUN
fbem-7835	80	63	.	.	PUNCT
fbem-7835	81	1	figure	figure	NOUN
fbem-7835	81	2	4	4	NUM
fbem-7835	81	3	.	.	PUNCT
fbem-7835	82	1	tornado	tornado	NOUN
fbem-7835	82	2	diagram	diagram	NOUN
fbem-7835	82	3	of	of	ADP
fbem-7835	82	4	one	one	NUM
fbem-7835	82	5	-	-	PUNCT
fbem-7835	82	6	way	way	NOUN
fbem-7835	82	7	sensitivity	sensitivity	NOUN
fbem-7835	82	8	analysis	analysis	NOUN
fbem-7835	82	9	figure	figure	NOUN
fbem-7835	82	10	5	5	NUM
fbem-7835	82	11	.	.	PUNCT
fbem-7835	82	12	cost	cost	NOUN
fbem-7835	82	13	-	-	PUNCT
fbem-7835	82	14	utility	utility	NOUN
fbem-7835	82	15	scatter	scatter	NOUN
fbem-7835	82	16	plot	plot	NOUN
fbem-7835	82	17	figure	figure	NOUN
fbem-7835	82	18	6	6	NUM
fbem-7835	82	19	.	.	PUNCT
fbem-7835	82	20	cost	cost	NOUN
fbem-7835	82	21	-	-	PUNCT
fbem-7835	82	22	utility	utility	NOUN
fbem-7835	82	23	acceptable	acceptable	ADJ
fbem-7835	82	24	curve	curve	NOUN
fbem-7835	82	25	182	182	NUM
fbem-7835	82	26	4	4	NUM
fbem-7835	82	27	.	.	PUNCT
fbem-7835	82	28	discussion	discussion	NOUN
fbem-7835	82	29	although	although	SCONJ
fbem-7835	82	30	most	most	ADJ
fbem-7835	82	31	of	of	ADP
fbem-7835	82	32	diffuse	diffuse	PROPN
fbem-7835	82	33	large	large	ADJ
fbem-7835	82	34	b	b	NOUN
fbem-7835	82	35	-	-	PUNCT
fbem-7835	82	36	cell	cell	NOUN
fbem-7835	82	37	lymphoma	lymphoma	NOUN
fbem-7835	82	38	patients	patient	NOUN
fbem-7835	82	39	can	can	AUX
fbem-7835	82	40	be	be	AUX
fbem-7835	82	41	cured	cure	VERB
fbem-7835	82	42	,	,	PUNCT
fbem-7835	82	43	some	some	DET
fbem-7835	82	44	patients	patient	NOUN
fbem-7835	82	45	still	still	ADV
fbem-7835	82	46	have	have	VERB
fbem-7835	82	47	refractory	refractory	NOUN
fbem-7835	82	48	or	or	CCONJ
fbem-7835	82	49	recurrent	recurrent	ADJ
fbem-7835	82	50	conditions	condition	NOUN
fbem-7835	82	51	after	after	ADP
fbem-7835	82	52	receiving	receive	VERB
fbem-7835	82	53	first	first	ADJ
fbem-7835	82	54	-	-	PUNCT
fbem-7835	82	55	line	line	NOUN
fbem-7835	82	56	treatment	treatment	NOUN
fbem-7835	82	57	,	,	PUNCT
fbem-7835	82	58	and	and	CCONJ
fbem-7835	82	59	about	about	ADP
fbem-7835	82	60	half	half	NOUN
fbem-7835	82	61	of	of	ADP
fbem-7835	82	62	these	these	DET
fbem-7835	82	63	patients	patient	NOUN
fbem-7835	82	64	may	may	AUX
fbem-7835	82	65	not	not	PART
fbem-7835	82	66	respond	respond	VERB
fbem-7835	82	67	to	to	ADP
fbem-7835	82	68	second	second	ADJ
fbem-7835	82	69	-	-	PUNCT
fbem-7835	82	70	line	line	NOUN
fbem-7835	82	71	rescue	rescue	NOUN
fbem-7835	82	72	chemotherapy	chemotherapy	NOUN
fbem-7835	82	73	.	.	PUNCT
fbem-7835	83	1	the	the	DET
fbem-7835	83	2	effect	effect	NOUN
fbem-7835	83	3	is	be	AUX
fbem-7835	83	4	not	not	PART
fbem-7835	83	5	optimistic	optimistic	ADJ
fbem-7835	83	6	and	and	CCONJ
fbem-7835	83	7	is	be	AUX
fbem-7835	83	8	not	not	PART
fbem-7835	83	9	suitable	suitable	ADJ
fbem-7835	83	10	for	for	ADP
fbem-7835	83	11	the	the	DET
fbem-7835	83	12	treatment	treatment	NOUN
fbem-7835	83	13	of	of	ADP
fbem-7835	83	14	hematopoietic	hematopoietic	ADJ
fbem-7835	83	15	stem	stem	NOUN
fbem-7835	83	16	cell	cell	NOUN
fbem-7835	83	17	transplantation[2][3].then	transplantation[2][3].then	ADV
fbem-7835	83	18	,	,	PUNCT
fbem-7835	83	19	after	after	ADP
fbem-7835	83	20	receiving	receive	VERB
fbem-7835	83	21	second	second	ADJ
fbem-7835	83	22	-	-	PUNCT
fbem-7835	83	23	line	line	NOUN
fbem-7835	83	24	rescue	rescue	NOUN
fbem-7835	83	25	treatment	treatment	NOUN
fbem-7835	83	26	failure	failure	NOUN
fbem-7835	83	27	,	,	PUNCT
fbem-7835	83	28	patients	patient	NOUN
fbem-7835	83	29	will	will	AUX
fbem-7835	83	30	be	be	AUX
fbem-7835	83	31	recommended	recommend	VERB
fbem-7835	83	32	to	to	PART
fbem-7835	83	33	choose	choose	VERB
fbem-7835	83	34	car	car	NOUN
fbem-7835	83	35	-	-	PUNCT
fbem-7835	83	36	t	t	NOUN
fbem-7835	83	37	for	for	ADP
fbem-7835	83	38	treatment[1	treatment[1	NUM
fbem-7835	83	39	]	]	PUNCT
fbem-7835	83	40	,	,	PUNCT
fbem-7835	83	41	which	which	PRON
fbem-7835	83	42	may	may	AUX
fbem-7835	83	43	cause	cause	VERB
fbem-7835	83	44	patients	patient	NOUN
fbem-7835	83	45	to	to	PART
fbem-7835	83	46	face	face	VERB
fbem-7835	83	47	a	a	DET
fbem-7835	83	48	greater	great	ADJ
fbem-7835	83	49	economic	economic	ADJ
fbem-7835	83	50	burden	burden	NOUN
fbem-7835	83	51	.	.	PUNCT
fbem-7835	84	1	therefore	therefore	ADV
fbem-7835	84	2	,	,	PUNCT
fbem-7835	84	3	for	for	ADP
fbem-7835	84	4	patients	patient	NOUN
fbem-7835	84	5	with	with	ADP
fbem-7835	84	6	r	r	NOUN
fbem-7835	84	7	/	/	SYM
fbem-7835	84	8	r	r	NOUN
fbem-7835	84	9	dlbcl	dlbcl	NOUN
fbem-7835	84	10	,	,	PUNCT
fbem-7835	84	11	a	a	DET
fbem-7835	84	12	treatment	treatment	NOUN
fbem-7835	84	13	regimen	regiman	NOUN
fbem-7835	84	14	that	that	PRON
fbem-7835	84	15	can	can	AUX
fbem-7835	84	16	significantly	significantly	ADV
fbem-7835	84	17	improve	improve	VERB
fbem-7835	84	18	the	the	DET
fbem-7835	84	19	survival	survival	NOUN
fbem-7835	84	20	benefit	benefit	NOUN
fbem-7835	84	21	during	during	ADP
fbem-7835	84	22	rescue	rescue	NOUN
fbem-7835	84	23	treatment	treatment	NOUN
fbem-7835	84	24	is	be	AUX
fbem-7835	84	25	needed	need	VERB
fbem-7835	84	26	.	.	PUNCT
fbem-7835	85	1	as	as	ADP
fbem-7835	85	2	an	an	DET
fbem-7835	85	3	antibody	antibody	NOUN
fbem-7835	85	4	-	-	PUNCT
fbem-7835	85	5	conjugated	conjugate	VERB
fbem-7835	85	6	drug	drug	NOUN
fbem-7835	85	7	,	,	PUNCT
fbem-7835	85	8	polatuzumab	polatuzumab	NOUN
fbem-7835	85	9	vedotin	vedotin	PROPN
fbem-7835	85	10	uses	use	VERB
fbem-7835	85	11	cd79b	cd79b	NOUN
fbem-7835	85	12	protein	protein	NOUN
fbem-7835	85	13	(	(	PUNCT
fbem-7835	85	14	almost	almost	ADV
fbem-7835	85	15	only	only	ADV
fbem-7835	85	16	expresses	express	VERB
fbem-7835	85	17	on	on	ADP
fbem-7835	85	18	b	b	NOUN
fbem-7835	85	19	cells	cell	NOUN
fbem-7835	85	20	)	)	PUNCT
fbem-7835	85	21	as	as	ADP
fbem-7835	85	22	a	a	DET
fbem-7835	85	23	targeted	targeted	ADJ
fbem-7835	85	24	antibody	antibody	NOUN
fbem-7835	85	25	,	,	PUNCT
fbem-7835	85	26	accurately	accurately	ADV
fbem-7835	85	27	targets	target	VERB
fbem-7835	85	28	to	to	ADP
fbem-7835	85	29	b	b	NOUN
fbem-7835	85	30	cells	cell	NOUN
fbem-7835	85	31	,	,	PUNCT
fbem-7835	85	32	and	and	CCONJ
fbem-7835	85	33	then	then	ADV
fbem-7835	85	34	releases	release	VERB
fbem-7835	85	35	drugs	drug	NOUN
fbem-7835	85	36	,	,	PUNCT
fbem-7835	85	37	which	which	PRON
fbem-7835	85	38	has	have	VERB
fbem-7835	85	39	a	a	DET
fbem-7835	85	40	cytotoxic	cytotoxic	ADJ
fbem-7835	85	41	effect	effect	NOUN
fbem-7835	85	42	on	on	ADP
fbem-7835	85	43	malignant	malignant	ADJ
fbem-7835	85	44	b	b	NOUN
fbem-7835	85	45	cells	cell	NOUN
fbem-7835	85	46	and	and	CCONJ
fbem-7835	85	47	can	can	AUX
fbem-7835	85	48	inhibit	inhibit	VERB
fbem-7835	85	49	the	the	DET
fbem-7835	85	50	proliferation	proliferation	NOUN
fbem-7835	85	51	and	and	CCONJ
fbem-7835	85	52	differentiation	differentiation	NOUN
fbem-7835	85	53	of	of	ADP
fbem-7835	85	54	b	b	NOUN
fbem-7835	85	55	cells	cell	NOUN
fbem-7835	85	56	to	to	PART
fbem-7835	85	57	achieve	achieve	VERB
fbem-7835	85	58	therapeutic	therapeutic	ADJ
fbem-7835	85	59	effects	effect	NOUN
fbem-7835	85	60	.	.	PUNCT
fbem-7835	86	1	related	relate	VERB
fbem-7835	86	2	clinical	clinical	ADJ
fbem-7835	86	3	trials	trial	NOUN
fbem-7835	86	4	have	have	AUX
fbem-7835	86	5	shown	show	VERB
fbem-7835	86	6	that	that	SCONJ
fbem-7835	86	7	its	its	PRON
fbem-7835	86	8	efficacy	efficacy	NOUN
fbem-7835	86	9	in	in	ADP
fbem-7835	86	10	the	the	DET
fbem-7835	86	11	treatment	treatment	NOUN
fbem-7835	86	12	of	of	ADP
fbem-7835	86	13	diffuse	diffuse	NOUN
fbem-7835	86	14	large	large	ADJ
fbem-7835	86	15	b	b	NOUN
fbem-7835	86	16	-	-	PUNCT
fbem-7835	86	17	cell	cell	NOUN
fbem-7835	86	18	lymphoma	lymphoma	NOUN
fbem-7835	86	19	is	be	AUX
fbem-7835	86	20	significantly	significantly	ADV
fbem-7835	86	21	improved	improve	VERB
fbem-7835	86	22	compared	compare	VERB
fbem-7835	86	23	with	with	ADP
fbem-7835	86	24	the	the	DET
fbem-7835	86	25	control	control	NOUN
fbem-7835	86	26	group[4],[12	group[4],[12	NOUN
fbem-7835	86	27	]	]	PUNCT
fbem-7835	86	28	,	,	PUNCT
fbem-7835	86	29	and	and	CCONJ
fbem-7835	86	30	its	its	PRON
fbem-7835	86	31	safety	safety	NOUN
fbem-7835	86	32	is	be	AUX
fbem-7835	86	33	also	also	ADV
fbem-7835	86	34	within	within	ADP
fbem-7835	86	35	the	the	DET
fbem-7835	86	36	tolerable	tolerable	ADJ
fbem-7835	86	37	range	range	NOUN
fbem-7835	86	38	.	.	PUNCT
fbem-7835	87	1	therefore	therefore	ADV
fbem-7835	87	2	,	,	PUNCT
fbem-7835	87	3	its	its	PRON
fbem-7835	87	4	emergence	emergence	NOUN
fbem-7835	87	5	provides	provide	VERB
fbem-7835	87	6	a	a	DET
fbem-7835	87	7	new	new	ADJ
fbem-7835	87	8	choice	choice	NOUN
fbem-7835	87	9	for	for	ADP
fbem-7835	87	10	clinical	clinical	ADJ
fbem-7835	87	11	experts	expert	NOUN
fbem-7835	87	12	and	and	CCONJ
fbem-7835	87	13	patients	patient	NOUN
fbem-7835	87	14	.	.	PUNCT
fbem-7835	88	1	nowadays	nowadays	ADV
fbem-7835	88	2	,	,	PUNCT
fbem-7835	88	3	in	in	ADP
fbem-7835	88	4	china	china	PROPN
fbem-7835	88	5	,	,	PUNCT
fbem-7835	88	6	medical	medical	ADJ
fbem-7835	88	7	insurance	insurance	NOUN
fbem-7835	88	8	negotiation	negotiation	NOUN
fbem-7835	88	9	has	have	AUX
fbem-7835	88	10	become	become	VERB
fbem-7835	88	11	an	an	DET
fbem-7835	88	12	important	important	ADJ
fbem-7835	88	13	means	mean	NOUN
fbem-7835	88	14	of	of	ADP
fbem-7835	88	15	adjusting	adjust	VERB
fbem-7835	88	16	the	the	DET
fbem-7835	88	17	national	national	PROPN
fbem-7835	88	18	medical	medical	PROPN
fbem-7835	88	19	insurance	insurance	NOUN
fbem-7835	88	20	catalogue	catalogue	NOUN
fbem-7835	88	21	,	,	PUNCT
fbem-7835	88	22	and	and	CCONJ
fbem-7835	88	23	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	88	24	evaluation	evaluation	NOUN
fbem-7835	88	25	provides	provide	VERB
fbem-7835	88	26	important	important	ADJ
fbem-7835	88	27	evidence	evidence	NOUN
fbem-7835	88	28	for	for	ADP
fbem-7835	88	29	medical	medical	ADJ
fbem-7835	88	30	insurance	insurance	NOUN
fbem-7835	88	31	negotiation	negotiation	NOUN
fbem-7835	88	32	and	and	CCONJ
fbem-7835	88	33	pricing	pricing	NOUN
fbem-7835	88	34	,	,	PUNCT
fbem-7835	88	35	which	which	PRON
fbem-7835	88	36	is	be	AUX
fbem-7835	88	37	particularly	particularly	ADV
fbem-7835	88	38	important	important	ADJ
fbem-7835	88	39	in	in	ADP
fbem-7835	88	40	the	the	DET
fbem-7835	88	41	process	process	NOUN
fbem-7835	88	42	of	of	ADP
fbem-7835	88	43	medical	medical	ADJ
fbem-7835	88	44	insurance	insurance	NOUN
fbem-7835	88	45	access[13	access[13	ADP
fbem-7835	88	46	]	]	X
fbem-7835	88	47	.	.	PUNCT
fbem-7835	89	1	especially	especially	ADV
fbem-7835	89	2	for	for	ADP
fbem-7835	89	3	exclusive	exclusive	ADJ
fbem-7835	89	4	patent	patent	NOUN
fbem-7835	89	5	innovative	innovative	ADJ
fbem-7835	89	6	drugs	drug	NOUN
fbem-7835	89	7	with	with	ADP
fbem-7835	89	8	obvious	obvious	ADJ
fbem-7835	89	9	benefits	benefit	NOUN
fbem-7835	89	10	but	but	CCONJ
fbem-7835	89	11	high	high	ADJ
fbem-7835	89	12	prices	price	NOUN
fbem-7835	89	13	,	,	PUNCT
fbem-7835	89	14	it	it	PRON
fbem-7835	89	15	is	be	AUX
fbem-7835	89	16	more	more	ADV
fbem-7835	89	17	necessary	necessary	ADJ
fbem-7835	89	18	to	to	PART
fbem-7835	89	19	use	use	VERB
fbem-7835	89	20	the	the	DET
fbem-7835	89	21	method	method	NOUN
fbem-7835	89	22	of	of	ADP
fbem-7835	89	23	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	89	24	evaluation	evaluation	NOUN
fbem-7835	89	25	to	to	PART
fbem-7835	89	26	carry	carry	VERB
fbem-7835	89	27	out	out	ADP
fbem-7835	89	28	value	value	NOUN
fbem-7835	89	29	-	-	PUNCT
fbem-7835	89	30	based	base	VERB
fbem-7835	89	31	negotiation	negotiation	NOUN
fbem-7835	89	32	pricing	pricing	NOUN
fbem-7835	89	33	.	.	PUNCT
fbem-7835	90	1	therefore	therefore	ADV
fbem-7835	90	2	,	,	PUNCT
fbem-7835	90	3	from	from	ADP
fbem-7835	90	4	the	the	DET
fbem-7835	90	5	perspective	perspective	NOUN
fbem-7835	90	6	of	of	ADP
fbem-7835	90	7	china	china	PROPN
fbem-7835	90	8	's	's	PART
fbem-7835	90	9	health	health	NOUN
fbem-7835	90	10	system	system	NOUN
fbem-7835	90	11	,	,	PUNCT
fbem-7835	90	12	this	this	DET
fbem-7835	90	13	study	study	NOUN
fbem-7835	90	14	constructed	construct	VERB
fbem-7835	90	15	a	a	DET
fbem-7835	90	16	partitioned	partition	VERB
fbem-7835	90	17	survival	survival	NOUN
fbem-7835	90	18	model	model	NOUN
fbem-7835	90	19	based	base	VERB
fbem-7835	90	20	on	on	ADP
fbem-7835	90	21	the	the	DET
fbem-7835	90	22	international	international	ADJ
fbem-7835	90	23	multi	multi	ADJ
fbem-7835	90	24	-	-	ADJ
fbem-7835	90	25	center	center	ADJ
fbem-7835	90	26	phase	phase	NOUN
fbem-7835	90	27	ii	ii	NOUN
fbem-7835	90	28	clinical	clinical	ADJ
fbem-7835	90	29	trial	trial	NOUN
fbem-7835	90	30	(	(	PUNCT
fbem-7835	90	31	go29365	go29365	PROPN
fbem-7835	90	32	)	)	PUNCT
fbem-7835	90	33	to	to	PART
fbem-7835	90	34	evaluate	evaluate	VERB
fbem-7835	90	35	the	the	DET
fbem-7835	90	36	economy	economy	NOUN
fbem-7835	90	37	of	of	ADP
fbem-7835	90	38	polatuzumab	polatuzumab	NOUN
fbem-7835	90	39	vedotin	vedotin	ADV
fbem-7835	90	40	combined	combine	VERB
fbem-7835	90	41	with	with	ADP
fbem-7835	90	42	bendamustine	bendamustine	NOUN
fbem-7835	90	43	and	and	CCONJ
fbem-7835	90	44	rituximab	rituximab	NOUN
fbem-7835	90	45	in	in	ADP
fbem-7835	90	46	r	r	NOUN
fbem-7835	90	47	/	/	SYM
fbem-7835	90	48	r	r	NOUN
fbem-7835	90	49	dlbcl	dlbcl	NOUN
fbem-7835	90	50	treatment	treatment	NOUN
fbem-7835	90	51	.	.	PUNCT
fbem-7835	91	1	the	the	DET
fbem-7835	91	2	results	result	NOUN
fbem-7835	91	3	of	of	ADP
fbem-7835	91	4	base	base	NOUN
fbem-7835	91	5	case	case	NOUN
fbem-7835	91	6	showed	show	VERB
fbem-7835	91	7	that	that	SCONJ
fbem-7835	91	8	compared	compare	VERB
fbem-7835	91	9	with	with	ADP
fbem-7835	91	10	the	the	DET
fbem-7835	91	11	br	br	PROPN
fbem-7835	91	12	group	group	NOUN
fbem-7835	91	13	,	,	PUNCT
fbem-7835	91	14	the	the	DET
fbem-7835	91	15	incremental	incremental	ADJ
fbem-7835	91	16	cost	cost	NOUN
fbem-7835	91	17	of	of	ADP
fbem-7835	91	18	patients	patient	NOUN
fbem-7835	91	19	in	in	ADP
fbem-7835	91	20	the	the	DET
fbem-7835	91	21	pola_br	pola_br	ADJ
fbem-7835	91	22	group	group	NOUN
fbem-7835	91	23	was	be	AUX
fbem-7835	91	24	231,117.90	231,117.90	NUM
fbem-7835	91	25	yuan	yuan	NOUN
fbem-7835	91	26	,	,	PUNCT
fbem-7835	91	27	the	the	DET
fbem-7835	91	28	incremental	incremental	ADJ
fbem-7835	91	29	quality	quality	NOUN
fbem-7835	91	30	-	-	PUNCT
fbem-7835	91	31	adjusted	adjust	VERB
fbem-7835	91	32	life	life	NOUN
fbem-7835	91	33	years	year	NOUN
fbem-7835	91	34	(	(	PUNCT
fbem-7835	91	35	qalys	qaly	NOUN
fbem-7835	91	36	)	)	PUNCT
fbem-7835	91	37	was	be	AUX
fbem-7835	91	38	1.17	1.17	NUM
fbem-7835	91	39	,	,	PUNCT
fbem-7835	91	40	and	and	CCONJ
fbem-7835	91	41	the	the	DET
fbem-7835	91	42	icur	icur	NOUN
fbem-7835	91	43	was	be	AUX
fbem-7835	91	44	197,434.75	197,434.75	NUM
fbem-7835	91	45	yuan	yuan	PROPN
fbem-7835	91	46	/	/	SYM
fbem-7835	91	47	qaly	qaly	PROPN
fbem-7835	91	48	.	.	PUNCT
fbem-7835	92	1	that	that	PRON
fbem-7835	92	2	is	be	AUX
fbem-7835	92	3	to	to	PART
fbem-7835	92	4	say	say	VERB
fbem-7835	92	5	,	,	PUNCT
fbem-7835	92	6	patients	patient	NOUN
fbem-7835	92	7	in	in	ADP
fbem-7835	92	8	the	the	DET
fbem-7835	92	9	pola_br	pola_br	ADJ
fbem-7835	92	10	group	group	NOUN
fbem-7835	92	11	need	need	VERB
fbem-7835	92	12	to	to	PART
fbem-7835	92	13	pay	pay	VERB
fbem-7835	92	14	197,434.75	197,434.75	NUM
fbem-7835	92	15	yuan	yuan	NOUN
fbem-7835	92	16	more	more	ADJ
fbem-7835	92	17	for	for	ADP
fbem-7835	92	18	each	each	DET
fbem-7835	92	19	additional	additional	ADJ
fbem-7835	92	20	qaly	qaly	NOUN
fbem-7835	92	21	than	than	ADP
fbem-7835	92	22	patients	patient	NOUN
fbem-7835	92	23	in	in	ADP
fbem-7835	92	24	the	the	DET
fbem-7835	92	25	br	br	PROPN
fbem-7835	92	26	group	group	NOUN
fbem-7835	92	27	,	,	PUNCT
fbem-7835	92	28	which	which	PRON
fbem-7835	92	29	is	be	AUX
fbem-7835	92	30	more	more	ADJ
fbem-7835	92	31	than	than	ADP
fbem-7835	92	32	1	1	NUM
fbem-7835	92	33	time	time	NOUN
fbem-7835	92	34	the	the	DET
fbem-7835	92	35	per	per	ADP
fbem-7835	92	36	capita	capita	X
fbem-7835	92	37	gdp	gdp	NOUN
fbem-7835	92	38	of	of	ADP
fbem-7835	92	39	china	china	PROPN
fbem-7835	92	40	in	in	ADP
fbem-7835	92	41	2022	2022	NUM
fbem-7835	92	42	,	,	PUNCT
fbem-7835	92	43	85,698	85,698	NUM
fbem-7835	92	44	yuan	yuan	NOUN
fbem-7835	92	45	.	.	PUNCT
fbem-7835	93	1	it	it	PRON
fbem-7835	93	2	shows	show	VERB
fbem-7835	93	3	that	that	SCONJ
fbem-7835	93	4	it	it	PRON
fbem-7835	93	5	is	be	AUX
fbem-7835	93	6	not	not	PART
fbem-7835	93	7	economical	economical	ADJ
fbem-7835	93	8	under	under	ADP
fbem-7835	93	9	this	this	DET
fbem-7835	93	10	threshold	threshold	NOUN
fbem-7835	93	11	.	.	PUNCT
fbem-7835	94	1	since	since	SCONJ
fbem-7835	94	2	the	the	DET
fbem-7835	94	3	results	result	NOUN
fbem-7835	94	4	of	of	ADP
fbem-7835	94	5	the	the	DET
fbem-7835	94	6	basic	basic	ADJ
fbem-7835	94	7	analysis	analysis	NOUN
fbem-7835	94	8	calculated	calculate	VERB
fbem-7835	94	9	by	by	ADP
fbem-7835	94	10	the	the	DET
fbem-7835	94	11	baseline	baseline	ADJ
fbem-7835	94	12	price	price	NOUN
fbem-7835	94	13	of	of	ADP
fbem-7835	94	14	polatuzumab	polatuzumab	NOUN
fbem-7835	94	15	vedotin	vedotin	PROPN
fbem-7835	94	16	shows	show	VERB
fbem-7835	94	17	that	that	SCONJ
fbem-7835	94	18	the	the	DET
fbem-7835	94	19	study	study	NOUN
fbem-7835	94	20	group	group	NOUN
fbem-7835	94	21	is	be	AUX
fbem-7835	94	22	not	not	PART
fbem-7835	94	23	economical	economical	ADJ
fbem-7835	94	24	under	under	ADP
fbem-7835	94	25	the	the	DET
fbem-7835	94	26	threshold	threshold	NOUN
fbem-7835	94	27	of	of	ADP
fbem-7835	94	28	1	1	NUM
fbem-7835	94	29	times	time	NOUN
fbem-7835	94	30	per	per	ADP
fbem-7835	94	31	capita	capita	X
fbem-7835	94	32	gdp	gdp	NOUN
fbem-7835	94	33	,	,	PUNCT
fbem-7835	94	34	this	this	DET
fbem-7835	94	35	study	study	NOUN
fbem-7835	94	36	assumes	assume	VERB
fbem-7835	94	37	that	that	SCONJ
fbem-7835	94	38	the	the	DET
fbem-7835	94	39	maximum	maximum	ADJ
fbem-7835	94	40	price	price	NOUN
fbem-7835	94	41	of	of	ADP
fbem-7835	94	42	polatuzumab	polatuzumab	NOUN
fbem-7835	94	43	vedotin	vedotin	NOUN
fbem-7835	94	44	is	be	AUX
fbem-7835	94	45	the	the	DET
fbem-7835	94	46	baseline	baseline	ADJ
fbem-7835	94	47	price	price	NOUN
fbem-7835	94	48	,	,	PUNCT
fbem-7835	94	49	while	while	SCONJ
fbem-7835	94	50	the	the	DET
fbem-7835	94	51	minimum	minimum	ADJ
fbem-7835	94	52	price	price	NOUN
fbem-7835	94	53	is	be	AUX
fbem-7835	94	54	20	20	NUM
fbem-7835	94	55	%	%	NOUN
fbem-7835	94	56	lower	low	ADJ
fbem-7835	94	57	than	than	ADP
fbem-7835	94	58	the	the	DET
fbem-7835	94	59	baseline	baseline	NOUN
fbem-7835	94	60	price	price	NOUN
fbem-7835	94	61	.	.	PUNCT
fbem-7835	95	1	the	the	DET
fbem-7835	95	2	results	result	NOUN
fbem-7835	95	3	of	of	ADP
fbem-7835	95	4	univariate	univariate	ADJ
fbem-7835	95	5	sensitivity	sensitivity	NOUN
fbem-7835	95	6	analysis	analysis	NOUN
fbem-7835	95	7	showed	show	VERB
fbem-7835	95	8	that	that	SCONJ
fbem-7835	95	9	the	the	DET
fbem-7835	95	10	drug	drug	NOUN
fbem-7835	95	11	cost	cost	NOUN
fbem-7835	95	12	of	of	ADP
fbem-7835	95	13	each	each	DET
fbem-7835	95	14	cycle	cycle	NOUN
fbem-7835	95	15	in	in	ADP
fbem-7835	95	16	pola_br	pola_br	PROPN
fbem-7835	95	17	group	group	NOUN
fbem-7835	95	18	,	,	PUNCT
fbem-7835	95	19	the	the	DET
fbem-7835	95	20	utility	utility	NOUN
fbem-7835	95	21	value	value	NOUN
fbem-7835	95	22	of	of	ADP
fbem-7835	95	23	pfs	pfs	PROPN
fbem-7835	95	24	status	status	PROPN
fbem-7835	95	25	,	,	PUNCT
fbem-7835	95	26	the	the	DET
fbem-7835	95	27	discount	discount	NOUN
fbem-7835	95	28	rate	rate	NOUN
fbem-7835	95	29	and	and	CCONJ
fbem-7835	95	30	the	the	DET
fbem-7835	95	31	cost	cost	NOUN
fbem-7835	95	32	of	of	ADP
fbem-7835	95	33	each	each	DET
fbem-7835	95	34	cycle	cycle	NOUN
fbem-7835	95	35	in	in	ADP
fbem-7835	95	36	br	br	PROPN
fbem-7835	95	37	group	group	NOUN
fbem-7835	95	38	,	,	PUNCT
fbem-7835	95	39	had	have	VERB
fbem-7835	95	40	a	a	DET
fbem-7835	95	41	greater	great	ADJ
fbem-7835	95	42	impact	impact	NOUN
fbem-7835	95	43	on	on	ADP
fbem-7835	95	44	the	the	DET
fbem-7835	95	45	results	result	NOUN
fbem-7835	95	46	of	of	ADP
fbem-7835	95	47	the	the	DET
fbem-7835	95	48	cost	cost	NOUN
fbem-7835	95	49	-	-	PUNCT
fbem-7835	95	50	utility	utility	NOUN
fbem-7835	95	51	analysis	analysis	NOUN
fbem-7835	95	52	,	,	PUNCT
fbem-7835	95	53	while	while	SCONJ
fbem-7835	95	54	the	the	DET
fbem-7835	95	55	incidence	incidence	NOUN
fbem-7835	95	56	of	of	ADP
fbem-7835	95	57	adverse	adverse	ADJ
fbem-7835	95	58	events	event	NOUN
fbem-7835	95	59	,	,	PUNCT
fbem-7835	95	60	the	the	DET
fbem-7835	95	61	cost	cost	NOUN
fbem-7835	95	62	of	of	ADP
fbem-7835	95	63	follow	follow	NOUN
fbem-7835	95	64	-	-	PUNCT
fbem-7835	95	65	up	up	ADP
fbem-7835	95	66	testing	testing	NOUN
fbem-7835	95	67	and	and	CCONJ
fbem-7835	95	68	other	other	ADJ
fbem-7835	95	69	parameters	parameter	NOUN
fbem-7835	95	70	had	have	VERB
fbem-7835	95	71	less	less	ADJ
fbem-7835	95	72	impact	impact	NOUN
fbem-7835	95	73	on	on	ADP
fbem-7835	95	74	the	the	DET
fbem-7835	95	75	results	result	NOUN
fbem-7835	95	76	,	,	PUNCT
fbem-7835	95	77	and	and	CCONJ
fbem-7835	95	78	the	the	DET
fbem-7835	95	79	results	result	NOUN
fbem-7835	95	80	would	would	AUX
fbem-7835	95	81	not	not	PART
fbem-7835	95	82	be	be	AUX
fbem-7835	95	83	reversed	reverse	VERB
fbem-7835	95	84	within	within	ADP
fbem-7835	95	85	the	the	DET
fbem-7835	95	86	set	set	NOUN
fbem-7835	95	87	parameter	parameter	NOUN
fbem-7835	95	88	range	range	NOUN
fbem-7835	95	89	.	.	PUNCT
fbem-7835	96	1	the	the	DET
fbem-7835	96	2	results	result	NOUN
fbem-7835	96	3	of	of	ADP
fbem-7835	96	4	probability	probability	NOUN
fbem-7835	96	5	sensitivity	sensitivity	NOUN
fbem-7835	96	6	analysis	analysis	NOUN
fbem-7835	96	7	show	show	VERB
fbem-7835	96	8	that	that	SCONJ
fbem-7835	96	9	when	when	SCONJ
fbem-7835	96	10	wtp	wtp	NOUN
fbem-7835	96	11	is	be	AUX
fbem-7835	96	12	1	1	NUM
fbem-7835	96	13	times	time	NOUN
fbem-7835	96	14	china	china	PROPN
fbem-7835	96	15	's	's	PART
fbem-7835	96	16	per	per	ADP
fbem-7835	96	17	capita	capita	X
fbem-7835	96	18	gdp	gdp	NOUN
fbem-7835	96	19	in	in	ADP
fbem-7835	96	20	2022	2022	NUM
fbem-7835	96	21	,	,	PUNCT
fbem-7835	96	22	the	the	DET
fbem-7835	96	23	probability	probability	NOUN
fbem-7835	96	24	that	that	SCONJ
fbem-7835	96	25	the	the	DET
fbem-7835	96	26	pola_br	pola_br	PROPN
fbem-7835	96	27	group	group	NOUN
fbem-7835	96	28	has	have	VERB
fbem-7835	96	29	a	a	DET
fbem-7835	96	30	cost	cost	NOUN
fbem-7835	96	31	-	-	PUNCT
fbem-7835	96	32	utility	utility	NOUN
fbem-7835	96	33	advantage	advantage	NOUN
fbem-7835	96	34	is	be	AUX
fbem-7835	96	35	0	0	NUM
fbem-7835	96	36	%	%	NOUN
fbem-7835	96	37	.	.	PUNCT
fbem-7835	97	1	when	when	SCONJ
fbem-7835	97	2	the	the	DET
fbem-7835	97	3	wtp	wtp	NOUN
fbem-7835	97	4	is	be	AUX
fbem-7835	97	5	172,000	172,000	NUM
fbem-7835	97	6	yuan	yuan	NOUN
fbem-7835	97	7	/	/	SYM
fbem-7835	97	8	qaly	qaly	PROPN
fbem-7835	97	9	,	,	PUNCT
fbem-7835	97	10	the	the	DET
fbem-7835	97	11	possibility	possibility	NOUN
fbem-7835	97	12	of	of	ADP
fbem-7835	97	13	cost	cost	NOUN
fbem-7835	97	14	-	-	PUNCT
fbem-7835	97	15	utility	utility	NOUN
fbem-7835	97	16	advantage	advantage	NOUN
fbem-7835	97	17	in	in	ADP
fbem-7835	97	18	pola_br	pola_br	PROPN
fbem-7835	97	19	group	group	NOUN
fbem-7835	97	20	begins	begin	VERB
fbem-7835	97	21	;	;	PUNCT
fbem-7835	97	22	under	under	ADP
fbem-7835	97	23	the	the	DET
fbem-7835	97	24	threshold	threshold	NOUN
fbem-7835	97	25	of	of	ADP
fbem-7835	97	26	3	3	NUM
fbem-7835	97	27	times	time	NOUN
fbem-7835	97	28	per	per	ADP
fbem-7835	97	29	capita	capita	X
fbem-7835	97	30	gdp	gdp	NOUN
fbem-7835	97	31	,	,	PUNCT
fbem-7835	97	32	the	the	DET
fbem-7835	97	33	probability	probability	NOUN
fbem-7835	97	34	of	of	ADP
fbem-7835	97	35	cost	cost	NOUN
fbem-7835	97	36	-	-	PUNCT
fbem-7835	97	37	utility	utility	NOUN
fbem-7835	97	38	advantage	advantage	NOUN
fbem-7835	97	39	in	in	ADP
fbem-7835	97	40	pola_br	pola_br	ADJ
fbem-7835	97	41	group	group	NOUN
fbem-7835	97	42	is	be	AUX
fbem-7835	97	43	only	only	ADV
fbem-7835	97	44	3.8	3.8	NUM
fbem-7835	97	45	%	%	NOUN
fbem-7835	97	46	;	;	PUNCT
fbem-7835	97	47	when	when	SCONJ
fbem-7835	97	48	the	the	DET
fbem-7835	97	49	probability	probability	NOUN
fbem-7835	97	50	of	of	ADP
fbem-7835	97	51	cost	cost	NOUN
fbem-7835	97	52	-	-	PUNCT
fbem-7835	97	53	utility	utility	NOUN
fbem-7835	97	54	advantage	advantage	NOUN
fbem-7835	97	55	in	in	ADP
fbem-7835	97	56	pola_br	pola_br	PROPN
fbem-7835	97	57	group	group	NOUN
fbem-7835	97	58	reached	reach	VERB
fbem-7835	97	59	50	50	NUM
fbem-7835	97	60	%	%	NOUN
fbem-7835	97	61	,	,	PUNCT
fbem-7835	97	62	the	the	DET
fbem-7835	97	63	wtp	wtp	NOUN
fbem-7835	97	64	reached	reach	VERB
fbem-7835	97	65	784,000	784,000	NUM
fbem-7835	97	66	.	.	PUNCT
fbem-7835	98	1	this	this	DET
fbem-7835	98	2	study	study	NOUN
fbem-7835	98	3	also	also	ADV
fbem-7835	98	4	has	have	VERB
fbem-7835	98	5	some	some	DET
fbem-7835	98	6	limitations	limitation	NOUN
fbem-7835	98	7	:	:	PUNCT
fbem-7835	98	8	(	(	PUNCT
fbem-7835	98	9	1	1	X
fbem-7835	98	10	)	)	PUNCT
fbem-7835	98	11	the	the	DET
fbem-7835	98	12	partitioned	partition	VERB
fbem-7835	98	13	survival	survival	NOUN
fbem-7835	98	14	model	model	NOUN
fbem-7835	98	15	depends	depend	VERB
fbem-7835	98	16	on	on	ADP
fbem-7835	98	17	the	the	DET
fbem-7835	98	18	complete	complete	ADJ
fbem-7835	98	19	report	report	NOUN
fbem-7835	98	20	of	of	ADP
fbem-7835	98	21	the	the	DET
fbem-7835	98	22	survival	survival	NOUN
fbem-7835	98	23	curve	curve	NOUN
fbem-7835	98	24	in	in	ADP
fbem-7835	98	25	clinical	clinical	ADJ
fbem-7835	98	26	trials	trial	NOUN
fbem-7835	98	27	.	.	PUNCT
fbem-7835	99	1	in	in	ADP
fbem-7835	99	2	the	the	DET
fbem-7835	99	3	currently	currently	ADV
fbem-7835	99	4	published	publish	VERB
fbem-7835	99	5	go29365	go29365	PROPN
fbem-7835	99	6	study	study	NOUN
fbem-7835	99	7	,	,	PUNCT
fbem-7835	99	8	the	the	DET
fbem-7835	99	9	os	os	NOUN
fbem-7835	99	10	curve	curve	NOUN
fbem-7835	99	11	and	and	CCONJ
fbem-7835	99	12	pfs	pfs	PROPN
fbem-7835	99	13	curve	curve	NOUN
fbem-7835	99	14	of	of	ADP
fbem-7835	99	15	the	the	DET
fbem-7835	99	16	two	two	NUM
fbem-7835	99	17	groups	group	NOUN
fbem-7835	99	18	of	of	ADP
fbem-7835	99	19	treatment	treatment	NOUN
fbem-7835	99	20	regimens	regimen	NOUN
fbem-7835	99	21	are	be	AUX
fbem-7835	99	22	not	not	PART
fbem-7835	99	23	yet	yet	ADV
fbem-7835	99	24	mature	mature	ADJ
fbem-7835	99	25	,	,	PUNCT
fbem-7835	99	26	which	which	PRON
fbem-7835	99	27	may	may	AUX
fbem-7835	99	28	affect	affect	VERB
fbem-7835	99	29	the	the	DET
fbem-7835	99	30	fitting	fitting	NOUN
fbem-7835	99	31	of	of	ADP
fbem-7835	99	32	the	the	DET
fbem-7835	99	33	survival	survival	NOUN
fbem-7835	99	34	curve	curve	NOUN
fbem-7835	99	35	.	.	PUNCT
fbem-7835	100	1	at	at	ADP
fbem-7835	100	2	the	the	DET
fbem-7835	100	3	same	same	ADJ
fbem-7835	100	4	time	time	NOUN
fbem-7835	100	5	,	,	PUNCT
fbem-7835	100	6	the	the	DET
fbem-7835	100	7	go29365	go29365	PROPN
fbem-7835	100	8	study	study	NOUN
fbem-7835	100	9	is	be	AUX
fbem-7835	100	10	a	a	DET
fbem-7835	100	11	multi	multi	ADJ
fbem-7835	100	12	-	-	ADJ
fbem-7835	100	13	center	center	ADJ
fbem-7835	100	14	phase	phase	NOUN
fbem-7835	100	15	ii	ii	NOUN
fbem-7835	100	16	clinical	clinical	ADJ
fbem-7835	100	17	trial	trial	NOUN
fbem-7835	100	18	with	with	ADP
fbem-7835	100	19	a	a	DET
fbem-7835	100	20	small	small	ADJ
fbem-7835	100	21	number	number	NOUN
fbem-7835	100	22	of	of	ADP
fbem-7835	100	23	patients	patient	NOUN
fbem-7835	100	24	(	(	PUNCT
fbem-7835	100	25	40	40	NUM
fbem-7835	100	26	in	in	ADP
fbem-7835	100	27	each	each	DET
fbem-7835	100	28	intervention	intervention	NOUN
fbem-7835	100	29	group	group	NOUN
fbem-7835	100	30	)	)	PUNCT
fbem-7835	100	31	and	and	CCONJ
fbem-7835	100	32	no	no	DET
fbem-7835	100	33	subgroup	subgroup	NOUN
fbem-7835	100	34	analysis	analysis	NOUN
fbem-7835	100	35	for	for	ADP
fbem-7835	100	36	the	the	DET
fbem-7835	100	37	asian	asian	ADJ
fbem-7835	100	38	population	population	NOUN
fbem-7835	100	39	.	.	PUNCT
fbem-7835	101	1	the	the	DET
fbem-7835	101	2	patient	patient	ADJ
fbem-7835	101	3	size	size	NOUN
fbem-7835	101	4	and	and	CCONJ
fbem-7835	101	5	the	the	DET
fbem-7835	101	6	difference	difference	NOUN
fbem-7835	101	7	in	in	ADP
fbem-7835	101	8	treatment	treatment	NOUN
fbem-7835	101	9	effects	effect	NOUN
fbem-7835	101	10	between	between	ADP
fbem-7835	101	11	different	different	ADJ
fbem-7835	101	12	ethnic	ethnic	ADJ
fbem-7835	101	13	groups	group	NOUN
fbem-7835	101	14	may	may	AUX
fbem-7835	101	15	affect	affect	VERB
fbem-7835	101	16	the	the	DET
fbem-7835	101	17	results	result	NOUN
fbem-7835	101	18	.	.	PUNCT
fbem-7835	102	1	(	(	PUNCT
fbem-7835	102	2	2	2	X
fbem-7835	102	3	)	)	PUNCT
fbem-7835	102	4	in	in	ADP
fbem-7835	102	5	this	this	DET
fbem-7835	102	6	study	study	NOUN
fbem-7835	102	7	,	,	PUNCT
fbem-7835	102	8	the	the	DET
fbem-7835	102	9	cost	cost	NOUN
fbem-7835	102	10	of	of	ADP
fbem-7835	102	11	subsequent	subsequent	ADJ
fbem-7835	102	12	treatment	treatment	NOUN
fbem-7835	102	13	was	be	AUX
fbem-7835	102	14	not	not	PART
fbem-7835	102	15	included	include	VERB
fbem-7835	102	16	in	in	ADP
fbem-7835	102	17	the	the	DET
fbem-7835	102	18	cost	cost	NOUN
fbem-7835	102	19	calculation	calculation	NOUN
fbem-7835	102	20	,	,	PUNCT
fbem-7835	102	21	mainly	mainly	ADV
fbem-7835	102	22	because	because	SCONJ
fbem-7835	102	23	in	in	ADP
fbem-7835	102	24	reality	reality	NOUN
fbem-7835	102	25	,	,	PUNCT
fbem-7835	102	26	the	the	DET
fbem-7835	102	27	subsequent	subsequent	ADJ
fbem-7835	102	28	treatment	treatment	NOUN
fbem-7835	102	29	of	of	ADP
fbem-7835	102	30	patients	patient	NOUN
fbem-7835	102	31	may	may	AUX
fbem-7835	102	32	be	be	AUX
fbem-7835	102	33	different	different	ADJ
fbem-7835	102	34	due	due	ADJ
fbem-7835	102	35	to	to	ADP
fbem-7835	102	36	different	different	ADJ
fbem-7835	102	37	individual	individual	ADJ
fbem-7835	102	38	characteristics	characteristic	NOUN
fbem-7835	102	39	,	,	PUNCT
fbem-7835	102	40	which	which	PRON
fbem-7835	102	41	is	be	AUX
fbem-7835	102	42	difficult	difficult	ADJ
fbem-7835	102	43	to	to	PART
fbem-7835	102	44	determine	determine	VERB
fbem-7835	102	45	.	.	PUNCT
fbem-7835	103	1	in	in	ADP
fbem-7835	103	2	addition	addition	NOUN
fbem-7835	103	3	,	,	PUNCT
fbem-7835	103	4	due	due	ADP
fbem-7835	103	5	to	to	ADP
fbem-7835	103	6	the	the	DET
fbem-7835	103	7	difficulty	difficulty	NOUN
fbem-7835	103	8	in	in	ADP
fbem-7835	103	9	obtaining	obtain	VERB
fbem-7835	103	10	data	datum	NOUN
fbem-7835	103	11	such	such	ADJ
fbem-7835	103	12	as	as	ADP
fbem-7835	103	13	the	the	DET
fbem-7835	103	14	cost	cost	NOUN
fbem-7835	103	15	of	of	ADP
fbem-7835	103	16	hematopoietic	hematopoietic	ADJ
fbem-7835	103	17	stem	stem	NOUN
fbem-7835	103	18	cell	cell	NOUN
fbem-7835	103	19	transplantation	transplantation	NOUN
fbem-7835	103	20	in	in	ADP
fbem-7835	103	21	china	china	PROPN
fbem-7835	103	22	,	,	PUNCT
fbem-7835	103	23	the	the	DET
fbem-7835	103	24	cost	cost	NOUN
fbem-7835	103	25	of	of	ADP
fbem-7835	103	26	follow	follow	NOUN
fbem-7835	103	27	-	-	PUNCT
fbem-7835	103	28	up	up	NOUN
fbem-7835	103	29	after	after	ADP
fbem-7835	103	30	transplantation	transplantation	NOUN
fbem-7835	103	31	,	,	PUNCT
fbem-7835	103	32	the	the	DET
fbem-7835	103	33	occurrence	occurrence	NOUN
fbem-7835	103	34	of	of	ADP
fbem-7835	103	35	infection	infection	NOUN
fbem-7835	103	36	,	,	PUNCT
fbem-7835	103	37	and	and	CCONJ
fbem-7835	103	38	the	the	DET
fbem-7835	103	39	related	relate	VERB
fbem-7835	103	40	treatment	treatment	NOUN
fbem-7835	103	41	costs	cost	NOUN
fbem-7835	103	42	,	,	PUNCT
fbem-7835	103	43	this	this	DET
fbem-7835	103	44	study	study	NOUN
fbem-7835	103	45	did	do	AUX
fbem-7835	103	46	not	not	PART
fbem-7835	103	47	consider	consider	VERB
fbem-7835	103	48	the	the	DET
fbem-7835	103	49	patients	patient	NOUN
fbem-7835	103	50	receive	receive	VERB
fbem-7835	103	51	the	the	DET
fbem-7835	103	52	hematopoietic	hematopoietic	ADJ
fbem-7835	103	53	stem	stem	NOUN
fbem-7835	103	54	cell	cell	NOUN
fbem-7835	103	55	transplantation	transplantation	NOUN
fbem-7835	103	56	which	which	PRON
fbem-7835	103	57	patients	patient	NOUN
fbem-7835	103	58	can	can	AUX
fbem-7835	103	59	be	be	AUX
fbem-7835	103	60	clinically	clinically	ADV
fbem-7835	103	61	cured	cure	VERB
fbem-7835	103	62	after	after	ADP
fbem-7835	103	63	receiving	receive	VERB
fbem-7835	103	64	rescue	rescue	NOUN
fbem-7835	103	65	treatment	treatment	NOUN
fbem-7835	103	66	and	and	CCONJ
fbem-7835	103	67	obtaining	obtain	VERB
fbem-7835	103	68	great	great	ADJ
fbem-7835	103	69	effect	effect	NOUN
fbem-7835	103	70	,	,	PUNCT
fbem-7835	103	71	which	which	PRON
fbem-7835	103	72	may	may	AUX
fbem-7835	103	73	underestimate	underestimate	VERB
fbem-7835	103	74	the	the	DET
fbem-7835	103	75	potential	potential	ADJ
fbem-7835	103	76	benefits	benefit	NOUN
fbem-7835	103	77	of	of	ADP
fbem-7835	103	78	polatuzumab	polatuzumab	NOUN
fbem-7835	103	79	vedotin	vedotin	ADV
fbem-7835	103	80	in	in	ADP
fbem-7835	103	81	this	this	DET
fbem-7835	103	82	study	study	NOUN
fbem-7835	103	83	.	.	PUNCT
fbem-7835	104	1	therefore	therefore	ADV
fbem-7835	104	2	,	,	PUNCT
fbem-7835	104	3	in	in	ADP
fbem-7835	104	4	the	the	DET
fbem-7835	104	5	future	future	NOUN
fbem-7835	104	6	,	,	PUNCT
fbem-7835	104	7	it	it	PRON
fbem-7835	104	8	is	be	AUX
fbem-7835	104	9	urgent	urgent	ADJ
fbem-7835	104	10	to	to	PART
fbem-7835	104	11	evaluate	evaluate	VERB
fbem-7835	104	12	based	base	VERB
fbem-7835	104	13	on	on	ADP
fbem-7835	104	14	the	the	DET
fbem-7835	104	15	mature	mature	ADJ
fbem-7835	104	16	subgroup	subgroup	NOUN
fbem-7835	104	17	survival	survival	PROPN
fbem-7835	104	18	analysis	analysis	NOUN
fbem-7835	104	19	data	datum	NOUN
fbem-7835	104	20	of	of	ADP
fbem-7835	104	21	the	the	DET
fbem-7835	104	22	chinese	chinese	ADJ
fbem-7835	104	23	population	population	NOUN
fbem-7835	104	24	and	and	CCONJ
fbem-7835	104	25	explore	explore	VERB
fbem-7835	104	26	the	the	DET
fbem-7835	104	27	choice	choice	NOUN
fbem-7835	104	28	of	of	ADP
fbem-7835	104	29	subsequent	subsequent	ADJ
fbem-7835	104	30	treatment	treatment	NOUN
fbem-7835	104	31	options	option	NOUN
fbem-7835	104	32	for	for	ADP
fbem-7835	104	33	the	the	DET
fbem-7835	104	34	above	above	ADJ
fbem-7835	104	35	two	two	NUM
fbem-7835	104	36	groups	group	NOUN
fbem-7835	104	37	of	of	ADP
fbem-7835	104	38	patients	patient	NOUN
fbem-7835	104	39	and	and	CCONJ
fbem-7835	104	40	the	the	DET
fbem-7835	104	41	treatment	treatment	NOUN
fbem-7835	104	42	costs	cost	NOUN
fbem-7835	104	43	before	before	ADV
fbem-7835	104	44	and	and	CCONJ
fbem-7835	104	45	after	after	ADP
fbem-7835	104	46	hematopoietic	hematopoietic	ADJ
fbem-7835	104	47	stem	stem	NOUN
fbem-7835	104	48	cell	cell	NOUN
fbem-7835	104	49	transplantation	transplantation	NOUN
fbem-7835	104	50	in	in	ADP
fbem-7835	104	51	the	the	DET
fbem-7835	104	52	real	real	ADJ
fbem-7835	104	53	world	world	NOUN
fbem-7835	104	54	.	.	PUNCT
fbem-7835	105	1	in	in	ADP
fbem-7835	105	2	summary	summary	NOUN
fbem-7835	105	3	,	,	PUNCT
fbem-7835	105	4	based	base	VERB
fbem-7835	105	5	on	on	ADP
fbem-7835	105	6	china	china	PROPN
fbem-7835	105	7	's	's	PART
fbem-7835	105	8	1	1	NUM
fbem-7835	105	9	times	time	NOUN
fbem-7835	105	10	per	per	ADP
fbem-7835	105	11	capita	capita	X
fbem-7835	105	12	gdp	gdp	NOUN
fbem-7835	105	13	threshold	threshold	NOUN
fbem-7835	105	14	and	and	CCONJ
fbem-7835	105	15	treatment	treatment	NOUN
fbem-7835	105	16	environment	environment	NOUN
fbem-7835	105	17	of	of	ADP
fbem-7835	105	18	china	china	PROPN
fbem-7835	105	19	,	,	PUNCT
fbem-7835	105	20	polatuzumab	polatuzumab	NOUN
fbem-7835	105	21	vedotin	vedotin	ADV
fbem-7835	105	22	combined	combine	VERB
fbem-7835	105	23	with	with	ADP
fbem-7835	105	24	br	br	NOUN
fbem-7835	105	25	regimen	regiman	NOUN
fbem-7835	105	26	for	for	ADP
fbem-7835	105	27	r	r	NOUN
fbem-7835	105	28	/	/	SYM
fbem-7835	105	29	r	r	NOUN
fbem-7835	105	30	dlbcl	dlbcl	NOUN
fbem-7835	105	31	unsuitable	unsuitable	ADJ
fbem-7835	105	32	for	for	ADP
fbem-7835	105	33	hematopoietic	hematopoietic	ADJ
fbem-7835	105	34	stem	stem	NOUN
fbem-7835	105	35	cell	cell	NOUN
fbem-7835	105	36	transplantation	transplantation	NOUN
fbem-7835	105	37	has	have	VERB
fbem-7835	105	38	no	no	DET
fbem-7835	105	39	economic	economic	ADJ
fbem-7835	105	40	advantage	advantage	NOUN
fbem-7835	105	41	compared	compare	VERB
fbem-7835	105	42	with	with	ADP
fbem-7835	105	43	br	br	NOUN
fbem-7835	105	44	regimen	regiman	NOUN
fbem-7835	105	45	alone	alone	ADV
fbem-7835	105	46	.	.	PUNCT
fbem-7835	106	1	at	at	ADP
fbem-7835	106	2	the	the	DET
fbem-7835	106	3	same	same	ADJ
fbem-7835	106	4	time	time	NOUN
fbem-7835	106	5	,	,	PUNCT
fbem-7835	106	6	in	in	ADP
fbem-7835	106	7	the	the	DET
fbem-7835	106	8	specific	specific	ADJ
fbem-7835	106	9	decision	decision	NOUN
fbem-7835	106	10	-	-	PUNCT
fbem-7835	106	11	making	making	NOUN
fbem-7835	106	12	,	,	PUNCT
fbem-7835	106	13	it	it	PRON
fbem-7835	106	14	is	be	AUX
fbem-7835	106	15	necessary	necessary	ADJ
fbem-7835	106	16	to	to	PART
fbem-7835	106	17	pay	pay	VERB
fbem-7835	106	18	attention	attention	NOUN
fbem-7835	106	19	to	to	ADP
fbem-7835	106	20	the	the	DET
fbem-7835	106	21	influence	influence	NOUN
fbem-7835	106	22	of	of	ADP
fbem-7835	106	23	variables	variable	NOUN
fbem-7835	106	24	such	such	ADJ
fbem-7835	106	25	as	as	ADP
fbem-7835	106	26	the	the	DET
fbem-7835	106	27	price	price	NOUN
fbem-7835	106	28	of	of	ADP
fbem-7835	106	29	polatuzumab	polatuzumab	NOUN
fbem-7835	106	30	vedotin	vedotin	ADJ
fbem-7835	106	31	,	,	PUNCT
fbem-7835	106	32	discount	discount	NOUN
fbem-7835	106	33	rate	rate	NOUN
fbem-7835	106	34	and	and	CCONJ
fbem-7835	106	35	pfs	pf	VERB
fbem-7835	106	36	state	state	NOUN
fbem-7835	106	37	utility	utility	NOUN
fbem-7835	106	38	value	value	NOUN
fbem-7835	106	39	on	on	ADP
fbem-7835	106	40	the	the	DET
fbem-7835	106	41	results	result	NOUN
fbem-7835	106	42	.	.	PUNCT
fbem-7835	107	1	acknowledgment	acknowledgment	NOUN
fbem-7835	107	2	this	this	DET
fbem-7835	107	3	study	study	NOUN
fbem-7835	107	4	has	have	AUX
fbem-7835	107	5	no	no	DET
fbem-7835	107	6	found	find	VERB
fbem-7835	107	7	to	to	PART
fbem-7835	107	8	support	support	VERB
fbem-7835	107	9	.	.	PUNCT
fbem-7835	108	1	183	183	NUM
fbem-7835	108	2	table	table	NOUN
fbem-7835	108	3	2	2	NUM
fbem-7835	108	4	.	.	PUNCT
fbem-7835	108	5	model	model	NOUN
fbem-7835	108	6	parameters	parameter	NOUN
fbem-7835	108	7	and	and	CCONJ
fbem-7835	108	8	distribution	distribution	NOUN
fbem-7835	108	9	parameter	parameter	NOUN
fbem-7835	108	10	base	base	NOUN
fbem-7835	108	11	value	value	NOUN
fbem-7835	108	12	minimum	minimum	NOUN
fbem-7835	108	13	value	value	NOUN
fbem-7835	108	14	maximum	maximum	ADJ
fbem-7835	108	15	value	value	NOUN
fbem-7835	108	16	distribution	distribution	NOUN
fbem-7835	108	17	polatuzumab	polatuzumab	NOUN
fbem-7835	108	18	vedotin	vedotin	NOUN
fbem-7835	108	19	price	price	NOUN
fbem-7835	108	20	112.66	112.66	NUM
fbem-7835	108	21	90.128	90.128	NUM
fbem-7835	108	22	112.66	112.66	NUM
fbem-7835	108	23	gamma	gamma	NOUN
fbem-7835	108	24	bendamustine	bendamustine	NOUN
fbem-7835	108	25	price	price	NOUN
fbem-7835	108	26	398.8	398.8	NUM
fbem-7835	108	27	360.3825	360.3825	NUM
fbem-7835	108	28	572	572	NUM
fbem-7835	108	29	gamma	gamma	NOUN
fbem-7835	108	30	rituximab	rituximab	NOUN
fbem-7835	108	31	price	price	VERB
fbem-7835	108	32	121,4	121,4	NUM
fbem-7835	108	33	958.5667	958.5667	NUM
fbem-7835	108	34	229	229	NUM
fbem-7835	108	35	4.44	4.44	NUM
fbem-7835	108	36	gamma	gamma	PROPN
fbem-7835	108	37	pola_br*_cycle	pola_br*_cycle	PROPN
fbem-7835	108	38	drug	drug	NOUN
fbem-7835	108	39	cost	cost	VERB
fbem-7835	108	40	25,437.11	25,437.11	NUM
fbem-7835	108	41	20,767.68	20,767.68	NUM
fbem-7835	108	42	34	34	NUM
fbem-7835	108	43	285.93	285.93	NUM
fbem-7835	108	44	/	/	SYM
fbem-7835	108	45	br#_cycle	br#_cycle	NOUN
fbem-7835	108	46	drug	drug	NOUN
fbem-7835	108	47	cost	cost	VERB
fbem-7835	108	48	12	12	NUM
fbem-7835	108	49	397.85	397.85	NUM
fbem-7835	108	50	10	10	NUM
fbem-7835	108	51	336.26	336.26	NUM
fbem-7835	108	52	21	21	NUM
fbem-7835	108	53	246.66	246.66	NUM
fbem-7835	108	54	/	/	SYM
fbem-7835	108	55	bed	bed	NOUN
fbem-7835	108	56	cost(unit	cost(unit	VERB
fbem-7835	108	57	)	)	PUNCT
fbem-7835	108	58	33	33	NUM
fbem-7835	108	59	1	1	NUM
fbem-7835	108	60	69	69	NUM
fbem-7835	108	61	gamma	gamma	NOUN
fbem-7835	108	62	registration	registration	NOUN
fbem-7835	108	63	cost(unit	cost(unit	PROPN
fbem-7835	108	64	)	)	PUNCT
fbem-7835	108	65	3	3	NUM
fbem-7835	108	66	0.5	0.5	NUM
fbem-7835	108	67	15	15	NUM
fbem-7835	108	68	gamma	gamma	NOUN
fbem-7835	108	69	intravenous	intravenous	ADJ
fbem-7835	108	70	injection	injection	NOUN
fbem-7835	108	71	cost	cost	VERB
fbem-7835	108	72	9.4	9.4	NUM
fbem-7835	108	73	3	3	NUM
fbem-7835	108	74	15.6	15.6	NUM
fbem-7835	108	75	gamma	gamma	NOUN
fbem-7835	108	76	imaging	imaging	NOUN
fbem-7835	108	77	detection	detection	NOUN
fbem-7835	108	78	cost	cost	VERB
fbem-7835	108	79	585.08	585.08	NUM
fbem-7835	108	80	420	420	NUM
fbem-7835	108	81	950	950	NUM
fbem-7835	108	82	gamma	gamma	NOUN
fbem-7835	108	83	blood	blood	NOUN
fbem-7835	108	84	biochemical	biochemical	ADJ
fbem-7835	108	85	test	test	NOUN
fbem-7835	108	86	cost	cost	VERB
fbem-7835	108	87	157	157	NUM
fbem-7835	108	88	89	89	NUM
fbem-7835	108	89	246	246	NUM
fbem-7835	108	90	gamma	gamma	NOUN
fbem-7835	108	91	routine	routine	ADJ
fbem-7835	108	92	blood	blood	NOUN
fbem-7835	108	93	test	test	NOUN
fbem-7835	108	94	cost	cost	VERB
fbem-7835	108	95	10.25	10.25	NUM
fbem-7835	108	96	5	5	NUM
fbem-7835	108	97	19	19	NUM
fbem-7835	108	98	gamma	gamma	NOUN
fbem-7835	108	99	routine	routine	ADJ
fbem-7835	108	100	urinalysis	urinalysis	NOUN
fbem-7835	108	101	cost	cost	VERB
fbem-7835	108	102	4.33	4.33	NUM
fbem-7835	108	103	1	1	NUM
fbem-7835	108	104	9	9	NUM
fbem-7835	108	105	gamma	gamma	NOUN
fbem-7835	108	106	treatment	treatment	NOUN
fbem-7835	108	107	cost	cost	NOUN
fbem-7835	108	108	of	of	ADP
fbem-7835	108	109	neutropenia	neutropenia	NOUN
fbem-7835	108	110	777.1189	777.1189	NUM
fbem-7835	108	111	341.3126	341.3126	NUM
fbem-7835	108	112	2	2	NUM
fbem-7835	108	113	389.388	389.388	NUM
fbem-7835	108	114	gamma	gamma	NOUN
fbem-7835	108	115	treatment	treatment	NOUN
fbem-7835	108	116	cost	cost	NOUN
fbem-7835	108	117	of	of	ADP
fbem-7835	108	118	thrombocytopenia	thrombocytopenia	NOUN
fbem-7835	108	119	10	10	NUM
fbem-7835	108	120	176.07	176.07	NUM
fbem-7835	108	121	8	8	NUM
fbem-7835	108	122	281.855	281.855	NUM
fbem-7835	108	123	11	11	NUM
fbem-7835	108	124	831.21	831.21	NUM
fbem-7835	108	125	gamma	gamma	NOUN
fbem-7835	108	126	treatment	treatment	NOUN
fbem-7835	108	127	cost	cost	NOUN
fbem-7835	108	128	of	of	ADP
fbem-7835	108	129	anemia	anemia	NOUN
fbem-7835	108	130	937.5912	937.5912	NUM
fbem-7835	108	131	712.7429	712.7429	NUM
fbem-7835	108	132	1	1	NUM
fbem-7835	108	133	069.148	069.148	NUM
fbem-7835	108	134	gamma	gamma	NOUN
fbem-7835	108	135	utility	utility	NOUN
fbem-7835	108	136	of	of	ADP
fbem-7835	108	137	pfs	pfs	PROPN
fbem-7835	108	138	0.83	0.83	NUM
fbem-7835	108	139	0.664	0.664	NUM
fbem-7835	108	140	0.996	0.996	NUM
fbem-7835	108	141	beta	beta	ADJ
fbem-7835	108	142	utility	utility	NOUN
fbem-7835	108	143	of	of	ADP
fbem-7835	108	144	pd	pd	PROPN
fbem-7835	108	145	0.39	0.39	NUM
fbem-7835	108	146	0.312	0.312	NUM
fbem-7835	108	147	0.468	0.468	NUM
fbem-7835	108	148	beta	beta	ADJ
fbem-7835	108	149	pola_br*_incidence	pola_br*_incidence	NOUN
fbem-7835	108	150	of	of	ADP
fbem-7835	108	151	neutropenia	neutropenia	NOUN
fbem-7835	108	152	0.325	0.325	PROPN
fbem-7835	108	153	0.26	0.26	NUM
fbem-7835	108	154	0.39	0.39	NUM
fbem-7835	108	155	beta	beta	ADJ
fbem-7835	108	156	pola_br*_incidence	pola_br*_incidence	NOUN
fbem-7835	108	157	of	of	ADP
fbem-7835	108	158	thrombocytopenia	thrombocytopenia	NOUN
fbem-7835	108	159	0.205	0.205	NUM
fbem-7835	108	160	0.164	0.164	NUM
fbem-7835	108	161	0.246	0.246	NUM
fbem-7835	108	162	beta	beta	ADJ
fbem-7835	108	163	pola_br*_incidence	pola_br*_incidence	NOUN
fbem-7835	108	164	of	of	ADP
fbem-7835	108	165	anemia	anemia	NOUN
fbem-7835	108	166	0.126	0.126	NUM
fbem-7835	108	167	0.1008	0.1008	NUM
fbem-7835	108	168	0.1512	0.1512	NUM
fbem-7835	108	169	beta	beta	ADJ
fbem-7835	108	170	br#_incidence	br#_incidence	NOUN
fbem-7835	108	171	of	of	ADP
fbem-7835	108	172	neutropenia	neutropenia	NOUN
fbem-7835	108	173	0.333	0.333	NUM
fbem-7835	108	174	0.2664	0.2664	NUM
fbem-7835	108	175	0.3996	0.3996	NUM
fbem-7835	108	176	beta	beta	ADJ
fbem-7835	108	177	br#_incidence	br#_incidence	NOUN
fbem-7835	108	178	of	of	ADP
fbem-7835	108	179	thrombocytopenia	thrombocytopenia	PROPN
fbem-7835	108	180	0.231	0.231	NUM
fbem-7835	108	181	0.1848	0.1848	NUM
fbem-7835	108	182	0.2772	0.2772	NUM
fbem-7835	108	183	beta	beta	NOUN
fbem-7835	108	184	br#_incidence	br#_incidence	NOUN
fbem-7835	108	185	of	of	ADP
fbem-7835	108	186	anemia	anemia	NOUN
fbem-7835	108	187	0.179	0.179	NUM
fbem-7835	108	188	0.1432	0.1432	NUM
fbem-7835	108	189	0.2148	0.2148	NUM
fbem-7835	108	190	beta	beta	NOUN
fbem-7835	108	191	discount	discount	NOUN
fbem-7835	108	192	ratio	ratio	NOUN
fbem-7835	108	193	5	5	NUM
fbem-7835	108	194	%	%	NOUN
fbem-7835	108	195	0	0	NUM
fbem-7835	108	196	8	8	NUM
fbem-7835	108	197	%	%	NOUN
fbem-7835	108	198	constant	constant	ADJ
fbem-7835	108	199	*	*	NOUN
fbem-7835	108	200	:	:	PUNCT
fbem-7835	108	201	polatuzumab	polatuzumab	NOUN
fbem-7835	108	202	vedotin	vedotin	ADV
fbem-7835	108	203	combined	combine	VERB
fbem-7835	108	204	with	with	ADP
fbem-7835	108	205	bendamustine	bendamustine	NOUN
fbem-7835	108	206	and	and	CCONJ
fbem-7835	108	207	rituximab	rituximab	NOUN
fbem-7835	108	208	;	;	PUNCT
fbem-7835	108	209	#	#	ADV
fbem-7835	108	210	:	:	PUNCT
fbem-7835	108	211	bendamustine	bendamustine	NOUN
fbem-7835	108	212	and	and	CCONJ
fbem-7835	108	213	rituximab	rituximab	NOUN
fbem-7835	108	214	table	table	NOUN
fbem-7835	108	215	3	3	NUM
fbem-7835	108	216	.	.	PUNCT
fbem-7835	109	1	the	the	DET
fbem-7835	109	2	value	value	NOUN
fbem-7835	109	3	and	and	CCONJ
fbem-7835	109	4	distribution	distribution	NOUN
fbem-7835	109	5	of	of	ADP
fbem-7835	109	6	efficacy	efficacy	NOUN
fbem-7835	109	7	parameters	parameter	NOUN
fbem-7835	109	8	base	base	NOUN
fbem-7835	109	9	value	value	NOUN
fbem-7835	109	10	minimum	minimum	NOUN
fbem-7835	109	11	value	value	NOUN
fbem-7835	109	12	maximum	maximum	ADJ
fbem-7835	109	13	value	value	NOUN
fbem-7835	109	14	distribution	distribution	NOUN
fbem-7835	109	15	meanlogpola_bros	meanlogpola_bro	VERB
fbem-7835	109	16	2.849383	2.849383	NUM
fbem-7835	109	17	2.340376	2.340376	NUM
fbem-7835	109	18	3.35839	3.35839	NUM
fbem-7835	109	19	lognormal	lognormal	ADJ
fbem-7835	109	20	sdlogpola_bros	sdlogpola_bro	NOUN
fbem-7835	109	21	1.470204	1.470204	NUM
fbem-7835	109	22	1.094152	1.094152	NUM
fbem-7835	109	23	1.975501	1.975501	NUM
fbem-7835	109	24	lognormal	lognormal	ADJ
fbem-7835	109	25	lambdabros	lambdabro	NOUN
fbem-7835	109	26	5.20063	5.20063	NUM
fbem-7835	109	27	3.337346	3.337346	NUM
fbem-7835	109	28	8.104212	8.104212	NUM
fbem-7835	109	29	log	log	NOUN
fbem-7835	109	30	-	-	PUNCT
fbem-7835	109	31	logistic	logistic	NOUN
fbem-7835	109	32	gammabros	gammabro	NOUN
fbem-7835	109	33	1.296436	1.296436	NUM
fbem-7835	109	34	0.959249	0.959249	NUM
fbem-7835	109	35	1.752146	1.752146	NUM
fbem-7835	109	36	log	log	NOUN
fbem-7835	109	37	-	-	PUNCT
fbem-7835	109	38	logistic	logistic	NOUN
fbem-7835	109	39	meanlogpola_brpfs	meanlogpola_brpf	NOUN
fbem-7835	109	40	2.268081	2.268081	NUM
fbem-7835	109	41	1.802605	1.802605	NUM
fbem-7835	109	42	2.733557	2.733557	NUM
fbem-7835	109	43	lognormal	lognormal	ADJ
fbem-7835	109	44	sdlogpola_brpfs	sdlogpola_brpf	NOUN
fbem-7835	109	45	1.420292	1.420292	NUM
fbem-7835	109	46	1.091311	1.091311	NUM
fbem-7835	109	47	1.848446	1.848446	NUM
fbem-7835	109	48	lognormal	lognormal	ADJ
fbem-7835	109	49	lambdabrpfs	lambdabrpf	VERB
fbem-7835	109	50	2.171925	2.171925	NUM
fbem-7835	109	51	1.423644	1.423644	NUM
fbem-7835	109	52	3.31351	3.31351	NUM
fbem-7835	109	53	log	log	NOUN
fbem-7835	109	54	-	-	PUNCT
fbem-7835	109	55	logistic	logistic	NOUN
fbem-7835	109	56	gammabrpfs	gammabrpf	NOUN
fbem-7835	109	57	1.268828	1.268828	NUM
fbem-7835	109	58	0.968311	0.968311	NUM
fbem-7835	109	59	1.662612	1.662612	NUM
fbem-7835	109	60	log	log	NOUN
fbem-7835	109	61	-	-	PUNCT
fbem-7835	109	62	logistic	logistic	NOUN
fbem-7835	109	63	table4	table4	NOUN
fbem-7835	109	64	.	.	PUNCT
fbem-7835	110	1	the	the	DET
fbem-7835	110	2	aic	aic	PROPN
fbem-7835	110	3	and	and	CCONJ
fbem-7835	110	4	bic	bic	PROPN
fbem-7835	110	5	value	value	NOUN
fbem-7835	110	6	of	of	ADP
fbem-7835	110	7	survival	survival	NOUN
fbem-7835	110	8	curve	curve	PROPN
fbem-7835	110	9	fitting	fitting	ADJ
fbem-7835	110	10	km	km	PROPN
fbem-7835	110	11	curve	curve	NOUN
fbem-7835	110	12	exponential	exponential	ADJ
fbem-7835	110	13	gamma	gamma	NOUN
fbem-7835	110	14	gompertz	gompertz	PROPN
fbem-7835	110	15	weibull	weibull	PROPN
fbem-7835	110	16	loglogistic	loglogistic	PROPN
fbem-7835	110	17	lognormal	lognormal	ADJ
fbem-7835	110	18	aic	aic	PROPN
fbem-7835	110	19	pola_bros	pola_bros	PROPN
fbem-7835	110	20	222.47	222.47	NUM
fbem-7835	110	21	223.58	223.58	NUM
fbem-7835	110	22	217.52	217.52	NUM
fbem-7835	110	23	222.68	222.68	NUM
fbem-7835	110	24	218.24	218.24	NUM
fbem-7835	110	25	217.13	217.13	NUM
fbem-7835	110	26	pola_brpfs	pola_brpf	NOUN
fbem-7835	110	27	239.09	239.09	NUM
fbem-7835	110	28	239.20	239.20	NUM
fbem-7835	110	29	232.15	232.15	NUM
fbem-7835	110	30	237.67	237.67	NUM
fbem-7835	110	31	231.71	231.71	NUM
fbem-7835	110	32	230.28	230.28	NUM
fbem-7835	110	33	bros	bros	ADP
fbem-7835	110	34	200.50	200.50	NUM
fbem-7835	110	35	200.68	200.68	NUM
fbem-7835	110	36	192.46	192.46	NUM
fbem-7835	110	37	198.89	198.89	NUM
fbem-7835	110	38	191.85	191.85	NUM
fbem-7835	110	39	192.60	192.60	NUM
fbem-7835	110	40	brpfs	brpf	NOUN
fbem-7835	110	41	191.59	191.59	NUM
fbem-7835	110	42	190.65	190.65	NUM
fbem-7835	110	43	183.26	183.26	NUM
fbem-7835	110	44	188.46	188.46	NUM
fbem-7835	111	1	182.54	182.54	NUM
fbem-7835	111	2	182.85	182.85	NUM
fbem-7835	111	3	bic	bic	NOUN
fbem-7835	111	4	pola_bros	pola_bro	NOUN
fbem-7835	111	5	224.16	224.16	NUM
fbem-7835	111	6	226.96	226.96	NUM
fbem-7835	111	7	220.90	220.90	NUM
fbem-7835	111	8	226.06	226.06	NUM
fbem-7835	111	9	221.62	221.62	NUM
fbem-7835	111	10	220.51	220.51	NUM
fbem-7835	111	11	pola_brpfs	pola_brpf	NOUN
fbem-7835	111	12	240.78	240.78	NUM
fbem-7835	111	13	242.58	242.58	NUM
fbem-7835	111	14	235.52	235.52	NUM
fbem-7835	111	15	241.05	241.05	NUM
fbem-7835	111	16	235.09	235.09	NUM
fbem-7835	111	17	233.65	233.65	NUM
fbem-7835	111	18	bros	bros	ADP
fbem-7835	111	19	202.19	202.19	NUM
fbem-7835	111	20	204.06	204.06	NUM
fbem-7835	111	21	195.84	195.84	NUM
fbem-7835	111	22	202.27	202.27	NUM
fbem-7835	111	23	195.23	195.23	NUM
fbem-7835	111	24	195.98	195.98	NUM
fbem-7835	111	25	brpfs	brpf	NOUN
fbem-7835	111	26	193.28	193.28	NUM
fbem-7835	111	27	194.03	194.03	NUM
fbem-7835	111	28	186.64	186.64	NUM
fbem-7835	111	29	191.84	191.84	NUM
fbem-7835	111	30	185.91	185.91	NUM
fbem-7835	111	31	186.23	186.23	NUM
fbem-7835	111	32	note	note	NOUN
fbem-7835	111	33	:	:	PUNCT
fbem-7835	111	34	aic	aic	PROPN
fbem-7835	111	35	:	:	PUNCT
fbem-7835	111	36	akaike	akaike	ADP
fbem-7835	111	37	information	information	NOUN
fbem-7835	111	38	criterion	criterion	NOUN
fbem-7835	111	39	;	;	PUNCT
fbem-7835	111	40	bic	bic	NOUN
fbem-7835	111	41	:	:	PUNCT
fbem-7835	111	42	bayesian	bayesian	NOUN
fbem-7835	111	43	information	information	NOUN
fbem-7835	111	44	criterion	criterion	NOUN
fbem-7835	111	45	;	;	PUNCT
fbem-7835	111	46	pola	pola	PROPN
fbem-7835	111	47	_	_	PUNCT
fbem-7835	112	1	bros	bros	INTJ
fbem-7835	112	2	:	:	PUNCT
fbem-7835	112	3	the	the	DET
fbem-7835	112	4	overall	overall	ADJ
fbem-7835	112	5	survival	survival	NOUN
fbem-7835	112	6	curve	curve	NOUN
fbem-7835	112	7	of	of	ADP
fbem-7835	112	8	the	the	DET
fbem-7835	112	9	polatuzumab	polatuzumab	NOUN
fbem-7835	112	10	vedotin	vedotin	ADV
fbem-7835	112	11	combined	combine	VERB
fbem-7835	112	12	with	with	ADP
fbem-7835	112	13	bendamustine	bendamustine	NOUN
fbem-7835	112	14	and	and	CCONJ
fbem-7835	112	15	rituximab	rituximab	NOUN
fbem-7835	112	16	group	group	NOUN
fbem-7835	112	17	;	;	PUNCT
fbem-7835	112	18	pola	pola	PROPN
fbem-7835	112	19	_	_	PUNCT
fbem-7835	112	20	brpfs	brpf	NOUN
fbem-7835	112	21	:	:	PUNCT
fbem-7835	112	22	progression	progression	NOUN
fbem-7835	112	23	-	-	PUNCT
fbem-7835	112	24	free	free	ADJ
fbem-7835	112	25	survival	survival	NOUN
fbem-7835	112	26	curve	curve	NOUN
fbem-7835	112	27	of	of	ADP
fbem-7835	112	28	the	the	DET
fbem-7835	112	29	polatuzumab	polatuzumab	NOUN
fbem-7835	112	30	vedotin	vedotin	ADV
fbem-7835	112	31	combined	combine	VERB
fbem-7835	112	32	with	with	ADP
fbem-7835	112	33	bendamustine	bendamustine	NOUN
fbem-7835	112	34	and	and	CCONJ
fbem-7835	112	35	rituximab	rituximab	NOUN
fbem-7835	112	36	group	group	NOUN
fbem-7835	112	37	;	;	PUNCT
fbem-7835	112	38	bros	bros	INTJ
fbem-7835	112	39	:	:	PUNCT
fbem-7835	112	40	overall	overall	ADJ
fbem-7835	112	41	survival	survival	NOUN
fbem-7835	112	42	curve	curve	NOUN
fbem-7835	112	43	of	of	ADP
fbem-7835	112	44	bendamustine	bendamustine	NOUN
fbem-7835	112	45	and	and	CCONJ
fbem-7835	112	46	rituximab	rituximab	NOUN
fbem-7835	112	47	group	group	NOUN
fbem-7835	112	48	;	;	PUNCT
fbem-7835	112	49	brpfs	brpf	NOUN
fbem-7835	112	50	:	:	PUNCT
fbem-7835	112	51	progression	progression	NOUN
fbem-7835	112	52	-	-	PUNCT
fbem-7835	112	53	free	free	ADJ
fbem-7835	112	54	survival	survival	NOUN
fbem-7835	112	55	curve	curve	NOUN
fbem-7835	112	56	of	of	ADP
fbem-7835	112	57	bendamustine	bendamustine	NOUN
fbem-7835	112	58	and	and	CCONJ
fbem-7835	112	59	rituximab	rituximab	NOUN
fbem-7835	112	60	group	group	NOUN
fbem-7835	112	61	references	reference	NOUN
fbem-7835	112	62	[	[	X
fbem-7835	112	63	1	1	NUM
fbem-7835	112	64	]	]	X
fbem-7835	112	65	chinese	chinese	ADJ
fbem-7835	112	66	anti	anti	ADJ
fbem-7835	112	67	-	-	ADJ
fbem-7835	112	68	cancer	cancer	ADJ
fbem-7835	112	69	association	association	NOUN
fbem-7835	112	70	lymphoma	lymphoma	NOUN
fbem-7835	112	71	professional	professional	PROPN
fbem-7835	112	72	committee	committee	NOUN
fbem-7835	112	73	.	.	PUNCT
fbem-7835	113	1	chinese	chinese	ADJ
fbem-7835	113	2	lymphoma	lymphoma	NOUN
fbem-7835	113	3	treatment	treatment	NOUN
fbem-7835	113	4	guidelines	guideline	NOUN
fbem-7835	113	5	(	(	PUNCT
fbem-7835	113	6	2021	2021	NUM
fbem-7835	113	7	edition	edition	NOUN
fbem-7835	113	8	)	)	PUNCT
fbem-7835	114	1	[	[	X
fbem-7835	114	2	j	j	X
fbem-7835	114	3	]	]	X
fbem-7835	114	4	.	.	PUNCT
fbem-7835	115	1	chinese	chinese	ADJ
fbem-7835	115	2	journal	journal	PROPN
fbem-7835	115	3	of	of	ADP
fbem-7835	115	4	oncology,2021,7:707	oncology,2021,7:707	PROPN
fbem-7835	115	5	-	-	PUNCT
fbem-7835	115	6	735	735	NUM
fbem-7835	115	7	.	.	PUNCT
fbem-7835	116	1	[	[	X
fbem-7835	116	2	2	2	X
fbem-7835	116	3	]	]	PUNCT
fbem-7835	116	4	sehn	sehn	NOUN
fbem-7835	116	5	lh	lh	PROPN
fbem-7835	116	6	,	,	PUNCT
fbem-7835	116	7	salles	salles	PROPN
fbem-7835	116	8	g.	g.	PROPN
fbem-7835	116	9	diffuse	diffuse	VERB
fbem-7835	116	10	large	large	ADJ
fbem-7835	116	11	b	b	NUM
fbem-7835	116	12	-	-	PUNCT
fbem-7835	116	13	cell	cell	NOUN
fbem-7835	116	14	lymphoma	lymphoma	NOUN
fbem-7835	116	15	.	.	PUNCT
fbem-7835	117	1	2021[j	2021[j	NUM
fbem-7835	117	2	]	]	PUNCT
fbem-7835	117	3	.	.	PUNCT
fbem-7835	118	1	n	n	PROPN
fbem-7835	118	2	engl	engl	PROPN
fbem-7835	118	3	j	j	PROPN
fbem-7835	118	4	med	med	PROPN
fbem-7835	118	5	,	,	PUNCT
fbem-7835	118	6	2021,384(9):842	2021,384(9):842	NUM
fbem-7835	118	7	-	-	SYM
fbem-7835	118	8	858	858	NUM
fbem-7835	118	9	.	.	PUNCT
fbem-7835	119	1	[	[	X
fbem-7835	119	2	3	3	X
fbem-7835	119	3	]	]	X
fbem-7835	119	4	sarkozy	sarkozy	PROPN
fbem-7835	119	5	c	c	AUX
fbem-7835	119	6	,	,	PUNCT
fbem-7835	119	7	sehn	sehn	PROPN
fbem-7835	119	8	lh	lh	PROPN
fbem-7835	119	9	.	.	PUNCT
fbem-7835	119	10	management	management	NOUN
fbem-7835	119	11	of	of	ADP
fbem-7835	119	12	relapsed	relapse	VERB
fbem-7835	119	13	/	/	SYM
fbem-7835	119	14	refractory	refractory	NOUN
fbem-7835	119	15	dlbcl	dlbcl	NOUN
fbem-7835	119	16	.	.	PUNCT
fbem-7835	120	1	2018[j	2018[j	NUM
fbem-7835	120	2	]	]	PUNCT
fbem-7835	120	3	.	.	PUNCT
fbem-7835	121	1	best	good	ADJ
fbem-7835	121	2	pract	pract	PROPN
fbem-7835	121	3	res	res	PROPN
fbem-7835	121	4	clin	clin	PROPN
fbem-7835	121	5	haematol	haematol	NOUN
fbem-7835	121	6	,	,	PUNCT
fbem-7835	121	7	2018,31(3):209	2018,31(3):209	NOUN
fbem-7835	121	8	-	-	PUNCT
fbem-7835	121	9	216	216	NUM
fbem-7835	121	10	.	.	PUNCT
fbem-7835	122	1	[	[	X
fbem-7835	122	2	4	4	X
fbem-7835	122	3	]	]	X
fbem-7835	122	4	laurie	laurie	PROPN
fbem-7835	122	5	hs	hs	PROPN
fbem-7835	122	6	,	,	PUNCT
fbem-7835	122	7	mark	mark	PROPN
fbem-7835	122	8	h	h	PROPN
fbem-7835	122	9	,	,	PUNCT
fbem-7835	122	10	stephen	stephen	PROPN
fbem-7835	122	11	o	o	PROPN
fbem-7835	122	12	,	,	PUNCT
fbem-7835	122	13	et	et	PROPN
fbem-7835	122	14	al	al	PROPN
fbem-7835	122	15	.	.	PROPN
fbem-7835	122	16	polatuzumab	polatuzumab	PROPN
fbem-7835	122	17	vedotin	vedotin	PROPN
fbem-7835	122	18	plus	plus	CCONJ
fbem-7835	122	19	bendamustine	bendamustine	NOUN
fbem-7835	122	20	and	and	CCONJ
fbem-7835	122	21	rituximab	rituximab	NOUN
fbem-7835	122	22	in	in	ADP
fbem-7835	122	23	relapsed/	relapsed/	NUM
fbem-7835	122	24	refractory	refractory	NOUN
fbem-7835	122	25	dlbcl	dlbcl	NOUN
fbem-7835	122	26	:	:	PUNCT
fbem-7835	122	27	survival	survival	NOUN
fbem-7835	122	28	update	update	NOUN
fbem-7835	122	29	and	and	CCONJ
fbem-7835	122	30	new	new	ADJ
fbem-7835	122	31	extension	extension	NOUN
fbem-7835	122	32	cohort	cohort	NOUN
fbem-7835	122	33	data	datum	NOUN
fbem-7835	122	34	.	.	PUNCT
fbem-7835	123	1	2022[j	2022[j	NUM
fbem-7835	123	2	]	]	PUNCT
fbem-7835	123	3	.	.	PUNCT
fbem-7835	124	1	blood	blood	NOUN
fbem-7835	124	2	advances	advance	NOUN
fbem-7835	124	3	,	,	PUNCT
fbem-7835	124	4	2022,6(2	2022,6(2	NUM
fbem-7835	124	5	):	):	PUNCT
fbem-7835	124	6	533	533	NUM
fbem-7835	124	7	-	-	SYM
fbem-7835	124	8	543	543	NUM
fbem-7835	124	9	.	.	PUNCT
fbem-7835	125	1	[	[	X
fbem-7835	125	2	5	5	X
fbem-7835	125	3	]	]	X
fbem-7835	125	4	liu	liu	PROPN
fbem-7835	125	5	guoen	guoen	PROPN
fbem-7835	125	6	.	.	PUNCT
fbem-7835	126	1	chinese	chinese	ADJ
fbem-7835	126	2	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	126	3	evaluation	evaluation	NOUN
fbem-7835	126	4	guide	guide	NOUN
fbem-7835	126	5	2020	2020	NUM
fbem-7835	127	1	[	[	X
fbem-7835	127	2	m	m	X
fbem-7835	127	3	]	]	X
fbem-7835	127	4	.	.	PUNCT
fbem-7835	128	1	beijing	beijing	PROPN
fbem-7835	128	2	:	:	PUNCT
fbem-7835	129	1	china	china	PROPN
fbem-7835	129	2	market	market	NOUN
fbem-7835	129	3	publisher	publisher	NOUN
fbem-7835	129	4	,	,	PUNCT
fbem-7835	129	5	2020:4	2020:4	NUM
fbem-7835	129	6	-	-	SYM
fbem-7835	129	7	16	16	NUM
fbem-7835	129	8	.	.	PUNCT
fbem-7835	130	1	[	[	X
fbem-7835	130	2	6	6	NUM
fbem-7835	130	3	]	]	X
fbem-7835	130	4	yao	yao	PROPN
fbem-7835	130	5	jiaqi	jiaqi	PROPN
fbem-7835	130	6	,	,	PUNCT
fbem-7835	130	7	guan	guan	PROPN
fbem-7835	130	8	xin	xin	PROPN
fbem-7835	130	9	,	,	PUNCT
fbem-7835	130	10	zhang	zhang	PROPN
fbem-7835	130	11	yao	yao	PROPN
fbem-7835	130	12	,	,	PUNCT
fbem-7835	130	13	et	et	PROPN
fbem-7835	130	14	al	al	PROPN
fbem-7835	130	15	.	.	PROPN
fbem-7835	130	16	discussion	discussion	NOUN
fbem-7835	130	17	and	and	CCONJ
fbem-7835	130	18	practice	practice	NOUN
fbem-7835	130	19	of	of	ADP
fbem-7835	130	20	correlating	correlate	VERB
fbem-7835	130	21	parameters	parameter	NOUN
fbem-7835	130	22	in	in	ADP
fbem-7835	130	23	sensitivity	sensitivity	NOUN
fbem-7835	130	24	analysis	analysis	NOUN
fbem-7835	130	25	of	of	ADP
fbem-7835	130	26	pharmacoeconomics	pharmacoeconomic	NOUN
fbem-7835	130	27	[	[	X
fbem-7835	130	28	j	j	X
fbem-7835	130	29	]	]	X
fbem-7835	130	30	.	.	PUNCT
fbem-7835	131	1	chinese	chinese	ADJ
fbem-7835	131	2	journal	journal	PROPN
fbem-7835	131	3	of	of	ADP
fbem-7835	131	4	drug	drug	NOUN
fbem-7835	131	5	evaluation	evaluation	NOUN
fbem-7835	131	6	,	,	PUNCT
fbem-7835	131	7	2019	2019	NUM
fbem-7835	131	8	,	,	PUNCT
fbem-7835	131	9	36(2	36(2	NUM
fbem-7835	131	10	):	):	PUNCT
fbem-7835	131	11	150	150	NUM
fbem-7835	131	12	-	-	SYM
fbem-7835	131	13	155	155	NUM
fbem-7835	131	14	.	.	PUNCT
fbem-7835	132	1	[	[	X
fbem-7835	132	2	7	7	NUM
fbem-7835	132	3	]	]	X
fbem-7835	132	4	shao	shao	PROPN
fbem-7835	132	5	rongjie	rongjie	PROPN
fbem-7835	132	6	,	,	PUNCT
fbem-7835	132	7	tang	tang	NOUN
fbem-7835	132	8	wenxi	wenxi	PROPN
fbem-7835	132	9	,	,	PUNCT
fbem-7835	132	10	ma	ma	PROPN
fbem-7835	132	11	aixia	aixia	PROPN
fbem-7835	132	12	.	.	PUNCT
fbem-7835	132	13	application	application	NOUN
fbem-7835	132	14	of	of	ADP
fbem-7835	132	15	partition	partition	NOUN
fbem-7835	132	16	survival	survival	NOUN
fbem-7835	132	17	model	model	NOUN
fbem-7835	132	18	in	in	ADP
fbem-7835	132	19	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	132	20	evaluation	evaluation	NOUN
fbem-7835	132	21	[	[	X
fbem-7835	132	22	j	j	X
fbem-7835	132	23	]	]	X
fbem-7835	132	24	.	.	PUNCT
fbem-7835	133	1	chinese	chinese	ADJ
fbem-7835	133	2	health	health	NOUN
fbem-7835	133	3	economics	economic	NOUN
fbem-7835	133	4	,	,	PUNCT
fbem-7835	133	5	2019	2019	NUM
fbem-7835	133	6	,	,	PUNCT
fbem-7835	133	7	38(9	38(9	NOUN
fbem-7835	133	8	):	):	PUNCT
fbem-7835	133	9	60	60	NUM
fbem-7835	133	10	-	-	SYM
fbem-7835	133	11	63	63	NUM
fbem-7835	133	12	.	.	PUNCT
fbem-7835	134	1	[	[	X
fbem-7835	134	2	8	8	NUM
fbem-7835	134	3	]	]	X
fbem-7835	134	4	shi	shi	PROPN
fbem-7835	134	5	fenghao	fenghao	PROPN
fbem-7835	134	6	,	,	PUNCT
fbem-7835	134	7	shang	shang	PROPN
fbem-7835	134	8	ye	ye	PROPN
fbem-7835	134	9	,	,	PUNCT
fbem-7835	134	10	rui	rui	PROPN
fbem-7835	134	11	mingjun	mingjun	PROPN
fbem-7835	134	12	,	,	PUNCT
fbem-7835	134	13	et	et	PROPN
fbem-7835	134	14	al	al	PROPN
fbem-7835	134	15	.	.	PUNCT
fbem-7835	134	16	application	application	NOUN
fbem-7835	134	17	of	of	ADP
fbem-7835	134	18	r	r	NOUN
fbem-7835	134	19	language	language	NOUN
fbem-7835	134	20	“	"	PUNCT
fbem-7835	134	21	survhe	survhe	NOUN
fbem-7835	134	22	”	"	PUNCT
fbem-7835	134	23	package	package	NOUN
fbem-7835	134	24	in	in	ADP
fbem-7835	134	25	health	health	NOUN
fbem-7835	134	26	economics	economic	NOUN
fbem-7835	134	27	evaluation	evaluation	NOUN
fbem-7835	135	1	[	[	X
fbem-7835	135	2	j	j	X
fbem-7835	135	3	]	]	X
fbem-7835	135	4	.	.	PUNCT
fbem-7835	136	1	chinese	chinese	ADJ
fbem-7835	136	2	health	health	NOUN
fbem-7835	136	3	economics	economic	NOUN
fbem-7835	136	4	,	,	PUNCT
fbem-7835	136	5	2020	2020	NUM
fbem-7835	136	6	,	,	PUNCT
fbem-7835	136	7	39(9	39(9	NUM
fbem-7835	136	8	):	):	PUNCT
fbem-7835	136	9	9	9	NUM
fbem-7835	136	10	-	-	SYM
fbem-7835	136	11	14	14	NUM
fbem-7835	136	12	.	.	PUNCT
fbem-7835	137	1	184	184	NUM
fbem-7835	138	1	[	[	X
fbem-7835	138	2	9	9	NUM
fbem-7835	138	3	]	]	X
fbem-7835	138	4	jia	jia	PROPN
fbem-7835	138	5	shihuan	shihuan	PROPN
fbem-7835	138	6	,	,	PUNCT
fbem-7835	138	7	zhao	zhao	PROPN
fbem-7835	138	8	mengmeng	mengmeng	PROPN
fbem-7835	138	9	,	,	PUNCT
fbem-7835	138	10	chen	chen	PROPN
fbem-7835	138	11	binbin	binbin	PROPN
fbem-7835	138	12	,	,	PUNCT
fbem-7835	138	13	et	et	PROPN
fbem-7835	138	14	al	al	PROPN
fbem-7835	138	15	.	.	PUNCT
fbem-7835	139	1	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	139	2	evaluation	evaluation	NOUN
fbem-7835	139	3	of	of	ADP
fbem-7835	139	4	rituximab	rituximab	NOUN
fbem-7835	139	5	(	(	PUNCT
fbem-7835	139	6	hanlikang	hanlikang	NOUN
fbem-7835	139	7	)	)	PUNCT
fbem-7835	139	8	combined	combine	VERB
fbem-7835	139	9	with	with	ADP
fbem-7835	139	10	chop	chop	NOUN
fbem-7835	139	11	chemotherapy	chemotherapy	NOUN
fbem-7835	139	12	regimen	regiman	NOUN
fbem-7835	139	13	for	for	ADP
fbem-7835	139	14	diffuse	diffuse	PROPN
fbem-7835	139	15	large	large	ADJ
fbem-7835	139	16	b	b	NOUN
fbem-7835	139	17	-	-	PUNCT
fbem-7835	139	18	cell	cell	NOUN
fbem-7835	139	19	lymphoma	lymphoma	NOUN
fbem-7835	140	1	[	[	X
fbem-7835	140	2	j	j	X
fbem-7835	140	3	]	]	X
fbem-7835	140	4	.	.	PUNCT
fbem-7835	141	1	china	china	PROPN
fbem-7835	141	2	journal	journal	PROPN
fbem-7835	141	3	of	of	ADP
fbem-7835	141	4	pharmaceutical	pharmaceutical	NOUN
fbem-7835	141	5	economics	economic	NOUN
fbem-7835	141	6	,	,	PUNCT
fbem-7835	141	7	2019	2019	NUM
fbem-7835	141	8	,	,	PUNCT
fbem-7835	141	9	14(10	14(10	NUM
fbem-7835	141	10	):	):	PUNCT
fbem-7835	141	11	20	20	NUM
fbem-7835	141	12	-	-	SYM
fbem-7835	141	13	27	27	NUM
fbem-7835	141	14	.	.	PUNCT
fbem-7835	142	1	[	[	X
fbem-7835	142	2	10	10	NUM
fbem-7835	142	3	]	]	X
fbem-7835	142	4	mingjun	mingjun	PROPN
fbem-7835	142	5	rui	rui	PROPN
fbem-7835	142	6	,	,	PUNCT
fbem-7835	142	7	zhengyang	zhengyang	PROPN
fbem-7835	142	8	fei	fei	PROPN
fbem-7835	142	9	,	,	PUNCT
fbem-7835	142	10	yingcheng	yingcheng	PROPN
fbem-7835	142	11	wang	wang	PROPN
fbem-7835	142	12	,	,	PUNCT
fbem-7835	142	13	et	et	PROPN
fbem-7835	142	14	al	al	PROPN
fbem-7835	142	15	.	.	PROPN
fbem-7835	143	1	costeffectiveness	costeffectiveness	NOUN
fbem-7835	143	2	analysis	analysis	NOUN
fbem-7835	143	3	of	of	ADP
fbem-7835	143	4	sintilimab	sintilimab	NOUN
fbem-7835	143	5	 	 	SPACE
fbem-7835	143	6	+	+	PROPN
fbem-7835	143	7	 	 	SPACE
fbem-7835	143	8	chemotherapy	chemotherapy	NOUN
fbem-7835	143	9	versus	versus	ADP
fbem-7835	143	10	camrelizumab	camrelizumab	PROPN
fbem-7835	143	11	 	 	SPACE
fbem-7835	143	12	+	+	PROPN
fbem-7835	143	13	 	 	SPACE
fbem-7835	143	14	chemotherapy	chemotherapy	NOUN
fbem-7835	143	15	for	for	ADP
fbem-7835	143	16	the	the	DET
fbem-7835	143	17	treatment	treatment	NOUN
fbem-7835	143	18	of	of	ADP
fbem-7835	143	19	first	first	ADJ
fbem-7835	143	20	-	-	PUNCT
fbem-7835	143	21	line	line	NOUN
fbem-7835	143	22	locally	locally	ADV
fbem-7835	143	23	advanced	advanced	ADJ
fbem-7835	143	24	or	or	CCONJ
fbem-7835	143	25	metastatic	metastatic	ADJ
fbem-7835	143	26	nonsquamous	nonsquamous	ADJ
fbem-7835	143	27	nsclc	nsclc	NOUN
fbem-7835	143	28	in	in	ADP
fbem-7835	143	29	china[j	china[j	PROPN
fbem-7835	143	30	]	]	PUNCT
fbem-7835	143	31	.	.	PUNCT
fbem-7835	144	1	journal	journal	PROPN
fbem-7835	144	2	of	of	ADP
fbem-7835	144	3	medical	medical	ADJ
fbem-7835	144	4	economics	economic	NOUN
fbem-7835	144	5	,	,	PUNCT
fbem-7835	144	6	2022	2022	NUM
fbem-7835	144	7	,	,	PUNCT
fbem-7835	144	8	25(1	25(1	NUM
fbem-7835	144	9	):	):	PUNCT
fbem-7835	144	10	618	618	NUM
fbem-7835	144	11	-	-	SYM
fbem-7835	144	12	629	629	NUM
fbem-7835	144	13	.	.	PUNCT
fbem-7835	145	1	[	[	X
fbem-7835	145	2	11	11	NUM
fbem-7835	145	3	]	]	X
fbem-7835	145	4	national	national	PROPN
fbem-7835	145	5	bureau	bureau	PROPN
fbem-7835	145	6	of	of	ADP
fbem-7835	145	7	statistics	statistic	NOUN
fbem-7835	145	8	.	.	PUNCT
fbem-7835	146	1	2022	2022	NUM
fbem-7835	146	2	statistical	statistical	ADJ
fbem-7835	146	3	bulletin	bulletin	NOUN
fbem-7835	146	4	of	of	ADP
fbem-7835	146	5	the	the	DET
fbem-7835	146	6	people	people	NOUN
fbem-7835	146	7	's	's	PART
fbem-7835	146	8	republic	republic	NOUN
fbem-7835	146	9	of	of	ADP
fbem-7835	146	10	china	china	PROPN
fbem-7835	146	11	on	on	ADP
fbem-7835	146	12	national	national	ADJ
fbem-7835	146	13	economic	economic	ADJ
fbem-7835	146	14	and	and	CCONJ
fbem-7835	146	15	social	social	ADJ
fbem-7835	146	16	development	development	NOUN
fbem-7835	147	1	[	[	X
fbem-7835	147	2	eb	eb	PROPN
fbem-7835	147	3	/	/	SYM
fbem-7835	147	4	ol	ol	PROPN
fbem-7835	147	5	]	]	PUNCT
fbem-7835	147	6	.	.	PUNCT
fbem-7835	148	1	(	(	PUNCT
fbem-7835	148	2	2023	2023	NUM
fbem-7835	148	3	-	-	SYM
fbem-7835	148	4	02	02	NUM
fbem-7835	148	5	-	-	PUNCT
fbem-7835	148	6	28	28	NUM
fbem-7835	148	7	)	)	PUNCT
fbem-7835	149	1	[	[	X
fbem-7835	149	2	2023	2023	NUM
fbem-7835	149	3	-	-	SYM
fbem-7835	149	4	03	03	NUM
fbem-7835	149	5	-	-	SYM
fbem-7835	149	6	31	31	NUM
fbem-7835	149	7	]	]	PUNCT
fbem-7835	149	8	.	.	PUNCT
fbem-7835	150	1	http://www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011	http://www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011	PROPN
fbem-7835	150	2	.	.	PUNCT
fbem-7835	151	1	html	html	NOUN
fbem-7835	151	2	.	.	PUNCT
fbem-7835	152	1	[	[	X
fbem-7835	152	2	12	12	NUM
fbem-7835	152	3	]	]	PUNCT
fbem-7835	152	4	yuqin	yuqin	NOUN
fbem-7835	152	5	song	song	NOUN
fbem-7835	152	6	,	,	PUNCT
fbem-7835	152	7	herve	herve	PROPN
fbem-7835	152	8	tilly	tilly	PROPN
fbem-7835	152	9	,	,	PUNCT
fbem-7835	152	10	shinya	shinya	PROPN
fbem-7835	152	11	rai	rai	PROPN
fbem-7835	152	12	,	,	PUNCT
fbem-7835	152	13	et	et	PROPN
fbem-7835	152	14	al	al	PROPN
fbem-7835	152	15	.	.	PROPN
fbem-7835	152	16	polatuzumab	polatuzumab	PROPN
fbem-7835	152	17	vedotin	vedotin	ADV
fbem-7835	152	18	in	in	ADP
fbem-7835	152	19	previously	previously	ADV
fbem-7835	152	20	untreated	untreated	ADJ
fbem-7835	152	21	dlbcl	dlbcl	NOUN
fbem-7835	152	22	:	:	PUNCT
fbem-7835	152	23	an	an	DET
fbem-7835	152	24	asia	asia	PROPN
fbem-7835	152	25	subpopulation	subpopulation	NOUN
fbem-7835	152	26	analysis	analysis	NOUN
fbem-7835	152	27	from	from	ADP
fbem-7835	152	28	the	the	DET
fbem-7835	152	29	phase	phase	NOUN
fbem-7835	152	30	3	3	NUM
fbem-7835	152	31	polarix	polarix	NOUN
fbem-7835	152	32	trial[j].blood	trial[j].blood	NOUN
fbem-7835	152	33	,	,	PUNCT
fbem-7835	152	34	2023	2023	NUM
fbem-7835	152	35	,	,	PUNCT
fbem-7835	152	36	141(2	141(2	NUM
fbem-7835	152	37	):	):	PUNCT
fbem-7835	152	38	130	130	NUM
fbem-7835	152	39	-	-	SYM
fbem-7835	152	40	166	166	NUM
fbem-7835	152	41	.	.	PUNCT
fbem-7835	153	1	[	[	X
fbem-7835	153	2	13	13	NUM
fbem-7835	153	3	]	]	X
fbem-7835	153	4	sun	sun	PROPN
fbem-7835	153	5	lei	lei	PROPN
fbem-7835	153	6	,	,	PUNCT
fbem-7835	153	7	zhou	zhou	PROPN
fbem-7835	153	8	dachuang	dachuang	PROPN
fbem-7835	153	9	,	,	PUNCT
fbem-7835	153	10	chen	chen	PROPN
fbem-7835	153	11	pingyu	pingyu	PROPN
fbem-7835	153	12	,	,	PUNCT
fbem-7835	153	13	et	et	PROPN
fbem-7835	153	14	al	al	PROPN
fbem-7835	153	15	.	.	PUNCT
fbem-7835	153	16	pharmacoeconomic	pharmacoeconomic	ADJ
fbem-7835	153	17	evaluation	evaluation	NOUN
fbem-7835	153	18	of	of	ADP
fbem-7835	153	19	ensatinib	ensatinib	NOUN
fbem-7835	153	20	in	in	ADP
fbem-7835	153	21	the	the	DET
fbem-7835	153	22	first	first	ADJ
fbem-7835	153	23	-	-	PUNCT
fbem-7835	153	24	line	line	NOUN
fbem-7835	153	25	treatment	treatment	NOUN
fbem-7835	153	26	of	of	ADP
fbem-7835	153	27	anaplastic	anaplastic	ADJ
fbem-7835	153	28	lymphoma	lymphoma	NOUN
fbem-7835	153	29	kinase	kinase	NOUN
fbem-7835	153	30	-	-	PUNCT
fbem-7835	153	31	positive	positive	ADJ
fbem-7835	153	32	advanced	advanced	ADJ
fbem-7835	153	33	non	non	ADJ
fbem-7835	153	34	-	-	ADJ
fbem-7835	153	35	small	small	ADJ
fbem-7835	153	36	cell	cell	NOUN
fbem-7835	153	37	lung	lung	NOUN
fbem-7835	153	38	cancer	cancer	NOUN
fbem-7835	154	1	[	[	X
fbem-7835	154	2	j	j	X
fbem-7835	154	3	]	]	X
fbem-7835	154	4	.	.	PUNCT
fbem-7835	155	1	china	china	PROPN
fbem-7835	155	2	pharmacy	pharmacy	PROPN
fbem-7835	155	3	,	,	PUNCT
fbem-7835	155	4	2022	2022	NUM
fbem-7835	155	5	,	,	PUNCT
fbem-7835	155	6	33(12	33(12	NUM
fbem-7835	155	7	):	):	PUNCT
fbem-7835	155	8	1479	1479	NUM
fbem-7835	155	9	-	-	SYM
fbem-7835	155	10	1484	1484	NUM
fbem-7835	155	11	.	.	PUNCT